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General introDuction anD scope of tHe tHesis
partly derived from: screening for prostate cancer in 2008 ii: 
the importance of molecular subforms of prostate-specific antigen and 
tissue kallikreins. european urology. 2009 march;55(3):563-74*
flip H. Jansen1
monique J. roobol1
Guido Jenster1
fritz H. schröder1
chris H. bangma1
1 Department of Urology, erasmus MC, Rotterdam, the netherlands
* Adapted with permission from european Urology
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1. the prostate
The prostate, derived from the Greek word προστάτης – prostates, meaning “the one 
who stands before”, is a walnut-sized exocrine gland, part of the male genitourinary 
tract. It produces and stores an alkaline fluid, which liquefies the semen and prolongs 
the life-span of the spermatozoa. Anatomically, the prostate is located underneath 
the bladder and in front of the rectum, surrounding the urethra. The prostate can be 
divided into four distinct zones: the peripheral zone, the central zone, the transition 
zone and the anterior fibromuscular zone. The majority of prostate cancers (PCa) 
originate from the peripheral zone. The transition zone is responsible for the disease 
of benign prostatic hyperplasia (BPH)1.
2. prostate-specific antigen
The epithelial cells of the prostate gland produce prostate-specific antigen (PSA), a 
34kD glycoprotein. It is also known as kallikrein III (KLK3), seminin, semenogelase, 
γ-seminoprotein or P-30 antigen. PSA is the protein in prostate fluid which is 
responsible for the lysis of the gel proteins, resulting in the liquefaction of the semen2. 
In 1971, PSA was discovered by a Japanese research group as a result from a forensic 
search to identify specific proteins present in the ejaculate and was originally named 
γ-seminoprotein3. Later, PSA was specifically linked to the prostate and prostatic 
disease and was shown to be almost exclusively present in the epithelial cells of the 
prostate4-6. PSA was first measured quantitatively in human serum by Papsidero and 
Kuriyama et al. in 19807-9.
Normally, PSA is confined within the prostate and only a minute amount leaks 
into the circulation. In men with PCa, PSA serum levels may be increased. Unlike 
what might be expected, these elevated serum concentrations in PCa patients are 
not the result of increased expression of PSA but of an increased release of PSA in 
the bloodstream, most likely resulting from disruption of the prostate architecture 
in PCa (Figure 1)10,11. As PSA is prostate-specific but not PCa-specific, increased 
PSA serum levels may also result from prostatitis, irritation or BPH. The clinical 
usefulness of PSA in PCa detection was first shown by Stamey et al. in 1987, who 
carried out the initial clinical validation12,13.
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In the circulation, several forms of PSA are present (Figure 1). A substantial fraction 
of PSA that enters the bloodstream is intact and forms a complex (designated cPSA) 
with the protease inhibitor α1-antichymotrypsin or other inhibitors. PSA that is 
catalytically inactive does not form complexes and circulates as free PSA (fPSA). 
The major part of fPSA comprises of three distinctive forms; an inactive form (iPSA) 
similar to active native PSA, a mixture of precursor isoforms of PSA (proPSA or 
pPSA), and a form designated benign prostatic hyperplasia–associated PSA or 
‘benign’ PSA (BPHA or BPSA), as it was initially found in men with BPH14. Total PSA 
(tPSA) is the sum of the free and complexed forms.
Normal Cancer
active PSAactive PSA
Prostate
gland lumen
Epithelial cells
Basal cells
Stroma
Capillary wall
Capillary lumen
active PSAactive PSA
complexed PSAcomplexed PSA
free PSAfree PSA
proPSAproPSA
inactive
PSA
inactive
PSA
Figure 1. A model of PSA synthesis and secretion. In normal secretory epithelial 
prostate tissue, proPSA is secreted into the seminal lumen after which active PSA is 
generated. After proteolysis, active PSA becomes inactive PSA. Minute fractions of 
both active and inactive PSA diffuse into the peripheral circulation. In PCa, loss of 
basal cells, disordering of the basement membrane and disruption of normal lumen 
architecture leads to a decrease in luminal processing and a relative increase of bound 
PSA and proPSA in the circulation (Figure adapted from reference10).
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3. characteristics, diagnosis and 
screening of prostate cancer
3.1 Characteristics of prostate cancer
Prostate cancer is mainly diagnosed within the elderly male population. As 
mentioned, PCa mostly originates from the peripheral zone of the prostate. Therefore, 
it may never cause any symptoms as most prostate tumours are slow-growing, and 
meanwhile patients die of other causes. However, in a minority of men cancer cells 
metastasize or progress locally, causing late symptoms such as pain or micturition 
complaints.
PCa constitutes a major health issue worldwide and is considered as one of the most 
common causes of cancer-related deaths. The American Cancer Society estimated 
that in 2013, 238,590 men will be diagnosed with PCa and 29,720 men will die of PCa 
within the United States15. Extrapolated, this means that one out of every six men 
will be diagnosed with PCa during his lifetime, and one out of every 36 men will die 
of it. This is in accordance with results from autopsy studies, showing microscopic 
PCa lesions in 50% of men in their sixth decade, increasing to more than 75% in men 
older than 85 years16,17.
Not surprisingly, this poses an enormous burden on total healthcare costs. In 2010, 
medical costs associated with PCa in the United States alone estimated $12 billion, 
expected to increase to $16 billion in 202018. In the Netherlands, 168 million euro’s 
were spend on PCa care in 2007, about 0.23% of the total national healthcare budget19. 
For several decades now there has been an extensive search for biomarkers for PCa, 
in order to detect PCa at an early stage in which curative treatment is still possible. 
In addition, it is important to distinguish aggressive from indolent disease, hereby 
limiting overtreatment of PCa.
3.2 The diagnosis of prostate cancer
Before the discovery of PSA, a digital rectal examination (DRE) was the only pre-
diagnostic tool to detect PCa. However, often the disease had progressed at time 
of diagnosis, limiting curative treatment. Originally, tPSA resembled the ideal 
biomarker for PCa detection. After its introduction and thereafter widespread use 
in the late 1980s, a dramatic change in the epidemiology of PCa was observed20. An 
enormous increase in the number of newly diagnosed PCa cases was seen, peaking 
in 1992 and declining thereafter, however not falling back to the level of the pre-PSA 
era (Figure 2)21,22. In addition, it has been suggested that increased PCa awareness 
as well as improved diagnostic means have also contributed to the increase in PCa 
incidence during the early 1990s23.
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Figure 2. Age-adjusted incidence of PCa (rate per 100,000) by year of diagnosis (all 
ages) for all races. Data adapted from Surveillance, Epidemiology, and End Results 
(SEER) Program (www.seer.cancer.gov).
Next to the increased number of detected PCa cases, the widespread use of PSA 
led to a stage shift, i.e. more cancers were detected at an earlier stage. This is 
illustrated by the fact that PCa diagnosed by PSA testing has a 70-80% change of 
being organ-confined, in contrast to only 20-30% before the introduction of PSA24,25.
Initially, tPSA levels below 4.0 ng/ml were considered more or less as ‘normal’, or 
associated with negligible risk of PCa. However, by evaluating prostate biopsies 
in men with tPSA values below 4.0 ng/ml it became clear that the risk of PCa is 
certainly not negligible in this patient category26. For example, the risk of being 
diagnosed with PCa at a tPSA level below 2.0 ng/ml is still 17%, including cases of 
high-grade PCa. By subsequently lowering the threshold limit for prostate biopsies, 
tPSA theoretically has the capacity to detect the great majority of prostate cancers, 
though at the cost of greatly increasing the number of false positive outcomes. 
This, in turn, would lead to an enormous increase in unnecessary biopsies with 
all the accompanying morbidity. So, tPSA should be regarded as a continuous 
variable providing a spectrum of PCa risk, rather than focusing on a fixed threshold 
level, which is set to acquire prostate biopsies or to withdraw from taking action. 
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In addition, personal risk factors can be added to this spectrum, such as age, 
ethnicity, family history of PCa, the presence of urinary symptoms and DRE results. 
Several PCa risk calculators have been developed combining tPSA results and these 
personal factors, leading indeed to a more accurate calculation of the probability 
of positive prostate biopsies than by utilizing tPSA alone27,28. Other strategies to 
enhance the diagnostic performance of tPSA include the use of age-specific tPSA 
cut-offs, tPSA density (tPSA/prostate volume) and tPSA velocity (tPSA over time), 
showing inconsistent results in increasing the diagnostic accuracy of tPSA29.
3.3 Prostate cancer screening
Today, many controversies about tPSA-based PCa screening exist. As it is known 
that most men die with PCa rather than from PCa, tPSA based screening leads 
to an overwhelming overdiagnosis, often resulting in overtreatment of low-risk 
PCa patients30,31. Several large studies have been performed or are still ongoing 
to answer the question whether or not screening for PCa actually saves lives and 
at what costs32-34. The rationale for this screening is that by regularly measuring 
tPSA levels in combination with performing a DRE, PCa might be identified in an 
early stage in which definitive cure is still possible. However, as PCa is generally 
a low-grade and slow-growing disease, it takes more than a decade to draw any 
conclusions whether or not men could actually benefit from this form of screening. 
The often low-grade and slow-growing nature of PCa also hampers large scale 
prospective testing and validation of novel promising biomarkers. A recent report 
of the Prostate, Lung, Colorectal and Ovary (PLCO) screening trial, involving more 
than 76,000 men between 55 and 74 years, concluded that PCa screening did not 
result in a decrease in mortality32. After thirteen years of follow-up, the cumulative 
mortality rates from PCa in the screening and control arms were 3.7 and 3.4 deaths 
per 10,000 person-years, respectively, resulting in a statistically non-significant 
difference. However, the failure to reach statistical significance might be caused by 
opportunistic screening in the control arm of this study. In addition, a substantial 
number of men were pre-screened before randomisation and inclusion. Therefore, 
it is questionable if this study has sufficient power to demonstrate an effect of 
screening on PCa mortality35. The results of the PLCO screening study are in contrast 
with the European Randomized Study of Screening for Prostate Cancer (ERSPC). 
This study involves more than 182,000 men aged 50 to 74 years. After a median 
follow-up of 11 years the relative reduction in risk of death from PCa in the screening 
group was 29%. The absolute reduction in mortality in the screening group was 
0.10 deaths per 1,000 person-years. To prevent one death from PCa at 11  years of 
follow-up, 1,055 men would need to be screened and 37 cancers would need to be 
detected34. In contrast to the PLCO study, the number of men pre-screened before 
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randomisation was estimated to be low and contamination in the control arm was at 
most 15%, making this study adequately powered to draw conclusions on the effect 
of screening on PCa mortality. However, based on the conflicting results of these 
and other screening programs in addition to the large number of men needed to treat 
for each avoided death, most international and national screening guidelines still 
recommend against population-based or opportunistic screening for PCa.
Surprisingly, there have not been many studies evaluating the economic 
consequences of PCa screening. Also from an economic perspective, PCa screening 
is debatable. Using data from the ERSPC, researchers estimated that $5.2 million 
would have to be spent on screening to prevent one death from PCa36. Extrapolated, 
this would be $262,758 per life-year saved. However, a recent ERSPC report showed 
that the number of cancers needed to detect to prevent one death from PCa is 
decreasing after further follow-up time. So, most likely the costs associated with 
screening will be lower than the initial estimates, however further studies regarding 
cost-effectiveness of PCa screening are needed37.
In conclusion, novel biomarkers are eagerly awaited, as these might help in the 
more selective identification of men with aggressive forms of PCa, thereby limiting 
overdiagnosis and overtreatment, and thus limiting overall healthcare costs.
4. biomarkers for prostate cancer
According to the National Institute of Health, a biomarker is defined as a 
characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention38. Specifically related to PCa, these biomarkers could serve 
four different purposes39:
1. Risk: these markers are used to identify men with an increased risk of developing 
PCa during their lifetime.
2. Diagnostic and screening: these biomarkers can replace classical 
histopathological characteristics in assessing the presence or absence of PCa 
and can be preferably implemented in large-scale screening programs to detect 
PCa at an early stage.
3. Prognostic, predictive and monitoring: these biomarkers are used to predict the 
outcome of patients diagnosed with PCa, predict the outcome of therapy, and 
monitor treatment.
4. Surrogate endpoint: these biomarkers are a substitute for a clinical endpoint.
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Ideally, a single biomarker would be able to define all characteristics as described 
above. However, it would be more realistic to suppose that a panel consisting of 
several biomarkers would be needed to reach such a goal.
4.1 Biomarkers of risk assessment for prostate cancer
It is known that some men have a familial predisposition for developing PCa40. Also, 
it has been shown that African American men have higher PCa incidences and 
mortality rates compared to European American men, followed by Asian American 
men and Hispanic men41,42. This might be based on certain gene polymorphisms, 
but might also be due to environmental or behavioural factors. Having a first-
degree relative with PCa increases the risk of developing PCa by approximately 
two- to three-fold43. This risk is further increased by early age at onset and multiple 
relatives with PCa44,45. In total, it has been estimated that 5-10% of PCa cases are 
accounted for by genetic susceptibility46. Since the last decades, genetic research 
has been conducted to identify the polymorphisms and genes responsible for 
this PCa susceptibility. Genome wide association studies (GWAS) have revealed 
more than forty germline variants of various genes or chromosomal loci that are 
significantly associated with PCa susceptibility47,48. However, for only a few of these 
their biological significance and function has been elucidated. In the future, larger 
GWAS analyses in diverse ethnic groups might provide further genetic insights. 
These could then be translated into risk estimation and the development of a reliable 
biomarker for identifying PCa susceptible men.
4.2 Diagnostic and screening biomarkers for prostate cancer
The perfect biomarker (or as mentioned before more likely a panel of biomarkers) 
would be able to state the diagnosis of PCa at near 100% sensitivity and specificity. 
Preferably, this marker would also state prognostic information or specifically 
detect aggressive forms of PCa that need to be treated. If such a biomarker would 
be available, all PCa cases could be detected with negligible false positive or false 
negative outcomes. As already extensively described above, the most widely used 
biomarker to detect PCa is PSA. In addition, PSA forms also the basis of all screening 
programs to detect PCa population-wide. During the last decades, several isoforms 
of PSA have been discovered, which have been evaluated in the detection of PCa.
4.2.1 Isoforms of prostate-specific antigen
PSA is produced as a prepro-protein, containing 261 amino acids. After removal of 
the 17-amino acid leader sequence, an inactive 244-amino acid precursor protein 
termed proPSA (or pPSA) results (Figure 3)49.
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Figure 3. PSA is initially produced as a 261 amino acid prepro-protein. After 
cotranslational removal of the amino-terminal leader sequence, the non-catalytic 
zymogen (-7)pPSA results. After cleavage by hK2, the 7 amino acid propeptide is 
removed and catalytically active mature PSA (237 amino acids) is formed. Alternatively, 
truncated forms of pPSA are formed due to cleavage within the propeptide. As a result 
of internal cleavages within active PSA between residues 145-146 and 182-183 the 
inactive BPHA can be produced (Figure adapted from reference10).
After cleavage by human kallikrein 2 (hK2) it is converted to mature, active PSA 
(237 amino acids)50,51. Originally, pPSA was defined as the only precursor form of 
PSA, consisting of 244 amino acids including a 7 amino-acid pro-peptide leader 
and was therefore named (-7)proPSA. However, later reports presented several 
other truncated forms of pPSA, such as (-1), (-2), (-4), and (-5)pPSA, containing 1, 
2, 4, or 5 amino acids in the pro-peptide leader, instead of the native 7 amino acids 
(Figure 3)52,53.
pPSA was shown to be differentially elevated in peripheral zone cancer and 
undetectable in most specimens of the transition zone, leading to the assumption 
that pPSA represented a more cancer-specific form of PSA54. Initial attempts 
to confirm the presence of pPSA in serum were unsuccessful, but later others 
unequivocally confirmed the presence of several pPSA forms in serum of PCa 
patients52,53,55,56. The molecular basis for the increased serum levels of truncated 
pPSA forms in PCa patients is unknown, but most likely reflects decreased cleavage 
Flip_Jansen.indd   18 30-7-2013   8:43:38
ChApteR 1 19
of (-7)proPSA by hK2 in PCa cells. Overall, roughly a third of the fPSA fraction in 
cancer serum consists of pPSA forms (Figure 4).
cPSA
(84%)
(-2)pPSA (1%) 
(-4)pPSA (2%) 
(-5, -7)pPSA (3%)
BPSA (4%)
iPSA (6%)
fPSA
(16%)
Figure 4. The partitioning of fPSA into various pPSA forms, BPHA and iPSA in PCa 
serum within the 4-10 ng/ml tPSA range (Figure adapted from reference57).
In 2000, Mikolajczyk et al. published a report in which PCa tissue was examined to 
further clarify the origin of pPSA54. Sequencing showed that the pPSA in peripheral 
zone cancer consisted mainly of (-2)pPSA. A subsequent study confirmed the 
presence of (-2)pPSA in serum of men with PCa, in which (-2)pPSA formed 25-95% of 
the fPSA fraction, in contrast with 6-19% in biopsy-negative men52. As a result of the 
presence of only a 2 amino acid pro peptide, hK2 was shown to be unable to activate 
(-2)pPSA to mature PSA, stabilizing (-2)pPSA as an inactive isoform of PSA in serum.
Further characterization of fPSA in normal, hyperplastic and cancerous prostatic 
tissue lead to the identification of a specific molecular form of clipped fPSA, called 
BPHA (or BPSA), most likely the consequence of posttranslational proteolytic 
processes within the prostate58. It was shown that BPHA contained 237 amino 
acids, like PSA, but is clipped at amino acid residues lysine 145-146 and lysine 
182-183 (Figure 3). %BPHA (BPHA/tPSA) was significantly increased within the 
transition zone of patients with BPH in comparison to patients without BPH. Initial 
measurements of BPHA concentrations in serum showed that BPHA represented 
25% of the fPSA fraction in biopsy-negative men59. Canto et al. showed BPHA 
and fPSA to be strongly correlated with both age and transition zone volume in 
91 biopsy-negative men60. Furthermore, BPHA outperformed fPSA as well as tPSA in 
the prediction of transition zone enlargement. A study from Naya et al. demonstrated 
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that BPHA, %BPHA and %fPSA (fPSA/tPSA) performed similarly in the prediction of 
prostate volume (PV).
In addition to tPSA, the specific value of PSA isoforms in the detection of PCa has 
been evaluated. Catalona et al. measured (-2)pPSA values in a cohort of 1091 serum 
samples of men with and without PCa within the tPSA ranges of 2-4 ng/ml and 
4-10 ng/ml61. This two-center study showed that (-2)pPSA levels were higher in PCa 
patients compared to non-PCa patients, but only in one of the two centres statistical 
significance was reached within the 2-4 ng/ml tPSA range. The predictive power 
of %(-2)pPSA (=(-2)pPSA/fPSA) was smaller compared to %pPSA. Mikolajczyk et al. 
later confirmed these results for the 4-10 ng/ml tPSA range in 380 serum samples62. 
However, as Naya et al. found no significant difference in (-2)pPSA or %(-2)pPSA 
levels in men with and without PCa, it remains unclear whether PSA isoforms do 
possess any additional value in the detection of PCa63,64. For BPHA, it was shown 
that BPHA could not predict the presence of PCa and was not related to tumour 
volume63.
4.2.2 Prostate cancer antigen 3 and the TMPRSS2:ERG fusion gene
Next to tPSA, the other commercially available and FDA (US Food and Drug 
Administration) approved test for the detection of PCa is the differential display 
clone 3 (DD3) or PCA3 assay (Progensa® PCA3 , Gen-Probe, San Diego, California)65. 
Following a digital rectal examination, PCA3 mRNA can be quantified in urine 
specimens together with PSA mRNA to generate a so-called PCA3 score. One of 
the aims of the PCA3 test was to decrease the number of unnecessary prostate 
biopsies. Several studies have indeed shown a slight increase in diagnostic accuracy 
over tPSA, although the sensitivity of PCA3 is limited in the tPSA zone of 2-10 ng/
ml38,66-68. Recently, PCA3 has also been assessed in a screening protocol for PCa. 
It was shown that PCA3 missed fewer cancers compared to tPSA (32 vs. 65%), but 
it should be mentioned that this was a tPSA-pre-screened cohort, so results in an 
unscreened population should be awaited. Alike the tPSA assay, the PCA3 score is 
also a continuous variable69. According to the summary of safety and effectiveness 
data as published by the FDA, a PCA3 score <25 is associated with a decreased 
likelihood of a positive prostate biopsy.
Another promising urinary based assay (which is not yet commercially available), 
is the TMPRSS2:ERG gene fusion test. The TMPRSS2:ERG gene fusion is a PCa-
specific genomic rearrangement consisting of a fusion between the strong androgen-
regulated TMPRSS2 gene and the proto-oncogene ERG, a member of the ETS 
transcription factor family. This results in an androgen-regulated TMPRSS2:ERG 
fusion gene and is found in approximately 50% of all prostate tumours70.
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In 108 PCa patients, urinary sediments were analysed for the presence of fusion 
transcripts. This resulted in a very high specificity of 93%, in contrast to a limited 
sensitivity of 37%71. A combination of the PCA3 test with the TMPRSS2:ERG assay 
has shown to further increase diagnostic accuracy. A study performed in 105 
men showed that PCA3 alone had an AUC (area under the curve) of 0.65, while 
the combination of PCA3 and TMPRSS2:ERG increased the AUC to 0.77. This was 
further increased to 0.80 by adding tPSA to this multivariate model72.
So, although the addition of PSA isoforms, PCA3 and TMPRSS2:ERG to the tPSA 
test seems promising, it is clear that more specific markers to identify men with PCa 
would be of tremendous value.
4.3 Prognostic, predictive and monitoring 
biomarkers for prostate cancer
4.3.1 Prognostic biomarkers for prostate cancer
Next to diagnosing PCa, an ideal biomarker would also state prognostic information. In 
this way, indolent disease, for which treatment could be deferred, can be differentiated 
from aggressive cases of PCa. In addition to the controversies surrounding tPSA in 
PCa diagnosis, there is an ongoing debate on the role of tPSA as a prognostic factor. It 
has been shown that higher preoperative tPSA values are associated with increased 
odds of extracapsular extension, positive surgical margins, seminal vesicle invasion 
and increased risk of biochemical progression73. However, when restricted to 
tumours identified by needle biopsy because of an elevated tPSA level (<10 ng/ml), 
pretreatment tPSA levels were only marginally related to biochemical progression. 
Another study showed that tPSA is an independent predictor of several pathologic 
stages and may improve the accuracy of multivariate models predicting pathologic 
stage74. Currently, the best predictor for survival at the time of PCa diagnosis is the 
pathologic grade of the tumour tissue (Gleason score) within the prostate biopsies. 
A Gleason score (GS) is given based upon the microscopic appearance of the tumour 
tissue (Figure 5). A first grade is assigned to the most common tumour pattern, 
and a second grade to the next most common tumour pattern. These two grades 
together form the GS, which ranges from 2 to 10 (Figure 5). The scoring system is 
named after Donald Gleason, a pathologist who developed the scoring system in 
the 1970s75. Tumours with a higher GS behave more aggressive and are significantly 
associated with a worse prognosis76. A drawback of the GS grading system is that 
it is partly subjective, showing significant observer variability77. In addition, due to 
the stage and grade shift of presently detected prostate cancers caused by tPSA 
screening, the prognostic power of the Gleason scoring system has diminished, as 
nowadays most patients present with a GS of 6, 7 or 878-80.
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Figure 5. Dr. Gleason’s drawing of the five Gleason grades75.
In the last decades, many alternative prognostic markers for PCa have been proposed, 
on protein as well as on RNA and genomic level. Examples of alternative markers 
on protein level are numerous, including various PSA-isoforms. A study by Catalona 
et al. specifically analysed pPSA forms in relationship to PCa aggressiveness81. It 
was shown that (-2)pPSA could not discriminate between cancers confined to the 
prostate and cancers with extracapsular extension and did not perform significantly 
better than %pPSA and %fPSA in the detection of cancers with a GS >7. These 
results were later confirmed by de Vries et al. in a smaller study82. A recent report by 
de Vries et al. describing 61 men diagnosed with PCa showed that also BPHA failed 
to discriminate between favourable and poor prognostic PCa82.
Also the possible role of PCA3 in PCa prognosis has been evaluated, resulting in 
conflicting outcomes. While some studies found a relationship between PCA3 and 
small volume tumours and insignificant PCa, others failed to find such a correlation83. 
Furthermore, PCA3 is not significantly associated with locally advanced disease 
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and it has limited value in the identification of aggressive tumours83. With regard 
to the TMPRSS2:ERG gene fusion, no significant relationship was found between 
the presence of the fusion transcripts and Gleason scores in prostate biopsies38,71,84. 
In addition, data on the association of TMPRSS2:ERG and patient outcome are 
conflicting85. Other markers that have been evaluated are PSCA (prostate stem 
cell antigen), hK2 (human kallikrein 2), EPCA (early prostate cancer antigen) and 
AMACR (alpha-methylacyl CoA racemase), but none of these has entered into 
routine clinical practice yet86-90. Currently, the best and independent pretreatment 
prognostic marker is the pathologic grade of the tumour tissue within the prostate 
biopsies, so prognostic blood or urine based biomarkers are urgently awaited76.
4.3.2 Monitoring and predictive biomarkers for prostate cancer
Regarding the monitoring of men treated for PCa with curative intent, either by 
radiation therapy (RT) or radical prostatectomy (RP), the use of tPSA has been 
extensively studied. After a successful RP, all prostatic tissue is removed and 
tPSA levels should become undetectable. Hence, detectable serum tPSA levels are 
indicative of residual prostatic tissue, which presumably represents locoregional 
or systemic cancer91. The American Urological Association (AUA) has defined a 
biochemical recurrence as a serum tPSA level ≥0.2 ng/ml, confirmed by a second 
determination, after initial undetectable tPSA levels following RP92. The kinetics 
of tPSA increment after RP are indicative of the location of tumour recurrence. If 
tPSA never falls to undetectable levels or is rising rapidly after RP, systemic disease 
is more likely than residual disease93,94. In contrast, if tPSA levels rise slowly after 
having been undetectable for a longer period of time, isolated local recurrence in 
the prostatic bed is more likely93,95. In this way, tPSA can be used to guide adjuvant 
therapy after RP.
After external RT, brachytherapy (internal RT) or cryotherapy (freezing of prostate 
tissue) tPSA may still be detectable, as the prostate gland is not removed. This 
makes it more difficult to define biochemical recurrence compared to RP. The decline 
in tPSA after RT is gradual and the mean time for tPSA to reach its nadir (the lowest 
level to which tPSA drops) is 18 months or longer96. This nadir is a strong indicator 
of treatment success, however, the rate of decline does not correlate to the risk of 
PCa relapse96-99. According to the latest definition, a tPSA level higher than 2 ng/
ml above the nadir is considered as a biochemical failure after RT100. A complicated 
issue is the phenomenon of a tPSA bounce after RT, typically occurring after 12 to 
18 months101. This can occur in the absence of disease and does not necessarily 
signify treatment failure. Up to date, there are no definitive methods or markers to 
distinguish a tPSA bounce from cancer recurrence. So, novel markers distinguishing 
the latter two conditions could have additional value in guiding patient therapy.
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4.4 Surrogate endpoint biomarkers for prostate cancer
As PCa is usually a low aggressive and slow-growing disease, trials and studies 
involving PCa are often of extensive duration. Therefore true endpoints, such as 
mortality from PCa, are often replaced by surrogate endpoints such as tPSA. An 
extensive review on tPSA as a surrogate endpoint marker for PCa concluded that 
tPSA is not a suitable replacement for survival, especially when second or third line 
treatments become more efficacious102. This is further illustrated by the fact that 
prognostic studies have shown that in hormone independent disease only 17% of 
survival is explained by time-dependent tPSA measurements, showing sufficient 
variation in survival unaccounted for by tPSA measurements103. Therefore, also from 
the viewpoint of surrogate endpoints, novel markers are currently awaited.
5. challenges in biomarker research
5.1 Biomarker research phases
The search for novel biomarkers for PCa can be divided into three distinctive phases. 
First, there is a discovery phase, resulting in the identification of a number of 
promising candidate markers. Then, during the verification phase, the list of potential 
candidates is narrowed, allowing only the most promising candidates to enter the 
validation phase, which should ultimately lead to the clinical implementation of a 
novel biomarker. All these three phases have their own difficulties and challenges.
5.2 Selection of biological specimen
When searching for a novel biomarker, the first question that should be addressed is 
which body fluid should be utilized. Preferably, this body fluid should be accessible 
in a non or minimally invasive way. So, the two body fluids that would be most 
appropriate are urine or blood. The drawback of utilizing the first one is that there 
are currently no biobanks available containing large numbers of urine samples 
with long-term follow-up, so large scale validation of novel markers is seriously 
hampered. Due to the slow-growing and low-grade characteristics of the majority of 
PCa cases, it would take up to a decade to draw any conclusions from a prospective 
urine-based study, especially from a prognostic point of view. So, at least for now, 
this favours blood (serum or plasma) as the more suitable of the two. In addition, as 
physicians are so familiar to PSA-based decision making, it is highly unlikely that a 
novel biomarker will replace PSA, meaning blood will we be drawn anyway.
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5.3 Selection of cellular material
The second question that should be addressed is which cellular material should be 
explored to look for novel markers. In short, this could be on metabolite, protein, 
RNA or DNA level. As proteins produced by cancer cells (or their microenvironment) 
may eventually enter the circulation, these could be directly assessed in the serum 
or plasma of men suspected of having PCa. This is the case for most successful 
tumour markers applied in the clinic today, such as alpha fetoprotein (AFP), beta 
human chorionic gonadotropin (β-hCG), cancer antigen 125 (CA125), and of course 
PSA.
Another advantage of a protein biomarker would be that standard detection 
techniques could be utilized, such as enzyme-linked immunosorbent assays 
(ELISA), facilitating incorporation into current clinical laboratory practice.
Next to protein markers, novel biomarkers could also be found on RNA and DNA 
levels, as genetic and epigenetic alterations are common events in PCa. In contrast 
to protein markers, these are usually detected in tissue samples, requiring invasive 
methods to obtain the tissue itself. Another option is the detection of RNA and DNA 
directly in serum or in circulating tumour cells, but this requires more elaborate 
techniques, currently not standard in clinical laboratory practice. However, recent 
publications have shown that RNA profiling of whole blood samples is a feasible 
technique which might yield prognostic information in PCa104,105.
5.4 Mass spectrometry for biomarker identification
One approach to discover novel biomarkers is by utilizing comparative mass 
spectrometry (MS), analysing human serum samples in search of tumour-specific 
proteins shed into the circulation by tumour cells. MS is an analytical chemistry 
technique based on the determination of the mass of an analyte ion. This analyte 
can be fragmented inside the mass spectrometer to give charged product ions. The 
masses of the fragment ions can then be determined in a second stage of MS, giving 
rise to the term MS/MS or tandem mass spectrometry. Improved specificity can be 
obtained by monitoring a precursor ion and one of its collision-induced dissociation-
generated product ions, a technique known as multiple reaction monitoring (MRM). 
This technique also reduces the possibility of a false-positive identification and 
inaccurate quantitation. As well, MRM analysis can be multiplexed, allowing the 
quantitation of hundreds or even thousands of target molecules in a single analysis. 
In addition, a recent multi-laboratory analysis showed that MRM results are 
reproducible between different laboratories106.
To identify specific proteins, a bottom-up approach can be used in which a proteolytic 
enzyme, typically trypsin, is used to degrade proteins into smaller peptides. 
Subsequently, these peptides can be introduced into the mass spectrometer and 
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identified. The identified masses can be used as input for a database search of 
predicted masses that would arise from digestion of a list of known proteins. If a 
protein sequence in the reference list gives rise to a significant number of predicted 
masses, there is evidence that this protein is present in the original sample.
However, serum is a highly complex fluid with a high variability between human 
serum samples. It has a vast dynamic range in protein concentrations (>1010) 
and dominance of a small number of high abundant proteins, such as albumin 
and immunoglobulins, which constitute more than 99% of the entire protein 
content, masking the presence of low abundant proteins, including possible novel 
biomarkers107.
To rule out these variables, hundreds to thousands of samples have to be analysed in 
order to identify discriminating proteins. In addition, current technologies, capable 
of analyzing protein concentrations spanning four orders of magnitude, would be 
missing the lower abundant proteins (such as PSA) which are likely to constitute the 
next generation of biomarkers.
1. Assay development and validation
A clinical assay is developed in this phase. The assay must discriminate
individuals with cancer from those without. The patients assessed in this phase
have established disease. The utility of the assay in detecting disease early is not
demonstrated in this phase.
2. Retrospective longitudinal clinical repository studies
Specimens collected and stored from a cohort of healthy individuals who were
monitored for development of cancer are used here. Evidence for the capacity of
the biomarker to detect preclinical disease is demonstrated in phase 2. 
3. Prospective screening studies
In this phase, individuals are screened with the assay and diagnostic procedures
are applied to those who screened positive. This can help to establish the tumor
stage or the nature of the disease at the time of detection.
4. Randomized control trials
The objective of this phase is to determine if screening reduces the burden of
cancer in the population.
Figure 6. The phases of biomarker validation (adapted from reference109).
5.5 Biomarker validation issues
After preclinical exploratory studies, in which promising biomarker candidates 
are identified, these should be enrolled in extensive validation programmes. This 
is necessary, as methods of marker discovery, study design, patient selection, 
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interpatient heterogeneity and intratumour heterogeneity are all confounding 
factors, especially in the case of PCa. Other important confounding factors are the 
danger of bias, the risk of overfitting of data and issues related to the handling 
and storage of clinical specimens108. Several phases can be identified in the process 
of biomarker validation, as depicted in Figure 6109. Ideally, all phases should be 
successfully completed before a biomarker enters clinical practice.
5.6 Biomarker standardisation issues
Another issue related to the validation of a biomarker is its standardisation or 
calibration. Preferably, before a biomarker enters clinical practice, identical 
calibration protocols and standards should be used, resulting in identical diagnostic 
performances amongst different assay platforms. Unfortunately, this is only partly 
the case for tPSA.
The number of ordered tPSA tests has increased dramatically during the last decade. 
In the Netherlands, almost 28% of men older than 65 years had their tPSA tested 
in 2001, increasing to over 45% in 2011110. As these tPSA tests are performed on 
various assay platforms, standardisation is of utmost importance to improve clinical 
interchangeability and to compare long-term results. Today, more than 30 different 
types of tPSA assay reagent sets are available111. In the past, several publications 
have shown that this wide variety of tPSA assays leads to significantly different 
values for tPSA. Possible causes of this lack of interchangeability are differences in 
assay design, differential epitope recognition, cross-reactivity to tPSA homologous 
antigens and the lack of equimolarity5,112-115.
As most clinicians are unaware of their local assay used to measure tPSA levels, 
misinterpretation of tPSA values will occur, for example influencing the decision 
to recommend that a patient undergoes a prostate biopsy for PCa detection113. To 
improve the interchangeability of tPSA assays, the First International Standard for 
tPSA was introduced in 1992 and later adopted by the World Health Organization 
(WHO)116,117. This indeed decreased differences between the various tPSA assays118-120. 
However, for certain tPSA assays, this restandardisation caused a shift in mass 
units, resulting in a potential under or over-recovery of tPSA values. Consequently, 
if this shift is not fully appreciated around the threshold for prostate biopsies, a 
change in PCa detection rates may result with possible life-altering consequences 
for individual patients.
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6. scope of the thesis
This thesis focuses on the full spectrum of PCa biomarkers, ranging from the 
discovery and (pre-) validation of novel markers, to assessing the clinical value of 
recently discovered PSA isoforms and the implications of the introduction of a tPSA 
calibration standard to decrease interassay variability.
In order to specifically detect proteins secreted into the circulation by PCa cells, we 
developed a xenograft model system (Chapter 2). In this system, human prostate 
cancer cell lines are transplanted onto athymic nude mice. We hypothesized 
that after successful inoculation, PCa cells would shed proteins into the mouse 
circulation, mimicking the situation in humans. Thus, a normal nude mouse would 
only have mouse proteins in its circulation, while the serum of a nude mouse 
bearing a human xenograft would also contain human proteins in addition to mouse 
proteins. In order to identify these tumour-derived proteins, the serum of normal and 
xenografted mice was analysed by mass spectrometry.
In Chapter 3, this xenograft model system was further exploited by utilizing the 
mouse immune system. We hypothesized that by immunizing immune-competent 
congenic mice with serum drawn from nude mice grafted with human prostate 
cancers, an immune response would occur, generating immunoglobulins specifically 
directed against PCa-derived proteins. Subsequently, protein microarrays were 
utilized to profile the antibody production and indirectly identify PCa xenograft-
derived antigens.
In Chapter 4, we analysed the diagnostic and prognostic performances of the PSA 
isoforms BPHA and p2PSA in a large multicenter study. We hypothesized that these 
isoforms, as well as its derivative phi (Beckman Coulter Inc. name for the “prostate 
health index,” a mathematical combination of PSA, fPSA and p2PSA, see www.
prostatehealthindex.org), would have significant additional value in PCa detection, 
next to tPSA and fPSA. Secondly, we hypothesized that these PSA isoforms could 
have additional value in discriminating aggressive from indolent disease and 
thereby aid in PCa prognosis.
Another essential step in the establishment of a biomarker is its international 
calibration or standardisation. In Chapter 5, we focused on the consequences of the 
implementation of an international calibration standard for tPSA assays, specifically 
for the Beckman Coulter tPSA assay. We hypothesized that the implementation 
of this international calibration standard would lead to a significant shift in tPSA 
results, thereby directly influencing PCa detection rates.
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abstract
Novel markers for prostate cancer (PCa) are needed because current established 
markers such as prostate-specific antigen lack diagnostic specificity and 
prognostic value. Proteomics analysis of serum from mice grafted with human PCa 
xenografts resulted in the identification of 44 tumour-derived proteins. Besides 
secreted proteins we identified several cytoplasmic proteins, among which were 
most subunits of the proteasome. Native gel electrophoresis and sandwich ELISA 
showed that these subunits are present as proteasome complexes in the serum from 
xenograft-bearing mice. We hypothesized that the presence of proteasome subunits 
and other cytoplasmic proteins in serum of xenografted mice could be explained by 
the secretion of small vesicles by cancer cells, so-called exosomes. Therefore, mass 
spectrometry and Western blotting analyses of the protein content of exosomes 
isolated from PCa cell lines was performed. This resulted in the identification of 
mainly cytoplasmic proteins of which several had previously been identified in the 
serum of xenografted mice, including proteasome subunits. The isolated exosomes 
also contained RNA, including the gene fusion TMPRSS2:ERG product. These 
observations suggest that although their function is not clearly defined cancer-
derived exosomes offer possibilities for the identification of novel biomarkers for PCa.
introduction
For several decades now, prostate-specific antigen (PSA) has been utilized as 
the “gold standard” biomarker for the detection of prostate cancer (PCa)13. Its 
introduction caused a dramatic decrease in the prevalence of advanced stages of 
PCa20. However, ongoing efforts are being made to discover new biomarkers for PCa 
because it became clear that PSA has limited diagnostic specificity and prognostic 
value, leading to an enormous increase in unnecessary biopsies and overtreatment 
of low risk PCa patients26. In the last decades, many alternative diagnostic or 
prognostic markers for PCa have been proposed on protein as well as on RNA and 
genomic levels. Examples of alternative markers on the protein level are numerous, 
including various PSA isoforms, prostate stem cell antigen, human kallikrein 2, 
early prostate cancer antigen, and α-methylacyl-CoA racemase86-90. On the RNA 
level, the PCA3 test and especially the recently discovered fusion of TMPRSS2 
with ETS transcription factors may hold promise for PCa detection and potentially 
prognosis in the near future121,122. One of the drawbacks of the latter two as markers 
for PCa is the fact that they are detected in urine, after a standardized prostatic 
massage, instead of in serum or plasma. This will hamper retrospective validation 
Flip_Jansen.indd   31 30-7-2013   8:43:40
Discovery anD valiDation of prostate cancer biomarkers32
as most historical biorepositories do not contain urine. Although several validation 
studies of promising candidates have been performed in the past or are currently 
underway, no single marker has yet outperformed PSA, justifying ongoing efforts 
in searching for PCa biomarkers. One approach is the screening of large series of 
serum samples from men with and without PCa. However, given the large sample 
variability, the high complexity, and dynamic range of proteins in serum samples, 
large numbers of human serum samples have to be analysed to achieve any 
statistical significance. Also identified proteins may be related to secondary body 
defence mechanisms rather than being directly derived from the tumour cells as are 
most tumour markers applied in the clinic today. To circumvent these problems, we 
have exploited the xenograft model system as a platform for the discovery of new 
biomarkers for PCa123. As has recently been reported, this model system is indeed 
capable of identifying human proteins that are shed into the circulation by human 
prostate cancer cells124. In the present study we further exploited this approach and 
performed an in-depth proteomics analysis of serum of mice carrying androgen-
sensitive (PC346) or androgen-independent prostate cancer xenografts (PC339). 
Among the discovered human proteins were numerous cytoplasmic proteins, such 
as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), lactate dehydrogenases 
A and B, and various subunits of the proteolytic proteasome complex124. Many of 
these cytoplasmic proteins are also present in the human plasma proteome as 
retrieved from the database of the Human Proteome Organisation Plasma Proteome 
Project125. We hypothesized that the presence of cytoplasmic tumour-derived 
proteins in the xenograft sera could be explained by the secretion of exosomes. 
Exosomes are small membrane vesicles secreted by virtually every cell type, 
including tumour cells126. Exosomes are formed in multivesicular bodies by inward 
budding, thereby encapsulating cytoplasmic components126,127. The exact function 
of exosomes in tumour cells has yet to be elucidated but is expected to relate to roles 
in cell-to-cell contact, tumour-stroma interaction, protein degradation, and antigen 
presentation126,127. In addition to containing proteins, it was recently discovered that 
exosomes also contain functional RNA, proposed as “exosomal shuttle RNA”128. 
To confirm our hypothesis that the cytoplasmic tumour-derived proteins in the 
serum of xenograft-bearing mice were the result of exosomal secretion, we isolated 
exosomes from the PC346C cell line and analysed their protein content. To further 
explore the contents of exosomes we isolated and analysed exosomal RNA from 
both the PC346C and VCaP cell lines.
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experimental procedures
Xenograft serum collection
Human prostate cancer xenografts were grown on immune-incompetent mice 
athymic male nude (nu/nu) BALB/c mice (n=9 for each xenograft; Taconic, Ry, 
Denmark)123,124. We used the human prostate cancer cell lines PC346 (androgen-
sensitive) and PC339 (androgen-independent). Specific characteristics have 
been described previously129. Prior control serum was collected by retro-orbital 
punction. Tumour-bearing mice were sacrificed after 4–5 weeks, and blood was 
collected. Samples were stored at -80 °C. The protocol was approved by the Animal 
Experiments Committee under the national Experiments on Animals Act and 
adhered to the rules laid down in this national law that serves the implementation 
of “Guidelines on the protection of experimental animals” by the council of Europe 
under Directive 86/609/EC.
Preparation of xenograft sera for mass spectrometry
After filtration using a 0.22-μm spin filter, high abundance proteins were removed 
utilizing Multi Affinity Removal Spin cartridges (Agilent Technologies, Wilmington, 
DE) according to the manufacturer’s instructions. Depleted samples were 
concentrated on 5-kDa-cutoff ultracentrifugation columns (Agilent Technologies). 
Total protein concentration was determined by the Bradford method (Bio-Rad). 
Precast 4–20% polyacrylamide linear gradient gels (Bio-Rad) were utilized to 
separate 10 μg of protein of depleted mouse serum (pooled from nine individual 
control mice, nine PC339 xenograft-bearing mice, or nine PC346 xenograft-bearing 
mice) by SDS-PAGE (Mini-Protean III, Bio-Rad). Prestained high range molecular 
weight markers (See- Blue, Invitrogen) were loaded on each gel. After running, gels 
were stained by Coomassie Brilliant Blue (Merck). Gel lanes (range, 5–200 kDa) 
were excised and divided into 3-mm sections. Gel slices were washed, destained 
twice (50% (v/v) acetonitrile in 50 mM ammonium bicarbonate), dehydrated (100% 
acetonitrile), and reduced with 6.5 mM DTT in 50 mM ammonium bicarbonate for 
1 h at 37 °C. After alkylation with 54 mM iodoacetamide in 50 mM ammonium 
bicarbonate, proteins were dehydrated in 100% acetonitrile and then rehydrated 
with the digestion solution containing 10 ng/l ultra grade sequencing trypsin 
(Promega, Madison, WI) for 30 min at room temperature. After addition of 30 µl of 
50 mM ammonium bicarbonate solution, gel particles were incubated overnight at 
37 °C. The peptides were extracted using 0.5% formic acid in 50% acetonitrile, dried 
completely in a vacuum centrifuge, and stored at 80 °C until analysis.
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Liquid chromatography-mass spectrometry of xenograft sera
Nanoflow LC-tandem mass spectrometry was performed for samples by coupling 
an Agilent 1100 HPLC system (Agilent Technologies), operated as described 
previously124, to a 7-tesla LTQ-FT mass spectrometer (FT-ICR-MS, Thermo Electron, 
Bremen, Germany). For protein identification, database searches were performed 
using Mascot version 2.0 (Matrix Science, London, UK) allowing 5-ppm mass 
deviation for the precursor ion, a 0.6-Da tolerance on the fragment ions, and trypsin 
as the digestion enzyme. A maximum number of one missed cleavage was allowed, 
and carbamidomethylated cysteine and oxidized methionine were set as fixed 
and optional modifications, respectively. Only peptides with Mascot scores >30 
were accepted. Scaffold (version 01_05_06, Proteome Software Inc., Portland, OR) 
was used to validate MS/MS-based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 90.0% 
probability as specified by the Peptide Prophet algorithm130. Protein identifications 
were accepted if they could be established at greater than 95.0% probability and 
contained at least two identified peptides. Protein probabilities were assigned by 
the Protein Prophet algorithm131. Before we annotated a certain peptide derived from 
the xenograft-bearing mice as human, a stringent selection procedure was followed 
(see Figure 1). First all peptide mass values identified in the serum from control 
mice and PC339 or PC346 xenograft-bearing mice were searched against both the 
International Protein Index (IPI) mouse and IPI human databases (version 3.18, 
containing 53,788 and 60,090 proteins, respectively). Then a selection was made 
of peptides uniquely present in the serum of PC346 or PC339 xenograft-bearing 
mice. These peptides were subsequently divided into a group of human-specific 
peptides (identified only in the IPI human database) and a group of homologous 
peptides (present in both the IPI human and IPI mouse databases). Homologous 
peptides were annotated as tumour-derived if four or more times higher abundant 
in the serum of PC339 or PC346 xenografted mice in comparison with control serum 
as listed in Scaffold. Additionally to double check human specificity, the identified 
human-specific peptides were blasted against the Swiss-Prot database of the 
National Center for Biotechnology Information (NCBI) database.
Two-dimensional SDS-PAGE analysis of proteasomes
To clean up samples from contaminants, for each xenograft-derived serum sample 
(50 μg of protein) the 2-D Clean-Up kit (Amersham Biosciences) was utilized 
according to the manufacturer’s instructions. Next samples were solubilised in 
125 µl of rehydration buffer (8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.2% DTT, trace of 
bromphenol blue, all dissolved in H2O). The samples were loaded onto Immobiline dry 
strip gels (pH 3–10, non-linear, 7 cm; Amersham Biosciences). Isoelectric focusing 
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was carried out as follows: 30 V for 10 h, 300 V for 2 h, 1000 V for 30 min, 5000 V for 90 
min, 5000 V for 30 min, and 20 V for 20 h. Before starting the second dimension, strips 
were reduced and alkylated for 15 min in DTT equilibration buffer (6 M urea, 50 mM 
Tris, pH 8.8, 20% glycerol, 2% SDS, 1% DTT) and iodoacetamide equilibration buffer 
(6 M urea, 50 mM Tris, pH 8.8, 20% glycerol, 2% SDS, 2.5% iodoacetamide). Next the 
IPG strips were placed upon a Criterion XT bis-Tris gel (12%; Bio-Rad). The second 
dimension was run at 100 V for ±2 h with XT MOPS buffer (Bio-Rad). After running 
the second dimension, gels were blotted onto Protran nitrocellulose membrane in 
Tris-glycine-SDS buffer (Bio-Rad). The immunoblot was blocked for 1 h and after 
washing twice incubated overnight at 4 °C with a monoclonal antibody (1:2000) 
against proteasome subunits 6, 2, 4, 5, 1, and 3 (clone MCP231, Biomol International, 
Exeter, UK). This corresponds with the subunits 1, 2, 3, 5, 6, and 7 according to 
the nomenclature of Baumeister et al.132. In addition, monoclonal antibodies 
specifically directed against the proteasome 1 subunit (PSMA1; 6 according to the 
Baumeister et al.132 nomenclature) (clone MCP20, Biomol International) or 3 subunits 
(PSMA3; 7 according to the Baumeister et al.132 nomenclature) (clone MCP72, Biomol 
International) were utilized. The immunoblot was washed and incubated for 1 h with 
a 1:1000 solution of a goat anti-mouse horseradish peroxidase-conjugated antibody 
(DakoCytomation, Glostrup, Denmark). The secondary antibody was visualized 
with a chemiluminescence detection kit (Roche Applied Science). For reprobing, 
blots were immersed in a 0.04 M Tris-HCl, 0.06 M Tris base, 0.07 M SDS, 0.10 M 
β-mercaptoethanol solution for 20 min at 50 °C.
Native gel electrophoresis of proteasomes
The protocol for characterization of the proteasome by native gel electrophoresis 
was followed as previously described by Elsasser et al.133. Depleted xenograft and 
control serum samples were mixed with 5sample buffer containing 250 mM Tris-
HCl, pH 7.4, 50% glycerol, 60 ng/ml xylene cyanol. Samples were either directly 
loaded or denatured by heating at 96 °C for 5 min. Gels were run for 3–4 h at 4 °C. 
Gels were transferred onto Protran nitrocellulose membranes at 250 mA for 1.5 h.
Sandwich ELISA for quantification of the proteasome
Serum proteasome concentrations were measured as previously described by 
Dutaud et al.134 with some minor modifications. Briefly serum from control (n=3) and 
PC339 (n=3) or PC346 (n=3) xenograft-bearing mice (1:20 diluted) was incubated for 
1 h on a plate coated with a 1:4500 dilution of a monoclonal antibody against PSMA1 
(clone MCP20, Biomol International). After addition of a 1:1500 solution of a rabbit 
anti-proteasome antibody (directed against β subunits of the proteasome; PW 8155, 
Biomol International) cells were extensively washed with PBS-Tween 20  buffer. 
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Then a 1:4000 solution of goat anti-rabbit horseradish peroxidase-conjugated 
antibody (DakoCytomation) was added, and the plate was incubated for 1 h in the 
dark. To reveal horseradish peroxidase activity, 50 mM phosphate, 25 mM citrate 
buffer, pH 5.0 was added to the cells. After 15 min, the reaction was stopped with 
2.5 M sulfuric acid. Absorbance values were measured at 492 nm. All analyses were 
performed in triplicate.
Cell culture and isolation of PC346C 
and VCaP-derived exosomes
The human prostate cancer cell line PC346C was cultured in Dulbecco’s modified 
Eagle’s medium-Ham’s F-12 medium (Cambrex Bio Science, Verviers, Belgium) 
supplemented with 0.1 nM R1881, 2% FCS (PAN Biotech, Aidenbach, Germany), 
1% insulin-transferrin-selenium (Invitrogen), 0.01% BSA (Roche Applied Science), 
10 ng/ml epidermal growth factor (Sigma-Aldrich), 100 units/ml penicillin and 
100 g/ml streptomycin antibiotics (Cambrex Bio Science), 100 ng/ml fibronectin 
(Harbor Bio-Products, Tebu-bio, the Netherlands), 20 g/ml fetuin (ICN Biomedicals, 
Zoetermeer, The Netherlands), 50 ng/ml cholera toxin (Sigma-Aldrich), 0.1 mM 
phosphoethanolamine (Sigma-Aldrich), and 0.6 ng/ml triiodothyronine (Sigma-
Aldrich)129. The human PCa cell line VCaP was cultured in RPMI 1640 medium 
(Cambrex Bio Science) supplemented with 10% dextran-coated charcoal-treated 
FCS (PAN Biotech) and 100 units/ml penicillin and 100 g/ml streptomycin 
antibiotics (Cambrex Bio Science). Exosomes were isolated according to the protocol 
described previously by Hegmans et al.135. Briefly PC346C and VCaP were cultured 
in their respective medium to 80% confluency. Cultures were washed twice with 
PBS and incubated for 48 h in a humidified atmosphere of 5% CO2, 95% air with 
serum-free medium consisting of Dulbecco’s modified Eagle’s medium-Ham’s 
F-12 or RPMI 1640 medium (Cambrex Bio Science) supplemented with 0.1 nM 
R1881. After incubation cell culture supernatants were subjected to successive 
centrifugations of 400 g (10 min), 3000 g (20 min), and 10,000 g (30 min). Exosomes 
were then pelleted at 64,000 g for 110 min using an SW28 rotor (Beckman Coulter 
Instruments, Fullerton, CA). Exosome pellets were resuspended in 0.32 M sucrose 
and centrifuged at 100,000  g for 1 h (SW60 rotor, Beckman Coulter Instruments). 
For several experiments, the isolated exosomes from PC346C were further purified 
by immobilization onto magnetic beads. In short, 25 µl of Dynabeads, precoated 
with goat anti-mouse immune globulin G (Invitrogen Dynal AS, Oslo, Norway) were 
incubated for 1 h with 30 µl of an anti-CD9 monoclonal antibody (clone MM2/57, 
Chemicon International, London, UK). Thereafter beads were incubated by rotation 
top end over with 20 µg of exosomes for 1 h at 4 °C. After washing four times, beads 
and exosomes were resuspended in PBS for further experiments.
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Electron microscopy of isolated exosomes
Exosomes from PC346C obtained after ultracentrifugation of cell culture 
supernatants were resuspended in 10 µl of Milli-Q and spotted onto Formvarcoated 
grids (200 mesh). Adsorbed exosomes were fixed in 2% paraformaldehyde for 5 min 
at room temperature. After fixation the exosomes were either directly negatively 
stained using uranyl acetate or immunolabeled with antibodies against CD9 (clone 
MM2/57, Chemicon International). Antigen-antibody complexes were visualized 
with protein A conjugated with 10-nm colloidal gold particles (1:20 dilution; Aurion, 
Wageningen, The Netherlands) followed by negative staining (see above). The 
specificity of the labelling procedure was tested by omitting the primary antibody. 
Grids were examined by a Philips CM100 electron microscope at 80 kV.
Mass spectrometry of exosomes
After resuspending the exosome pellet in PBS, 10 µg of isolated exosomes and 
10 µg of supernatant fraction were applied onto two 10% SDS-polyacrylamide 
gels. After running, one of the gels was silver-stained as described previously by 
Mortz et al.136. This gel was used to identify distinct bands present in the exosome 
fraction (see Figure 4b). Subsequently these bands were excised from a Coomassie 
Brilliant Blue (Merck)- stained gel and cut in 3-mm sections. Preparation for mass 
spectrometry was performed using the protocol described under “Preparation 
of Xenograft Sera for Mass Spectrometry”. Peptide separation was performed on 
a nanoscale liquid chromatography system (nanoLC Ultimate 3000) (Dionex, 
Sunnyvale, CA) with a 50-min gradient (5–40% acetonitrile, H2O, 0.1% formic acid). 
The injection volume was 5 µl of the tryptically digested sample. Peptides were 
separated on a C18 PepMap column (150 mm 75 μm inner diameter) (Dionex) at 
200 nl/min after preconcentration on a trap column (1 mm 300 μm inner diameter). 
Separated peptides were detected by a linear ion trap Orbitrap (LTQ-Orbitrap) 
mass spectrometer (Finnigan LTQ Orbitrap XL, Thermo Electron). Samples were 
measured in a data-dependent acquisition mode. In the measurement method used, 
the peptide masses are measured in a survey scan at a maximum resolution of 60,000. 
To obtain a maximum mass accuracy a prescan is used to keep the ion population 
in the Orbitrap for each scan approximately the same. During the high resolution 
scan in the Orbitrap the five most intense monoisotopic peaks in the spectra were 
fragmented and measured in the LTQ. The fragment ion masses were measured in 
the LTQ to have a maximum sensitivity and a maximum amount of MS/MS data. For 
a full analysis of the exosomal proteome, 10 µg of the isolated exosome fraction was 
applied onto a 10% SDS-polyacrylamide gel and run for 1.5 cm inside the running 
gel. Thereafter this gel section was excised and divided into 3-mm sections, 
washed, destained (100% acetonitrile followed by 50 mM ammonium bicarbonate), 
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dehydrated (100% acetonitrile), and reduced with 6.5 mM DTT in 50 mM ammonium 
bicarbonate for 45 min at 60 °C. After alkylation with 54 mM iodoacetamide in 50 mM 
ammonium bicarbonate, proteins were dehydrated in 100% acetonitrile and then 
rehydrated with the digestion solution containing 10 ng/l ultra grade sequencing 
trypsin (Promega) for 30 min on ice. After removal of the redundant trypsin solution 
and addition of 50 mM ammonium bicarbonate solution to cover the gel pieces, gel 
particles were incubated overnight at 37 °C. After extraction, the peptides were 
dissolved in 5% formic acid and stored at -80 °C until analysis. Mass spectrometry 
was performed using the protocol described under “Liquid Chromatography-Mass 
Spectrometry of Xenograft Sera.” For protein identification, database searches 
were performed using Mascot version 2.2 (Matrix Science) allowing 5-ppm mass 
deviation for the precursor ion, a 0.6-Da tolerance on the fragment ions, and trypsin 
as the digestion enzyme. A maximum number of one missed cleavage was allowed, 
and carbamidomethylated cysteine and oxidized methionine were set as fixed and 
optional modifications, respectively. All peptide mass values identified in the isolated 
exosomes were searched against the IPI human database (version 3.37, containing 
69,164 proteins). Only peptides with Mascot scores >30 were accepted. Scaffold 
(version 2_01_02, Proteome Software Inc., Portland, OR) was used to validate MS/
MS-based peptide and protein identifications. Peptide identifications were accepted 
if they could be established at greater than 90.0% probability as specified by the 
Peptide Prophet algorithm130. Protein identifications were accepted if they could be 
established at greater than 95.0% probability and contained at least two identified 
peptides. Protein probabilities were assigned by the Protein Prophet algorithm131.
One-dimensional SDS-PAGE analysis and western blotting
For one-dimensional electrophoresis, samples containing 10 µg of protein 
were mixed with Laemmli sample buffer (1:1 ratio) and loaded onto 10% SDS-
polyacrylamide gels. Gels were transferred onto a Protran nitrocellulose membrane 
for Western blotting. The following antibodies were used: CD9 (1:500 dilution; clone 
MM2/57, Chemicon International), RAB5A (1:200 dilution; clone FL-215, Santa Cruz 
Biotechnology, Santa Cruz, CA), RAB11A (1:100 dilution; Invitrogen), hepatocyte 
growth factor-regulated tyrosine kinase substrate (HGS; previously known as 
HRS; 1:500 dilution; Alexis Biochemicals, San Diego, CA), GAPDH (1:500 dilution; 
clone 7B, LabFrontier, Seoul, Korea), ENO1 (1:1000 dilution; clone H300, Santa Cruz 
Biotechnology), 14-3-3 θ (1:1000 dilution; clone 3B9, Calbiochem, San Diego, CA), 
PSA (1:500 dilution; clone A0562, DakoCytomation), proteasome subunits 6, 2, 4, 5, 1, 
and 3 (1:2000 dilution; clone MCP231, Biomol International), PSMA1 (1:1000 dilution; 
clone MCP20, Biomol International), PSMA3 (1:1000 dilution; clone MCP72, Biomol 
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International), and proteasome subunit β1 (PSMB1; β6 according to the Baumeister 
et al.132 nomenclature; Biomol International).
Isolation and analysis of exosomal RNA
Exosomal total RNA was isolated using the RNeasy Mini kit (Qiagen, Hilden, 
 Germany) as described by Valadi et al.128. In short, pelleted exosomes were  disrupted 
and homogenized in 350 µl of buffer RLT (Qiagen), and 1050 µl of 100% ethanol was 
added before samples were transferred to the RNeasy Mini spin column. Hereafter 
the procedure was followed as described by the manufacturer’s protocol.  Analysis of 
RNA expression was performed by RT-PCR. One microgram of exosomal RNA was 
reverse transcribed using Moloney murine leukaemia virus reverse  transcriptase 
(Invitrogen) and an oligo- (dT)12 primer. Primer combinations used were as  follows: 
PSA-4A (5-ACGTGTGTGCAAGTTCACC-3) and PSA-5B (5-TGTACAGGGAA-
GGCCTTTCG- 3), TMPRSS2-E1 (5-AGCGCGGCAGGAAGCCTTA- 3) and ERG-R 
(5-GTAGGCACACTCAAACAACGACTGG-3), and GAPDH 462U17 (5-CATGT-
TCGTCATGGGTG-3) and GAPDH 589L20 (5-ACTGTGGTCATGAGTCCTTC-3). 
PCR was performed for 27 cycles at an annealing temperature of 58 °C.
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results
Identification of 44 tumor-derived proteins in xenografted mice
The selection procedure followed to annotate identified proteins as tumour-derived 
in the circulation of human prostate cancer-xenografted mice is depicted in Figure 1.
After serum collection from control mice (n=9) and PC346 (n=9) and PC339 (n=9) 
xenografted mice, samples were pooled and depleted of high abundance proteins, 
and proteins were separated by one-dimensional gel electrophoresis. Following 
tryptic digestion, peptides were subsequently analysed by LTQ-FT-ICR-MS/MS. 
After data analysis, 44 proteins were identified as tumour-derived (at greater than 
95.0% probability and with two or more identified peptides) (Table 1). Of those, 
22 were annotated as cytoplasmic proteins by the Gene Ontology database. The 
cytoplasmic proteins contained 12 of the subunits of the proteasome of which seven 
were identified based on the presence of human-specific peptides in the serum of 
xenograft-bearing mice.
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(control / PC346 / PC339)
(n=14.254)
peptides uniquely present in PC346 
or PC339 xenografted mice
(n=1.221)
IPI human database 
search
IPI mouse database 
search
human specic peptides (i.e. 
peptides only identied in the 
IPI human database)
homologous peptides (i.e. 
present in both the IPI mouse  
and human database) 
xenograft-derived 
proteins
(n=44)
homologous proteins 4 or more  
times higher abundant in PC339  
or PC346 xenografted-mice in 
comparison with control serum
(n=111)
blasting against Swiss-Prot to 
double-check human specicity 
(n=79)
Figure 1. The selection procedure followed to annotate identified proteins as tumour-
derived proteins.
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Table 1. List of 44 proteins annotated as tumour-derived proteins in xenograft-bearing 
mice. Identified peptides were divided into a group of human specific peptides 
(identified only in the IPI human database) and a group of homologous peptides 
(present in both the IPI human and IPI mouse database). Homologous peptides were 
annotated as tumour-derived when 4 or more times higher abundant in the serum 
of PC339 or PC346 xenografted-mice in comparison with control serum. Annotations 
are derived from the Gene Ontology database. Proteins marked with an asterisk have 
earlier been identified by others in isolated exosomes from various origin.
protein name
Gene 
symbol
ipi accession 
no.
human/
homologue
no. of unique 
peptides
% sequence 
coverage Xenograft Molecular function biological process location
14-3-3 protein gamma* yWhAG ipi00230707 homologue 5 20.65 pC339 protein kinase C binding regulation of signal 
transduction
cytoplasm
14-3-3 protein theta* yWhAQ ipi00018146 human 4 15.92 pC339 protein kinase C inhibitor 
activity
regulation of progression 
through cell cycle
cytoplasm
alpha-enolase* enO1 ipi00465248 human 4 26.67 pC339 phosphopyruvate hydratase 
activity
glycolysis cytoplasm
apolipoprotein A-i precursor ApOA1 ipi00021841 human 3 16.24 pC339 lipid binding cholesterol metabolism secreted
cathepsin Z precursor CtsZ ipi00002745 homologue 2 5.61 pC346 cysteine-type peptidase 
activity
proteolysis lysosome
chromosome 20 orf 114 C20orf114 ipi00291410 human 2 4.34 pC346 lipid binding    
coactosin-like protein COtl1 ipi00017704 homologue 2 9.15 pC339 actin binding    
coagulation factor v f5 ipi00406603 homologue 6 3.55 pC339 oxidoreductase activity blood coagulation secreted
cofilin, non-muscle isoform* Cfl1 ipi00012011 homologue 3 21.69 pC339 protein binding cytoskeleton organization 
and biogenesis
cytoplasm
complement component C8 beta chain 
precursor
C8b ipi00294395 homologue 2 5.66 pC339   immune response secreted
cytochrome c CyCs ipi00465315 homologue 2 17.14 pC346/339 heme binding caspase activation via 
cytochrome c
mitochondrion 
matrix
fructose-bisphosphate aldolase A* AlDOA ipi00465439 human/
homologue
11 30.77 pC346/339 fructose-bisphosphate 
aldolase activity
glycolysis  
glutathione peroxidase 3 precursor GpX3 ipi00026199 human 5 23.01 pC339 gluthatione peroxidase 
activity
hydrogen peroxide 
catabolism
secreted
glyceraldehyde-3-phosphate 
dehydrogenase*
GApDh ipi00219018 human 7 25.97 pC346/339 glyceraldehyde-3-phosphate 
dehydrogenase activity
  cytoplasm
inter-alpha (globulin) inhibitor h3 itih3 ipi00028413 homologue 2 3.03 pC346 serine-type endopeptidase 
inhibitor activity
hyaluronan metabolism secreted
junction plakoglobin JUp ipi00554711 homologue 2 2.81 pC339 cytoskeletal protein binding cell adhesion  
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glutathione peroxidase 3 precursor GpX3 ipi00026199 human 5 23.01 pC339 gluthatione peroxidase 
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hydrogen peroxide 
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secreted
glyceraldehyde-3-phosphate 
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GApDh ipi00219018 human 7 25.97 pC346/339 glyceraldehyde-3-phosphate 
dehydrogenase activity
  cytoplasm
inter-alpha (globulin) inhibitor h3 itih3 ipi00028413 homologue 2 3.03 pC346 serine-type endopeptidase 
inhibitor activity
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protein name
Gene 
symbol
ipi accession 
no.
human/
homologue
no. of unique 
peptides
% sequence 
coverage Xenograft Molecular function biological process location
lactate dehydrogenase A* lDhA ipi00217966 human/
homologue
9 21.69 pC346/339 l-lactate dehydrogenase 
activity
anaerobic glycolysis cytoplasm
lactate dehydrogenase b* lDhb ipi00219217 human 10 29.94 pC346/339 l-lactate dehydrogenase 
activity
anaerobic glycolysis cytoplasm
lumican precursor lUM ipi00020986 homologue 2 5.92 pC339 collagen binding collagen fibril 
organization
secreted
lysozyme C precursor lyZ ipi00019038 human/
homologue
4 23.65 pC346/339 lysozyme activity inflammatory response  
maltase-glucoamylase, intestinal* MGAM ipi00220143 human 3 1.18 pC346/339 protein binding carbohydrate metabolism cell membrane
myosin heavy chain, skeletal muscle, 
adult 2
Myh2 ipi00007856 homologue 3 4.94 pC346 actin binding    
myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle 
isoform 1
Myl6b ipi00335168, 
ipi00413922
homologue 3 14.42 pC339 structural component of 
muscle
muscle filament sliding  
nucleoside diphosphate kinase A nMe1 ipi00012048 human/
homologue
6 46.71 pC339 nucleoside diphosphate 
kinase activity
negative regulation of 
cell proliferation
cytoplasm
nucleoside diphosphate kinase b nMe2 ipi00026260 homologue 6 42.76 pC339 nucleoside diphosphate 
kinase activity
negative regulation of 
cell proliferation
cytoplasm
peroxiredoxin-2* pRDX2 ipi00000874, 
ipi00027350
human/
homologue
3 13.13 pC339 thioredoxin peroxidase 
activity
anti-apoptosis cytoplasm
proteasome subunit alpha type 1 psMA1 ipi00472442 human/
homologue
6 24.91 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit alpha type 2 psMA2 ipi00219622 homologue 5 22.64 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit alpha type 4 psMA4 ipi00299155 human 5 17.30 pC339 peptidase activity proteolysis cytoplasm
proteasome subunit alpha type 6 psMA6 ipi00029623 homologue 9 37.80 pC346 peptidase activity proteolysis cytoplasm
proteasome subunit alpha type 7 psMA7 ipi00024175 human 6 21.37 pC339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 1 psMb1 ipi00025019 human/
homologue
7 34.02 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 2 psMb2 ipi00028006 homologue 2 12.44 pC346 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 3* psMb3 ipi00028004 homologue 3 18.05 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 4 psMb4 ipi00556607 human/
homologue
5 17.80 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 5 psMb5 ipi00479306 human/
homologue
10 38.78 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 6 psMb6 ipi00000811 human 3 12.97 pC346/339 peptidase activity proteolysis cytoplasm
proteasome subunit beta type 8 psMb8 ipi00000783 homologue 2 5.88 pC346 protein binding proteolysis cytoplasm
prothrombin precursor f2 ipi00019568 homologue 2 2.25 pC346 thrombin activity regulation of progression 
through cell cycle
secreted
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Gene 
symbol
ipi accession 
no.
human/
homologue
no. of unique 
peptides
% sequence 
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protein name
Gene 
symbol
ipi accession 
no.
human/
homologue
no. of unique 
peptides
% sequence 
coverage Xenograft Molecular function biological process location
splice isoform 1 of Complement factor 
b precursor 
Cfp ipi00639937 homologue 2 4.90 pC346/339 complement binding complement activation secreted
thrombospondin-1 precursor* thbs1 ipi00296099 homologue 7 7.26 pC346/339 signal transducer activity cell motility secreted 
transcobalamin-2 tCn2 ipi00136556 homologue 3 6.09 pC339 cobalamin transporter 
activity
cobalamin transport secreted
triosephosphate isomerase 1 variant * tpi1 ipi00465028 human/
homologue
5 22.09 pC346/339 triose-phosphate isomerase 
activity
glycolysis  
voltage-dependent anion channel 2 vDAC2 ipi00455531 homologue 2 7.77 pC346 voltage-gated anion  
channel porin activity
anion transport mitochondrion 
outer membrane
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Validation and characterization of proteasome 
subunits in xenograft sera
To specify and validate the presence of tumour-derived proteasome subunits in 
the circulation of the xenografted mice, two-dimensional SDS-PAGE analysis of 
xenograft-derived serum samples was performed. Figure 2 shows a comparison 
between serum from control mice (n=3) and serum from PC339 (n=3) and PC346 
(n=3) xenografted mice.
37kD
37kD
37kD
25kD
25kD
25kD
CM
PC346
PC339
4 5 6 7
PSMA3 PSMA1
Figure 2. 2D PAGE Western blotting analysis of depleted serum from control mice 
(CM), PC346 xenograft-bearing mice (PC346), and PC339 xenograft-bearing mice 
(PC339). Spots were detected by using a monoclonal antibody to proteasome subunits 
6, 2, 4, 5, 1, and 3. The presence of PSMA1 and PSMA3 proteasome subunits was 
confirmed with specific monoclonal antibodies. Strong signals are visible in the serum 
from both the PC346 and PC339 mice. Also faint signals were detected in the control 
serum because of crossreactivity with mouse proteasome subunits, which are present 
under normal conditions in the mouse serum.
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Proteasome subunits were detected using a monoclonal antibody directed against 
subunits 6, 2, 4, 5, 1, and 3 of the proteasome. Strong signals were observed in the 
serum from both the PC346 and PC339 xenografted mice. As the proteasome antibody 
recognizes both mouse and human proteasome subunits, also faint signals were visible 
in the control serum that are known to be normally present in the mouse circulation. 
This is in line with the identification of mouse-specific proteasome peptides as 
detected by FT-ICRMS/ MS (data not shown). After stripping, blots were reprobed, 
and two of the spots could be specifically identified in the serum of PC339 and PC346 
xenografted mice as the PSMA1 and PSMA3 subunits by using specific monoclonal 
antibodies directed against these proteins. The identified spots were consistent 
regarding molecular weight and pI with an earlier study performed by Claverol et al.137.
Proteasome subunits are circulating as 
a complex in xenograft sera
To investigate whether the identified proteasome subunits were present as 
proteasome complexes in the serum of xenografted mice, native gel electrophoresis 
of control serum and serum from xenograft-bearing mice was performed. Figure 3a 
shows the presence of high molecular weight proteasome complexes in the 
xenograft sera. In both the 12.5% gel and 3.5% gel high molecular weight complexes 
are visible in the samples that were run under native conditions. After denaturation, 
the high molecular weight complexes disappeared, indicating disintegration into 
single proteasome subunits. The same effect is seen in the endogenous proteasome 
subunits of the control mouse. The presence of intact proteasome complexes was 
also investigated by sandwich ELISA.
Serum samples from control (n=3) and xenograft mice (n=6) were diluted 1:20 and 
analysed in triplicate under native conditions and after denaturation by heating at 
96 °C for 5 min. Proteasome levels (mean ± S.D.) under native conditions in control, 
PC346, and PC339 serum were 10.5 ± 10.6, 32,759 ± 1720.0, and 20,339 ± 5062.2 
ng/ml, respectively. After denaturation, proteasome concentrations (mean ± S.D.) 
decreased to 0.040 ± 0.03, 0.17 ± 0.16, and 0.28 ± 0.10 ng/ml in control, PC346, 
and PC339 serum, respectively (Figure 3b). Because the capture antibody of the 
sandwich ELISA is directed against the 1 subunit (PSMA1) of the proteasome 
whereas the detection antibody is directed against β subunits, this confirms the 
presence of proteasome complexes in the serum of the xenografted mice.
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Electron microscopy of isolated exosomes
A large portion of the cytoplasmic tumour-derived proteins identified in the xenograft 
model has previously been identified as part of the human exosomal protein content. 
To explore the origin of the cytoplasmic proteins identified in the xenograft serum, 
exosomes were isolated from the PC346C cell line. To confirm that the structures 
isolated were indeed exosomes, they were examined by electron microscopy 
(Figure 4a). This showed a homogenous mixture of small bilayer membrane vesicles 
with an average diameter of 140 nm. ImmunoGold labelling of exosomes with an 
antibody to CD9 (Tetraspanin 29), an established marker for tumour cell-derived 
exosomes, showed positive exosome membrane staining (Figure 4a).
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Figure 3. a, native 1D gel electrophoresis of serum from control mice (CM) and 
PC346 or PC339 xenograft-bearing mice showing the presence of intact proteasome 
complexes. High molecular weight complexes are visible under native conditions in 
both 12.5 and 3.5% gels. After denaturation, mostly single subunits are visible in the 
12.5% gel, and the high molecular weight complexes in the 3.5% gel have disappeared. 
Bands were detected by a monoclonal antibody directed against the PSMA1 subunit 
of the proteasome. b, proteasome concentrations in xenograft-bearing mice and 
control mice serum samples under native (left) and denatured (right) conditions 
as measured by sandwich ELISA. After serum denaturation proteasome levels are 
strongly diminished, indicating the existence of proteasome complexes in xenograft 
and control serum samples. Error bars represent standard deviations.
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Figure 4. a, electron microscopy of exosomes isolated from the PC346C cell line. Left, 
electron micrograph of negatively stained exosomes showing a homogenous mixture 
of isolated vesicles; middle, ImmunoGold labelling of exosomes with the exosomal 
marker CD9 (Tetraspanin 29); right, increased magnification of the middle image 
shows positive CD9 membrane staining of exosomes (see arrow). b, separation of 
PC346C cell-derived exosomal proteins by 1D SDS-PAGE followed by silver staining. 
The indicated protein bands were excised and identified by LTQ-Orbitrap.
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Proteomics analysis of exosomes
Supernatant and exosome fractions of the PC346C cell line were separated by 1D 
SDS-PAGE followed by silver staining (Figure 4b). The exosome fractions showed 
several distinct bands, which were absent in the supernatant fraction. Several bands 
were excised and subjected to LTQ-Orbitrap mass spectrometry (MS/MS) leading 
to the identification of five proteins: programmed cell death 6 protein (PDCD6IP; 
10 unique peptides, 10.65% sequence coverage), poly(A)-binding protein 1 (PABC1; 
12 unique peptides, 18.71% sequence coverage), eukaryotic translation elongation 
factor 1 α 1 (EEF1A1; three unique peptides, 6.28% sequence coverage), α-actin-2 
(ACTA2; 13 unique peptides, 45.62% sequence coverage), and syndecan-binding 
protein (syntenin; four unique peptides, 14.77% sequence coverage). An in-depth 
proteomics analysis of the whole exosome fraction was performed by LTQ-FT-ICR-
MS/MS. A total of 48 unique proteins were discovered in the exosome fraction of 
the PC346C cell line at a protein identification probability of 99% and 2 peptides 
per protein (Table 2). At a protein probability of 99% and 1 peptide per protein 126 
proteins were identified. Among those proteins identified with two or more peptides 
per protein were two of the proteins that had earlier been identified in the serum of 
xenograft-bearing mice (GAPDH and lactate dehydrogenase B)124. Also the presence 
of the exosomal marker CD9 and the prostate-specific protein folate hydrolase 1 
(FOLH1; prostate-specific membrane antigen) were confirmed. ENO1 and fructose-
bisphosphate aldolase A, also previously identified in the serum of xenograft-bearing 
mice, were positively identified at a probability of one peptide per protein (data not 
shown). All proteins identified in the specific exosome bands but ACTA2 (Figure 4b) 
were also recovered in the in-depth proteomics analysis.
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Table 2. List of 48 proteins identified by two or more peptides in the exosome fraction of 
the PC346C cell line. Annotations are derived from the Gene Ontology database. 
protein name
Gene 
symbol
protein 
accession 
numbers
no. of 
unique 
peptides
% sequence 
coverage Molecular function biological process location
Actin, gamma 1 ACtG1 ipi00021440 15 40.30 structural constituent of cytoskeleton cell motility cytoplasm
ADAM metallopeptidase domain 10 ADAM10 ipi00013897 3 3.88 protein homodimerization activity protein amino acid 
phosphorylation
cell membrane
ADAM metallopeptidase domain 15 ADAM15 ipi00013302 4 6.39 proteolysis and peptidolysis cell adhesion cell membrane
Annexin A2 AnXA2 ipi00418169 7 24.90 phospholipase inhibitor activity skeletal development secreted protein
Annexin A6 AnXA6 ipi00002459 3 7.20 calcium ion binding    
Atpase, na+/k+ transporting, alpha 1 
polypeptide
Atp1A1  ipi00006482 5 5.96 sodium:potassium-exchanging Atpase 
activity
sodium ion transport cell membrane
brain abundant, membrane attached 
signal protein 1
bAsp1 ipi00299024 4 40.10     cell membrane
Chromosome 1 open reading frame 58 C1orf58 ipi00065500 2 10.70      
Capping protein (actin filament) muscle 
Z-line, alpha 1
CApZA1 ipi00005969 2 7.69 actin binding cell motility  
CD151 molecule (tetraspanin 24) CD151 ipi00298851 2 5.93 protein binding cell adhesion cell membrane
CD2-associated protein CD2Ap ipi00412771 6 11.60 structural constituent of cytoskeleton cell migration cytoplasm
CD9 molecule CD9 ipi00215997 3 15.40 protein binding cell motility cell membrane
Chromatin modifying protein 4b ChMp4b  ipi00025974 2 8.93     cytoplasm
Clathrin, heavy chain 1 CltC ipi00024067 10 6.81 signal transducer activity receptor-mediated 
endocytosis
cell membrane
eukaryotic translation elongation factor 
1 alpha 1
eef1A1 ipi00396485 14 37.20 translation elongation factor activity translation elongation cytoplasm
eh domain-containing protein 1 ehD1 ipi00017184 2 5.06 Atp binding   cell membrane
f11 receptor f11R ipi00001754 5 16.40   cell motility cell membrane
family with sequence similarity 125, 
member A 
fAM125A ipi00744702 3 16.10     cytoplasm
formin binding protein 1-like fnbp1l  ipi00015580 2 3.47     cytoplasm
folate hydrolase (prostate-specific 
membrane antigen) 1
fOlh1 ipi00028514 7 12.30 dipeptidase activity proteolysis cell membrane
Glyceraldehyde-3-phosphate 
dehydrogenase
GApDh ipi00219018 3 14.00 glyceraldehyde-3-phosphate dehydrogenase 
activity
glycolysis cytoplasm
histone cluster 1, h1c hist1h1C ipi00217465 2 10.30 DnA binding nucleosome assembly nucleus
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protein name
Gene 
symbol
protein 
accession 
numbers
no. of 
unique 
peptides
% sequence 
coverage Molecular function biological process location
histone cluster 1, h2ab hist1h2Ab  ipi00026272 2 21.50 DnA binding nucleosome assembly nucleus
heat shock protein 90kDa alpha 
(cytosolic), class b member 1
hsp90Ab1 ipi00334775 4 6.49 unfolded protein binding response to unfolded protein cytoplasm
heat shock 70kDa protein 1b hspA1b  ipi00807640 6 16.50 unfolded protein binding anti-apoptosis cytoplasm
heat shock 70kDa protein 8 hspA8 ipi00003865 13 25.50 Atpase activity protein folding cytoplasm
immunoglobulin superfamily, member 8 iGsf8  ipi00056478 6 12.60 protein binding cell motility cell membrane
integrin beta-1 itGb1 ipi00217563 3 3.89 protein heterodimerization activity cell migration cell membrane
lactate dehydrogenase b lDhb ipi00219217 2 7.78 l-lactate dehydrogenase activity anaerobic glycolysis cytoplasm
Milk fat globule-eGf factor 8 prot MfGe8 ipi00002236 2 4.91   cell adhesion cell membrane
poly(A) binding protein, cytoplasmic 1 pAbpC1  ipi00008524 16 25.90 translation activator activity mRnA stabilization cytoplasm
poly(A) binding protein, cytoplasmic 4 pAbpC4 ipi00555747 5 18.40 protein / RnA binding RnA processing cytoplasm
protein kinase C and casein kinase 
substrate in neurons 2
pACsin2 ipi00027009 4 8.85 transporter activity intracellular protein 
transport
cytoplasm
poly(rC)-binding protein 2 pCbp2 ipi00012066 2 7.46 protein / RnA binding mRnA metabolic process cytoplasm
programmed cell death 6 interacting 
protein
pDCD6ip  ipi00246058 21 22.40 signal transducer activity apoptosis cytoplasm
prostaglandin f2 receptor negative 
regulator
ptGfRn  ipi00022048 7 9.33 protein binding negative regulation of 
protein biosynthetic process
cell membrane
Ribosomal protein s27a Rps27A ipi00179330 5 31.40 structural constituent of ribosome translation cytoplasm
syndecan binding protein (syntenin) sDCbp ipi00299086 3 15.10 protein heterodimerization activity cell migration cell membrane
serine incorporator 5 seRinC5 ipi00328883 2 4.97     cell membrane
sh3-domain GRb2-like 1 sh3Gl1  ipi00019169 8 23.60 protein binding signal transduction cell membrane
solute carrier family 3, member 2 slC3A2  ipi00027493 2 5.48 catalytic activity amino acid transport cell membrane
sphingomyelin phosphodiesterase, acid-
like 3b
sMpDl3b  ipi00550115 2 4.73 hydrolase activity carbohydrate metabolism secreted protein
sorting nexin-9 snX9 ipi00001883 2 5.38 protein binding protein localization  
tumor-associated calcium signal 
transducer 1 
tACstD1 ipi00296215 5 21.30     cell membrane
tumor susceptibility gene 101 protein tsG101 ipi00018434 7 21.30 transcription corepressor activity regulation of cell growth cytoplasm
tubulin, beta tUbb ipi00011654 3 7.43 structural constituent of cytoskeleton spindle assembly  
vacuolar protein sorting 37 homolog b vps37b  ipi00002926 3 10.20      
tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
zeta polypeptide
yWhAZ ipi00021263 5 22.90 transcription factor binding signal transduction cytoplasm
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Figure 5. a, 1D PAGE and Western blotting analysis comparing the exosome and 
supernatant fractions of the PC346C cell line for CD9, the members of the RAS 
oncogene family RAB5A and RAB11A, HRS, GAPDH, ENO1, YWHAQ (14-3-3 protein θ), 
proteasome subunits, and PSA. CD9, RAB5A, RAB11A, HRS, GAPDH, and YWHAQ 
were uniquely identified in the isolated exosomes, whereas PSA could only be detected 
in the supernatant of the PC346 cell line. b, 1D PAGE and Western blotting analysis 
of the exosome fraction after purification with magnetic beads. This figure shows 
that the CD9 and proteasome β1 (PSMB1) signals are visible in the exosome fraction 
both before and after purification with magnetic beads, indicating that proteasome 
subunits are present inside exosomes or exosomal membranes.
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Analysis of exosomes by one-dimensional SDS-PAGE analysis
One-dimensional SDS-PAGE and Western blotting were performed to verify the 
presence in exosomes of several proteins previously identified by LTQ-FT-ICR-
MS/MS in the xenograft model. CD9, RAB5A, RAB11A, HRS, GAPDH, and 14-3-
3 protein θ (YWHAQ) were uniquely present in the isolated exosome fraction and 
could not be detected in the PC346C cell line supernatant, whereas α-enolase 
(ENO1) and subunits of the proteasome were present in both fractions. PSA was 
uniquely present in the supernatant fraction and could not be detected in the 
isolated exosomes (Figure 5a). To certify that the proteasome subunits present in 
the exosome fraction were not the result of simultaneous pelleting of exosomes and 
proteasome complexes during ultracentrifugation, exosomes were further purified 
by magnetic beads coated with a CD9 antibody. After exosomal purification, bead-
exosome complexes were loaded onto one-dimensional SDS-polyacrylamide gels. 
Blots were incubated with a monoclonal antibody to CD9 (Chemicon International) 
or a polyclonal antibody against the PSMB1 subunit of the proteasome. Figure 5b 
shows that both the CD9 and PSMB1 subunit signals are visible in the exosome 
fraction as well as in the immunobead-purified exosome fraction.
Analysis of exosomal RNA
As the PCa-specific TMPRSS2:ERG gene fusion is expressed in the majority of PCa 
patients, we analysed exosomes for the presence of the gene fusion product70,138. 
RNA was isolated from PC346C and VCaP cells and analysed by RT-PCR. Both cell 
lines express PSA, whereas the TMPRSS2:ERG gene fusion is only present in VCaP 
and not in PC346 cells138. KLK3 (PSA) and GAPDH RNAs were present in both VCaP 
and PC346C exosomes as well as in the total RNA fraction from both cell lines. The 
gene fusion product TMPRSS2:ERG was only detected in VCaP exosomes and in the 
VCaP cell line and was not detected in PC346C-derived exosomes and the PC346C 
cell line (Figure 6).
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Figure 6. RT-PCR analysis of VCaP and PC346C cell lines and exosomes. 
The TMPRSS2:ERG fusion gene is exclusively expressed in both the VCaP cell line and 
exosomes, whereas both cell lines and exosomes express KLK3 (PSA) and GAPDH. 
H2O and RT controls were negative (data not shown).
Discussion
The present study shows the identification of 44 tumour-derived proteins by mass 
spectrometry in xenograft models for PCa. Virtually all subunits of the proteasome 
were among the proteins identified, a finding that was verified by two-dimensional 
gel electrophoresis of xenograft-bearing and control mouse sera. Several of these 
proteasome subunits are part of the normal human plasma proteome as was shown 
by the Human Proteome Organisation Plasma Proteome Project125. Increased 
proteasome levels have been related to haematological malignancies, especially 
multiple myeloma139, but also to solid tumours, such as melanoma and colon 
carcinoma140. Recently Byrne et al.141 identified the proteasome β6 subunit in a 
proteomics analysis of serum from patients with PCa. Abnormal gene expression of 
proteasome subunits has been reported in several cancer types139,142. High plasma 
proteasome levels reflect the dysregulation of protein synthesis and degradation in 
cancer cells in contrast to normal cells in which the proteasome complex plays a 
crucial role in controlling essential cellular functions such as transcription, stress 
response, cell cycle regulation, cellular differentiation, and DNA repair143. This is 
also illustrated by the fact that in malignancies proteasome inhibitors induce 
apoptosis, have in vivo antitumour efficacy, and sensitize malignant cells for 
conventional therapies143. The secretion mechanism of circulating proteasomes in 
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cancer patients and healthy donors is still unknown. Elevated proteasome 
concentrations in culture media of human leukemic cell lines have been reported, 
suggesting a proteasome secretion mechanism by tumour cells144. In this study, we 
have shown, using native gel electrophoresis and sandwich ELISA of sera from 
xenografted and control male mice, that at least part of the circulating proteasome 
subunits are present as proteasome complexes. This is in line with the observation 
that circulating proteasomes are intact and enzymatically active in plasma from 
healthy donors and patients with autoimmune disease or leukaemia145,146. About half 
of the tumour-derived proteins circulating in the xenograft-bearing mice, including 
proteasome subunits, are not secreted proteins but are annotated as being 
cytoplasmic. One possible explanation for their presence could be the occurrence of 
necrosis or apoptosis in the xenografts, a well known characteristic of most cancers. 
Although we did not find evidence for necrosis in the xenografts used for this study, 
protein secretion via cell death cannot be excluded. Microarray expression data of 
the identified cytoplasmic proteins showed that these indeed corresponded to genes 
that are highly expressed in PCa. However, none of the proteins of the 100 most 
highly expressed genes in PCa (such as ribosomal and cytoskeletal genes) have 
been identified in the circulation of the xenograft-bearing mice (data not shown). 
One would expect to detect the proteins of these highly expressed genes if these are 
the result of tumour apoptosis. Although this does not rule out the contribution of 
apoptosis or necrosis, this points toward certain specific processes responsible for 
the secretion of cytoplasmic proteins. We hypothesized that one such specific 
process could be the secretion of proteins via exosomes. A literature search revealed 
that 13 of the 44 (30%) identified proteins in the xenograft model had earlier been 
identified in exosomes among which was also the β3 subunit of the proteasome 
(Table 1). First, we showed that the human PCa cell line PC346C is indeed capable 
of the secretion of exosomes (Figure 4a). Second, LTQ-FT-ICR-MS/MS and Western 
blotting analyses of isolated exosomes showed the presence of mainly cytoplasmic 
proteins, including GAPDH, fructose-bisphosphate aldolase A, ENO1, lactate 
dehydrogenase B, 14-3-3 protein θ, and proteasome subunits (see Table 2 and Figure 
5a). Also the exosomal marker CD9 and several proteins up-regulated in PCa, among 
which was FOLH1, were identified. In addition RAB5A, RAB11A, and HRS, proteins 
involved in vesicular and endosomal trafficking, were present in the exosome 
fraction as shown by Western blotting (Figure 5a). The detection of HRS by Western 
blotting confirmed the identification of HRS by LTQ-FT-ICR-MS/MS at a setting of 
one peptide per protein (data not shown). To argue against the fact that the 
proteasome signal in the exosome fraction was the result of simultaneous pelleting 
of exosomes and proteasome complexes, exosomes were further purified by 
immunoaffinity precipitation utilizing anti-CD9 antibody-coated magnetic beads. 
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This strengthened our finding that proteasomes are present inside exosomes and/or 
tightly associated with exosomal membranes or external macromolecules. Our 
observation is in agreement with Almeida et al.147 and Dong et al.148 who showed the 
presence of proteasomes in late endosomes from which exosomes are formed by 
invagination and budding. To our knowledge, the present study is the first to 
describe a specific clearance mechanism for proteasome subunits in cancer cells, 
providing a possible explanation for the increased proteasome serum levels that 
have been observed in several types of cancer patients. An important observation is 
that PSA was not detectable in the exosome pellets but was abundant in the 
supernatant. This means that we experimentally separated protein secretion via 
two different secretion pathways: (i) the typical secretion of signal peptide-
containing proteins via the rough endoplasmic reticulum and Golgi apparatus 
secretory pathway and (ii) the multivesicular body-exosome secretion route. This is 
in line with our observation that of a total of 48 proteins identified in the exosome 
fraction the majority are annotated as cytoplasmic whereas only two proteins are 
annotated as secreted according to the Gene Ontology database. In contrast, 10 of 
44 tumour-derived proteins identified in the serum of xenograft-bearing mice are 
annotated as secreted proteins (Tables 1 and 2). Thus, it seems that several of the 
cytoplasmic proteins, including proteasome subunits, present in xenograft sera are 
at least partly secreted via the exosome pathway in contrast with proteins such as 
PSA that are typically secreted via the Golgi consecutive secretory pathway. The 
putative in vivo analogues of exosomes could be prostasomes, secreted vesicles in 
human seminal fluid, secreted by epithelial prostate cells. Proteomics analysis of 
human prostasomes revealed 139 proteins, showing a small overlap (7 of 139) with 
the proteins identified in exosomes in the present study. Among the proteins 
identified in prostasomes were several glycolysis-related enzymes, heat-shock 
proteins, and proteins of the annexin family149. In contrast, no proteasome subunits 
or members of the tetraspanin family were identified in prostasomes isolated from 
seminal fluid. It was recently reported by Valadi et al.128 that exosomes not only 
contain proteins but also mRNAs, suggesting a potential novel mechanism of 
genetic exchange between cells. By RNase and trypsin treatment of the isolated 
exosomes it was confirmed that the mRNA was indeed confined within exosomes 
and not on external structures or macromolecules. This prompted us to isolate 
exosomal RNA from the PC346C and VCaP cell lines. Of these cell lines it has been 
shown that the VCaP cell line expresses the TMPRSS2:ERG fusion gene, whereas 
PC346C does not70,138. RT-PCR analysis correctly showed that the PCa-specific 
TMPRSS2:ERG fusion gene is present in exosomal RNA from the VCaP cell line 
whereas it is absent in exosomal RNA from the PC346C cell line. As it has been 
reported that exosomes exist in human serum, prostate-specific proteins present in 
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the membrane of exosomes, such as FOLH1, could be used to isolate prostate-
specific exosomes to discover and validate new markers for PCa150. For example, this 
could lead to the development of a serum test for RNA transcribed from the 
TMPRSS2:ERG gene fusion. The specific role of exosomes in cancer is still not fully 
understood, and involvement in processes such as cell-cell communication and 
antigen representation has been suggested126-128. The content of exosomes may 
represent a fingerprint of the cytoplasm of the cancer cell and may establish a 
unique environment that allows for the occurrence of specific processes. For 
example, Stoeck et al.151 showed that exosomes may be a platform for ectodomain 
shedding of transmembrane proteins. In the present study, the presence of a distinct 
30-kDa ENO1 band specifically present in the exosome fraction may point toward 
the occurrence of unique proteolytic activity inside exosomes (Figure 5a). It has 
recently been suggested that exosomes secreted from cancer cells support immune 
escape as well as tumour growth127. Also exosomes have been reported to induce 
angiogenesis and to transfer metastatic activity from highly to poorly metastatic 
tumour cells152. Of the proteins identified in the exosomes in the present study, 
CD151 and the metalloproteinases ADAM10 and ADAM15 have been linked to 
tumour invasiveness and prognosis153-155. The proteasomes identified in exosomes 
may harbour a similar function. In conclusion, the present study shows that, 
although their function is unclear, exosomes offer unique possibilities for PCa 
biomarker discovery as they give insight information about the interior of the cancer 
cell both on the protein and RNA levels. Future studies will focus on the validation 
of several identified exosomal proteins as well as on the detection of exosomal RNA, 
including the TMPRSS2:ERG and other gene fusion transcripts in exosomes isolated 
from patient populations, to establish new biomarkers for PCa diagnosis and 
prognosis.
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abstract
This study describes a novel xenograft-based biomarker discovery platform 
and proves its usefulness in the discovery of serum markers for prostate cancer. 
By  immunizing immuno-competent mice with serum from nude mice bearing 
prostate cancer xenografts, an antibody response against xenograft-derived 
antigens was elicited. By probing protein microarrays with serum from immunized 
mice, several prostate cancer-derived antigens were identified, of which a subset 
was successfully retrieved in serum from mice bearing prostate cancer xenografts 
and prevalidated in human serum samples of prostate cancer patients. Among the 
discovered and validated proteins were the members of the TAM receptor family 
(TYRO3, AXL, and MERTK), ACY1, and PSMA1. In conclusion, this novel method 
allows for the identification of low abundant cancer-derived serum proteins, 
circumventing dynamic range and host-response issues in standard patient cohort 
proteomics comparisons.
introduction
For several decades, prostate specific antigen (PSA) is the “gold standard” biomarker 
for the detection of prostate cancer (PCa)13. However, additional biomarkers are 
urgently needed, as PSA lacks diagnostic specificity and prognostic value, causing 
an enormous increase in unnecessary biopsies and overtreatment of low-risk PCa 
patients26. A possible approach to discover new serum-shed markers for PCa is by 
screening large series of human serum samples for tumour-associated proteins. 
However, this approach is hampered by the large variability and complexity of 
protein content, with a vast dynamic range in protein concentrations (>1010) and 
dominance of a small number of high abundant proteins that constitute 99% of 
the entire protein content, masking the detection of other proteins107. Due to these 
high abundant proteins and unequal protein concentrations, current technologies, 
capable of analyzing protein concentrations spanning four orders of magnitude, 
can only detect proteins ranging over two orders of magnitude, missing the lower 
abundant proteins (such as PSA) which are likely to constitute the next generation 
of biomarkers. In general, studies exploiting this approach so far have only reported 
changes in relatively abundant and/or acute phase proteins156-159.
To evade these dilemmas, xenograft model systems have been exploited to 
discover new biomarkers, by comparing serum of tumour-bearing with serum of 
non-tumour-bearing mice124,160,161. Although more specific and with less variability, 
this approach is still hampered by serum protein complexity and with standard 
liquid chromatography mass spectroscopy (LC-MS) technology will only result in 
detection of high abundant proteins.
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In analogy to previous efforts to detect tumour-associated markers, we also 
utilized the highly sensitive and specific mouse immune system by developing a 
xenograft-based biomarker discovery platform, in which immuno-competent mice 
are immunized with serum from PCa xenograft-bearing nude mice (Figure 1)162. 
As the donor and recipient mice are congenic, human PCa-derived proteins will 
generate immunoglobulin biomarkers. After an initial verification of the immune 
response, a protein microarray based approach was utilized to profile the antibody 
production and identify PCa xenograft-derived antigens. Subsequently, several 
identified candidate biomarkers were pre-validated on serum samples of men with 
and without PCa.
Human xenograft PC346 or PC339
Athymic nude mouse (nu-/-) Immuno-competent mouse (nu-/+)
Serum with xenograft-
derived proteins
Immunize (+ boost)
Serum with antibodies 
against xenograft-
derived proteins
Antigen 
identication by 
protein microarray
ELISA validation of identied 
antigens in serum of xenograft-
bearing mice and humans
Human serum samples
Figure 1. Study outline.
Antibodies against xenograft-derived proteins were generated after immunization of 
immuno-competent mice with serum from nude mice harbouring human PCa xenografts. 
A large scale identification of generated antibodies was performed by utilizing protein 
microarrays. Identified xenograft-derived antigens were validated in serum of xenograft-
bearing mice and in human serum samples of men with and without PCa.
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methods
Immunization protocol
An overview of the animal experiments is given in Figure 1. Human PCa xenografts 
were grown in immune-incompetent athymic male nude (nu/nu) BALB/c mice 
(n=3 for each xenograft, Taconic, Ry, Denmark)123,124. We utilized the human PCa 
cell lines PC346 (androgen-sensitive) and PC339 (androgen-independent). Specific 
characteristics of both cell lines have been described previously129. Prior to tumour 
inoculation, control serum was collected by retro-orbital punction. Tumour-bearing 
mice were sacrificed when tumours reached a volume of 500-700 mm3 and blood was 
collected (annotated as PC346 mouse serum and PC339 mouse serum, respectively). 
A portion of the collected serum was depleted from high-abundant serum proteins. 
A portion of the collected serum was depleted from high-abundant serum proteins 
utilizing Multi Affinity Removal Spin Cartridges (Agilent Technologies, Wilmington, 
DE, USA) according to manufacturer’s instructions. Depleted serum samples were 
concentrated on 5 kDa cut off ultracentrifugation columns (Agilent Technologies, 
Wilmington, DE, USA). All samples were stored at -80°C.
Ten immuno-competent male nude (nu/+) BALB/c mice were immunized with 
pools (n=3) of either depleted control serum (two mice, annotated as control boost), 
depleted PC346 serum (three mice, annotated as PC346 boost depleted), depleted 
PC339 serum (three mice, annotated as PC339 boost depleted), full PC346 serum (one 
mouse, annotated as PC346 boost full) or full PC339 serum (one mouse, annotated 
as PC339 boost full). Prior to immunization, preimmune serum was collected. For 
immunization, mice were subcutaneously injected with 100 µl of a mixture of 10 µg 
serum and 50 µl complete Freund’s adjuvant. After 3 weeks a boost-immunization 
was performed with a mixture of 10 µg serum and 50 µl incomplete Freund’s 
adjuvant. After 6 weeks a second boost-immunization with full serum derived from 
PC346 or PC339 bearing mice was performed in two mice previously immunized 
with either depleted PC346 or PC339 serum (annotated as PC346 depleted-full or 
PC339 depleted-full, respectively). Four weeks after the last boost-immunization, 
mice were sacrificed and serum was collected. The protocol was approved by the 
Animal Experiments Committee under the national Experiments on Animals Act 
(DEC EUR 310; OZP102-04-03 and EUR 593; OZP102-05-12) and adhered to the rules 
laid down in this national law that serves the implementation of “Guidelines on 
the protection of experimental animals” by the council of Europe under Directive 
86/609/EC.
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Mouse serum concentration
For several experiments, 15 times concentrated mouse serum was utilized. This 
was obtained by concentration of 4,5 mL of either pooled control mouse serum or 
serum from mice inoculated with a PC346 or PC339 xenografts. Concentration was 
performed on 5 kDa cut off ultracentrifugation columns (Agilent Technologies). All 
samples were stored at -80°C.
One-dimensional SDS-PAGE analysis and western blotting
For one-dimensional electrophoresis 10 µg of PC346 and LNCaP cell line protein 
extracts was mixed with Laemmli sample buffer (1:1 ratio) and loaded onto a 10% 
SDS-PAGE gel163. Gels were transferred onto a Protran nitrocellulose membrane for 
western blotting. Blots were developed with 1:250 diluted serum samples derived 
from either control mice or mice immunized with serum from mice bearing PC346 or 
PC339 xenografts. Blots were exposed for equal amounts of time.
Measurement of serum PSA concentrations 
and detection of antibodies against PSA
From each mouse utilized in the immunization protocol (normal nude mice, and 
mice grafted with a PC339 or PC346 xenograft) 10 µl of serum was taken to measure 
serum PSA concentrations. PSA concentrations were determined by routine clinical 
chemistry applying the Access Hybritech Total PSA assay (Beckman-Coulter, Inc., 
Fullerton, CA) which has a lower detection limit of 0.10 ng/ml.
To detect antibodies directed against PSA in mice immunized with serum from mice 
inoculated with a PC346 or PC339 xenograft, 96-well plates were coated with 300 ng 
of purified PSA (Sigma-Aldrich, Milan, Italy) diluted in 0.1 M carbonate-bicarbonate 
buffer (pH 9.5) and incubated overnight at 4ºC. After washing with PBS-Tween 
(0.05%), plates were blocked for 1 hour by addition of a 1% BSA/PBS-Tween (0.05%) 
solution and incubated at 37 ºC. Thereafter, serum samples diluted in PBS-Tween 
were added and incubated for 1 hour at 37 ºC. As a reference standard, a dilution 
of a polyclonal rabbit antibody directed against PSA (DakoCytomation, Glostrup, 
Denmark) was utilized. Then, a 1:5,000 solution in 0.5% BSA/PBS-Tween of HRP 
conjugated goat anti-rabbit IgG or goat-anti mouse antibody (DakoCytomation) was 
added and samples were incubated for 1 hr in the dark. To reveal HRP activity, 50 
mM phosphate / 25 mM citrate buffer, pH 5.0 containing 4 mM o-phenylenediamine 
and 0.0015% H2O2 was added to the wells. After 15 min, the reaction was stopped 
with 2.5 M sulphuric acid. Absorbance values were measured at 492 nm and PSA 
antibody levels determined as compared to the dilution series of the commercial 
PSA polyclonal rabbit antibody reference. All samples were measured in duplo.
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Detection of antibodies against human 
PCa xenograft-derived antigens
For immune response profiling of immunized mice ProtoArrays were utilized (Human 
Protein Microarray version 4.0, Invitrogen Life Technologies, Carlsbad, CA). The 
4.0 version contains approximately 8,000 unique human proteins immobilized on 
a hydrophobic surface. Proteins are expressed as GST fusion proteins, purified and 
double spotted within distinct subarrays with a number of assay-specific positive 
and negative controls. ProtoArrays were developed according to the protocol of the 
manufacturer. In short, after blocking, arrays were incubated with serum 1:500 
diluted in PBS with 1% BSA and 0.1% Tween. ProtoArrays were developed using 
two pools both consisting of two serum samples obtained prior to immunization 
(annotated preimmune (1) and (2)), a pool of two serum samples obtained from mice 
immunized with depleted serum from mice without a xenograft (control boost), two 
serum samples obtained from mice immunized with depleted serum from mice 
carrying either a PC346 or PC339 xenograft (PC346 depleted and PC339 depleted, 
respectively), two serum samples obtained from mice immunized with full serum 
from mice carrying either a PC346 or PC339 xenograft (PC346 full and PC339 full, 
respectively), and two serum samples obtained from mice immunized with depleted 
and full serum from mice carrying either a PC346 or PC339 xenograft (annotated 
as PC346 depleted-full and PC339 depleted-full, respectively). After 90 minutes at 
4ºC, arrays were washed and incubated with Alexa Fluor 647 conjugated rabbit 
anti-mouse IgG (H+L) (Invitrogen) 1:2,000 diluted in PBS-Tween with 1% BSA for 
90 minutes at 4°C. As a control, one ProtoArray was developed without serum 
incubation utilizing only the Alexa Fluor 647 conjugated rabbit anti-mouse IgG 2nd 
antibody. After washing, arrays were dried and immediately scanned in a ScanArray 
Express HT (Perkin Elmer, The Netherlands). Spot intensities were quantified using 
Prospector Imager (version 4.0, Invitrogen) and ProtoArray Prospector (version 4.0.0, 
Invitrogen). Spot signals were normalized per mean array intensity. Spots were 
sorted based on their preferential expression in mice immunized with serum from 
xenograft-bearing animals vs. their expression in preimmune serum and serum 
from mice immunized with serum from non-xenograft bearing mice. Spots with a 
normalized expression value of >6 in either the preimmune (1), preimmune (2) or 
control boost samples were excluded as well as spots with a normalized expression 
<2 in mice immunized with serum from xenograft-bearing animals. The normalized 
expression value of one of the spots developed with serum from xenograft-bearing 
animals was set to exceed a value of three. The ProtoArray data discussed in this 
publication are MIAME (Minimum Information About a Microarray Experiment) 
compliant, have been deposited in NCBI’s Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE16220 (http://www.ncbi.nlm.
nih.gov/geo/).
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Patient samples
Serum samples of men without PCa were obtained from the biorepository of 
the Rotterdam arm of the ERSPC164. The medical ethical committee of the 
Erasmus University Medical Centre approved the ERSPC study (MEC number 
138.741/1994/152). All participants provided written informed consent. To exclude 
the presence of PCa in these men (n=40), PSA serum concentrations had to be below 
0.4 ng/ml and no tumour had to be detected after transrectal ultrasound-guided 
needle biopsy (≥6 cores). To ensure the absence of PCa, men without PCa were 
only selected if there was no evidence of PCa in a twelve year follow-up period. 
Samples of men with histologically proven PCa (≥6 core biopsy) were obtained from 
the Department of Urology at the Erasmus MC, Rotterdam. These consisted of men 
(n=40) with localized PCa treated with radical prostatectomy and no evidence of 
biochemical recurrence in the follow-up (minimal 5 years), men with localized PCa 
treated with radical prostatectomy and biochemical recurrence in the follow-up 
(n=40), and men with bone and/or lymph metastasis, evidenced by bone scan and/or 
histologically proven, at the moment of blood draw (n=33). All radical prostatectomy 
patients reached a PSA nadir of <0.1 ng/ml within three months after surgery. 
Biochemical recurrence was defined as PSA level ≥0.3 ng/ml. Patient characteristics 
are depicted in Table 1. 
Table 1. Patient characteristics. General characteristics of patients used for a 
pre-validation of candidate biomarkers. (RP=radical prostatectomy)
  frequency (n)
Mean age 
(years) (range)
Median psA 
(ng/ml) (range)
Median fU after Rp 
(months) (range)
no-pCa 40 59 (55-66) 0.2 (0.1-0.4) -
pCa non-
recurrence
40 62 (51-74) 6.2 (0.8-65.7) 128 (66-160)
pCa recurrence 40 64 (50-72) 7.9 (0.3-33.1) 140 (70-185)
pCa metastasis 33 68 (50-91) 23.5 (0.1-2550) -
ELISA for quantification of proteasome subunits
Proteasome concentrations were measured as previously described by Dutaud 
et al. with some minor modifications134. Briefly, human or mouse serum (1:20 and 
1:10 diluted with PBS containing 0.3% sodium citrate, respectively) or xenograft 
protein extract was incubated for 1hr on a plate coated with a 1:4,500 dilution 
of a monoclonal antibody against PSMA1 (clone MCP20, Biomol International). 
After addition of a 1:1,500 solution of a rabbit anti-proteasome antibody (directed 
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against beta subunits of the proteasome, PW8155, Biomol International) plates 
were extensively washed with PBS-Tween buffer. Then, a 1:4,000 solution of HRP 
conjugated goat anti-rabbit IgG (DakoCytomation) was added and the plate was 
incubated for 1 hr in the dark. To reveal HRP activity, 50 mM phosphate / 25 mM 
citrate buffer, pH 5.0 containing 4 mM o-phenylenediamine and 0.0015% H2O2 was 
added to the wells. After 15 min, the reaction was stopped with 2.5 M sulphuric 
acid. Absorbance values were measured at 492 nm. A standard curve using purified 
human 20S proteasomes (Biomol International) was calculated using a computer 
generated 4-PL curve-fit.
ELISA for quantification of ACY1
Human serum (1:20 diluted with PBS containing 0.3% sodium citrate) or 15 times 
concentrated mouse serum or xenograft protein extract was incubated for 1hr on a 
plate coated overnight with a 1:500 dilution of a mouse monoclonal antibody against 
ACY1 (clone 4F1-B7, Abnova, Taipei, Taiwan). Mouse serum (control as well as 
serum from xenografted mice) was concentrated to enhance the ELISA signal. After 
addition of a 1:400 solution of a polyclonal antibody (R&D Systems) directed against 
human ACY1 wells were washed with PBS-Tween buffer. Then, a 1:4,000 solution 
of HRP conjugated rabbit anti-goat IgG (DakoCytomation) was added and the plate 
was incubated for 1 hr in the dark. To reveal HRP activity, 50 mM phosphate / 25 
mM citrate buffer, pH 5.0 containing 4 mM o-phenylenediamine and 0.0015% H2O2 
was added to the wells. After 20 min, the reaction was stopped with 2.5 M sulphuric 
acid. Absorbance values were measured at 492 nm. A standard curve using purified 
ACY1 antigen (R&D Systems) was calculated using a computer generated 4-PL 
curve-fit.
Measurement of TYRO3 concentrations
The TYRO3 assay was performed according to the instructions of the manufacturer 
(R&D Systems Minneapolis, MN, USA). Briefly, 96-well plates were coated overnight 
with diluted capture antibody. After blocking with PBS and 1% BSA, human (1:20 
dilution with 1% BSA/PBS), 15 times concentrated mouse serum samples or xenograft 
protein extracts were incubated for 2 hours at room temperature. Mouse serum 
(control as well as serum from xenografted mice) was concentrated to enhance the 
ELISA signal. After addition of the detection antibody (diluted in 1% BSA/PBS) and 
Streptavidin-HRP solution, a 1:1 mixture of H2O2 and tetramethylbenzidine was 
added. The optical density of each well was determined at 450 nm, with wavelength 
correction at 570 nm. A standard curve using purified TYRO3 antigen provided with 
the assay was calculated using a computer generated 4-PL curve-fit.
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Measurement of AXL and MERTK concentrations
The AXL and MERTK assays were performed according to the instructions of the 
manufacturer (R&D Systems Minneapolis, MN, USA). Briefly, 96-well plates were 
coated overnight with diluted capture antibody. After blocking with PBS and 1% 
BSA, human serum samples were 1:20 diluted either in 1% BSA/PBS for the AXL 
assay or a solution of 1% NP-40, 20 mM Tris, 137 mM NaCl, 10% glycerol, 2 mM EDTA 
and 1mM activated sodium orthovanadate for the MERTK ELISA. Samples were 
incubated for 2 hours at room temperature. After addition of the detection antibody 
(diluted in 1% BSA/PBS or a solution of 20 mM Tris, 137 mM NaCl, 0.05% Tween 
20 and 0.1% BSA for the AXL and MERTK assays, respectively) and Streptavidin-
HRP solution, a 1:1 mixture of H2O2 and tetramethylbenzidine was added. The 
absorbance of each well was determined at 450 nm, with wavelength correction at 
570 nm. A standard curve using purified AXL and MERTK antigen provided with 
the assay was calculated using a computer generated 4-PL curve-fit.
Statistical analysis
Statistical analyses were performed using the SPSS v15.0 software package (SPSS 
Inc., Chicago, IL, USA). Differences in variables analysed by ELISA (TYRO3, 
MERTK, AXL and ACY1) between the various sample groups were examined using 
the Mann-Whitney U-test with two-sided P values. ROC curves were calculated 
for TYRO3, MERTK, AXL and ACY1 to assess the diagnostic performances in PCa 
detection of the various assays.
results
Proof-of-principle of the experimental setup
When inbred immuno-competent mice are immunized with serum from nude mice 
bearing human PCa xenografts, antibodies to human tumour antigens should be 
produced162. To test this experimental set-up, western blots loaded with protein 
extracts of the PC346 or LNCaP PCa cell lines were visualized with preimmune 
serum or serum from immuno-competent mice immunized with full serum from 
PC346 and PC339 bearing athymic nude mice (Figure 2). After equal exposure times, 
several bands emerged in the lanes of the blots developed with immunized mouse 
serum, in contrast with the blots developed with preimmune serum, indicating an 
immune response in mice immunized with serum from xenograft-bearing mice.
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Figure 2. General immune responses in immunized mice. 1D SDS-PAGE western 
blots loaded with 10µg of PC346 cell line protein and LNCaP cytoplasmic and nuclear 
protein extracts and developed with preimmune serum or mice immunized with full 
serum from PC346 and PC339 bearing mice. Blots were exposed for the same amount 
of time.
For a more specific confirmation of this immune response an assay was developed 
for the detection of antibodies against PSA. First, PSA concentrations were 
measured in the serum of mice utilized for the immunization experiment, showing 
undetectable PSA concentrations in normal nude mice and mice grafted with a 
PC339 xenograft and high levels of PSA in mice bearing a PC346 xenograft. This 
is in accordance with the androgen sensitive nature of the PC346 xenograft and 
androgen unresponsiveness of the PC339 xenograft (see insert Figure 3).
The immunoassay for PSA antibody detection clearly demonstrated the presence of 
PSA-antibodies in mice immunized with either full serum, serum depleted of high 
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abundant proteins (depleted serum), or both from PC346-bearing mice (Figure 3). 
No PSA-antibodies were detected in preimmune serum or in serum from mice 
immunized with normal mouse serum. No or very low levels of PSA antibodies were 
detected in mice immunized with either depleted serum, full serum or both from 
PC339-bearing mice.
Summarizing, these experiments demonstrate that an antibody response against 
xenograft-derived antigens, such as PSA, is generated in mice immunized with 
serum from xenograft-bearing mice.
Pr
ei
m
m
un
e 
(1
)
Pr
ei
m
m
un
e 
(2
)
Co
nt
ro
l i
m
m
un
ize
d
PC
34
6 
im
m
un
ize
d 
(d
ep
le
te
d)
PC
34
6 
im
m
un
ize
d 
(d
ep
l.-
fu
ll)
PC
34
6 
im
m
un
ize
d 
(fu
ll)
PC
33
9 
im
m
un
ize
d 
(d
ep
le
te
d)
PC
33
9 
im
m
un
ize
d 
(d
ep
l.-
fu
ll)
PC
33
9 
im
m
un
ize
d 
(fu
ll)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
P
SA
 A
b
 c
on
ce
n
tr
at
io
n
 (
m
g
/m
L
)
Nu
de
 m
ice
PC
34
6 
xe
no
gr
af
te
d 
m
ice
PC
33
9 
xe
no
gr
af
te
d 
m
ice
1
10
100
1000
10000
P
SA
 (
m
g
/m
L
)
Figure 3. Detection of antibodies directed against PSA. PSA specific antibodies were 
detected in mice immunized with serum from PC346-bearing mice. No antibodies 
were detected in preimmune serum and mice immunized with normal mouse serum. 
PSA antibodies were absent or present in very low amounts in mice immunized with 
serum from PC339-bearing mice, in accordance with the non-PSA producing nature 
of this xenograft. Insert; PSA concentrations in serum of normal nude mice and nude 
mice bearing PC339 or PC346 xenografts. High levels of PSA are detectable in serum 
of PC346-xenografted mice whereas PSA levels are undetectable in normal nude mice 
and mice bearing PC339 xenografts.
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Identification of antibodies against human PCa-derived proteins
To perform a large-scale identification of antibodies generated against human PCa-
derived proteins, sera from mice immunized with either depleted serum, full serum 
or both from PC346 and PC339-bearing mice as well as preimmune serum and serum 
from mice immunized with normal mouse serum, were incubated onto ProtoArrays. 
These ProtoArrays contain approximately 8,000 partial and full-length human 
proteins. Antibodies bound to spotted proteins were detected using a fluorescent 
labelled secondary antibody. Processed ProtoArrays showed R2 >0.96 for duplicated 
spots across all proteins. 99 Proteins to which an antibody response was observed 
were identified (Table 2). The fluorescent expression values of the 25 top-ranked 
identified proteins are depicted in Figure 4.
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Table 2. Identified PCa-derived candidate biomarkers. Normalized expression values 
of identified PCa-derived proteins expressed in immunized mice as identified by 
ProtoArray analysis (NEV = normalized expression value).
no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
1 nM_000666.1 95 Aminoacylase 1 ACy1 0.20 1.18 2.12 3.42 21.53
2 bC015356.1 5682 proteasome (prosome, macropain) subunit, alpha type, 1 psMA1 0.23 0.59 0.20 0.51 3.73
3 bC008656.1 55812 spermatogenesis associated 7 spAtA7 0.20 0.31 0.20 0.38 0.76
4 nM_201262.1 56521 DnaJ (hsp40) homolog, subfamily C, member 12 DnAJC12 0.20 0.77 0.49 0.77 0.85
5 nM_016497.2 51258 Mitochondrial ribosomal protein l51 MRpl51 0.20 0.34 0.20 0.62 1.03
6 pv3828 7301 tyRO3 protein tyrosine kinase tyRO3 0.20 0.42 0.22 1.33 0.40
7 bC026175.1 1386 Activating transcription factor 2 Atf2 0.51 1.61 0.20 0.71 2.18
8 nM_016286.1 51181 Dicarbonyl/l-xylulose reductase DCXR 0.20 1.06 1.08 0.65 4.43
9 nM_004832.1 9446 Glutathione s-transferase omega 1 GstO1 0.20 0.37 0.24 0.36 0.95
10 nM_006555.2 10652 ykt6 v-snARe homolog (s. cerevisiae) ykt6 0.20 0.55 0.22 1.34 2.38
11 nM_004355.1 972 CD74 molecule, major histocompatibility complex, 
class ii invariant chain
CD74 0.20 0.62 0.20 0.81 1.05
12 pv3627 10461 C-mer proto-oncogene tyrosine kinase MeRtk 0.20 0.31 0.20 0.35 1.61
13 nM_020525.4 50616 interleukin 22 il22 0.20 0.56 4.28 0.57 1.20
14 p2227 5578 protein kinase C, alpha pRkCA 0.20 0.53 1.83 2.76 0.22
15 nM_000594.2 7124 tumor necrosis factor (tnf superfamily, member 2) tnf 0.20 1.78 0.25 0.86 1.87
16 XM_378350.2 400027 hypothetical gene supported by bC047417 lOC400027 0.86 1.40 0.20 0.99 1.43
17 pv3827 157 Adrenergic, beta, receptor kinase 2 ADRbk2 0.20 0.20 0.20 0.76 0.25
18 pv4131 904 Cyclin t1 CCnt1 0.47 0.38 1.12 1.67 0.32
19 pv3840 2044 eph receptor A5 ephA5 0.20 0.78 0.20 0.46 0.58
20 bC010537.1 10923 sUb1 homolog (s. cerevisiae) sUb1 0.20 0.38 0.77 1.20 0.65
21 bC017046.1 309 Annexin A6 AnXA6 0.20 0.78 1.05 3.36 1.87
22 pv3612 6790 Aurora kinase A AURkA 0.44 0.29 3.60 1.32 0.32
23 bC031262.1 1495 Catenin (cadherin-associated protein), alpha 1, 102kDa CtnnA1 0.21 0.95 0.76 1.65 1.01
24 nM_007194.2 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.24 0.20 0.29 0.52
25 nM_007045.2 11116 fGfR1 oncogene partner fGfR1Op 0.23 1.68 0.20 2.63 1.42
26 nM_133443.1 84706 Glutamic pyruvate transaminase (alanine 
aminotransferase) 2
Gpt2 0.23 0.70 0.99 0.67 1.04
27 bC008902.2 79571 GRip and coiled-coil domain containing 1 GCC1 0.20 1.05 0.20 1.69 1.34
28 bC029046.1 3005 h1 histone family, member 0 h1f0 0.20 0.90 1.15 2.54 1.43
29 nM_020423.1 57147 sCy1-like 3 (s. cerevisiae) sCyl3 0.20 0.45 0.85 0.59 1.10
30 nM_018297.2 55768 n-glycanase 1 nGly1 0.20 0.41 0.20 0.42 0.80
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Table 2. Identified PCa-derived candidate biomarkers. Normalized expression values 
of identified PCa-derived proteins expressed in immunized mice as identified by 
ProtoArray analysis (NEV = normalized expression value).
no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
1 nM_000666.1 95 Aminoacylase 1 ACy1 0.20 1.18 2.12 3.42 21.53
2 bC015356.1 5682 proteasome (prosome, macropain) subunit, alpha type, 1 psMA1 0.23 0.59 0.20 0.51 3.73
3 bC008656.1 55812 spermatogenesis associated 7 spAtA7 0.20 0.31 0.20 0.38 0.76
4 nM_201262.1 56521 DnaJ (hsp40) homolog, subfamily C, member 12 DnAJC12 0.20 0.77 0.49 0.77 0.85
5 nM_016497.2 51258 Mitochondrial ribosomal protein l51 MRpl51 0.20 0.34 0.20 0.62 1.03
6 pv3828 7301 tyRO3 protein tyrosine kinase tyRO3 0.20 0.42 0.22 1.33 0.40
7 bC026175.1 1386 Activating transcription factor 2 Atf2 0.51 1.61 0.20 0.71 2.18
8 nM_016286.1 51181 Dicarbonyl/l-xylulose reductase DCXR 0.20 1.06 1.08 0.65 4.43
9 nM_004832.1 9446 Glutathione s-transferase omega 1 GstO1 0.20 0.37 0.24 0.36 0.95
10 nM_006555.2 10652 ykt6 v-snARe homolog (s. cerevisiae) ykt6 0.20 0.55 0.22 1.34 2.38
11 nM_004355.1 972 CD74 molecule, major histocompatibility complex, 
class ii invariant chain
CD74 0.20 0.62 0.20 0.81 1.05
12 pv3627 10461 C-mer proto-oncogene tyrosine kinase MeRtk 0.20 0.31 0.20 0.35 1.61
13 nM_020525.4 50616 interleukin 22 il22 0.20 0.56 4.28 0.57 1.20
14 p2227 5578 protein kinase C, alpha pRkCA 0.20 0.53 1.83 2.76 0.22
15 nM_000594.2 7124 tumor necrosis factor (tnf superfamily, member 2) tnf 0.20 1.78 0.25 0.86 1.87
16 XM_378350.2 400027 hypothetical gene supported by bC047417 lOC400027 0.86 1.40 0.20 0.99 1.43
17 pv3827 157 Adrenergic, beta, receptor kinase 2 ADRbk2 0.20 0.20 0.20 0.76 0.25
18 pv4131 904 Cyclin t1 CCnt1 0.47 0.38 1.12 1.67 0.32
19 pv3840 2044 eph receptor A5 ephA5 0.20 0.78 0.20 0.46 0.58
20 bC010537.1 10923 sUb1 homolog (s. cerevisiae) sUb1 0.20 0.38 0.77 1.20 0.65
21 bC017046.1 309 Annexin A6 AnXA6 0.20 0.78 1.05 3.36 1.87
22 pv3612 6790 Aurora kinase A AURkA 0.44 0.29 3.60 1.32 0.32
23 bC031262.1 1495 Catenin (cadherin-associated protein), alpha 1, 102kDa CtnnA1 0.21 0.95 0.76 1.65 1.01
24 nM_007194.2 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.24 0.20 0.29 0.52
25 nM_007045.2 11116 fGfR1 oncogene partner fGfR1Op 0.23 1.68 0.20 2.63 1.42
26 nM_133443.1 84706 Glutamic pyruvate transaminase (alanine 
aminotransferase) 2
Gpt2 0.23 0.70 0.99 0.67 1.04
27 bC008902.2 79571 GRip and coiled-coil domain containing 1 GCC1 0.20 1.05 0.20 1.69 1.34
28 bC029046.1 3005 h1 histone family, member 0 h1f0 0.20 0.90 1.15 2.54 1.43
29 nM_020423.1 57147 sCy1-like 3 (s. cerevisiae) sCyl3 0.20 0.45 0.85 0.59 1.10
30 nM_018297.2 55768 n-glycanase 1 nGly1 0.20 0.41 0.20 0.42 0.80
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no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
31 bC053861.1 23133 phD finger protein 8 phf8 0.20 0.87 0.20 1.24 1.12
32 pv3501 5347 polo-like kinase 1 (Drosophila) plk1 0.84 0.43 4.30 0.85 0.40
33 nM_199415.1 22888 fAst kinase domains 5 UbOX5 0.20 0.94 0.20 2.11 1.36
34 nM_133336.1 7468 Wolf-hirschhorn syndrome candidate 1 WhsC1 0.20 0.59 3.96 1.33 5.87
35 bC010125.1 56941 Chromosome 3 open reading frame 37 C3orf37 2.52 0.20 3.51 0.20 0.22
36 nM_000485.1 353 Adenine phosphoribosyltransferase ApRt 0.20 3.14 0.22 0.84 2.00
37 bC034245.1 55118 Cartilage acidic protein 1 CRtAC1 0.20 1.33 0.27 2.16 1.33
38 pv3367 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.42 0.33 1.01 0.69
39 nM_005804.2 10212 DeAD (Asp-Glu-Ala-Asp) box polypeptide 39 DDX39 0.20 0.76 0.20 1.71 3.29
40 pv3870 4921 Discoidin domain receptor tyrosine kinase 2 DDR2 0.20 0.81 0.53 0.50 0.99
41 bC051695.1 83786 feRM domain containing 8 fRMD8 0.20 0.20 3.07 0.20 0.22
42 nM_194299.1 221711 synaptonemal complex protein 2-like syCp2l 0.20 0.92 0.35 1.30 1.55
43 nM_002461.1 4597 Mevalonate (diphospho) decarboxylase MvD 0.20 1.06 0.91 0.97 1.44
44 pv3682 11183 Mitogen-activated protein kinase kinase kinase kinase 5 MAp4k5 0.20 0.29 0.36 1.31 0.38
45 pv3757 85366 Myosin light chain kinase 2 Mylk2 0.65 1.73 0.20 1.37 1.63
46 nM_005884.2 10298 p21(CDkn1A)-activated kinase 4 pAk4 0.20 0.64 2.22 1.41 1.21
47 pv3813 5613 protein kinase, X-linked pRkX 0.22 2.04 4.08 2.06 6.41
48 nM_006621.3 10768 s-adenosylhomocysteine hydrolase-like 1 AhCyl1 0.20 0.80 1.52 0.20 0.22
49 pv3830 9748 ste20-like kinase (yeast) slk 0.23 0.75 0.91 3.10 0.75
50 nM_031472.1 83707 tRnA phosphotransferase 1 tRpt1 0.51 0.87 3.61 0.61 1.16
51 bC060786.1 55616 Development and differentiation enhancing factor-like 1 DDefl1 0.20 0.90 0.20 1.00 1.28
52 p3078 7525 v-yes-1 yamaguchi sarcoma viral oncogene homolog 1 yes1 0.20 1.29 0.20 2.29 1.49
53 nM_001615.2 72 Actin, gamma 2, smooth muscle, enteric ACtG2 0.20 0.86 0.46 0.95 1.68
54 nM_152328.3 122622 Adenylosuccinate synthase like 1 ADssl1 0.20 0.20 1.77 0.20 0.22
55 nM_005738.1 10124 ADp-ribosylation factor-like 4A ARl4A 0.20 0.43 0.27 0.87 0.74
56 nM_001124.1 133 Adrenomedullin ADM 0.20 0.80 0.43 1.01 1.53
57 bC047673.1 63941 n-terminal ef-hand calcium binding protein 3 neCAb3 0.20 0.20 2.02 0.20 0.22
58 nM_005434.3 7851 Mal, t-cell differentiation protein-like MAll 0.20 0.36 2.41 0.44 0.73
59 pv3826 1198 CDC-like kinase 3 Clk3 0.20 1.29 0.82 1.62 1.23
60 bC059950.1 6136 Ribosomal protein l12 Rpl12 0.23 0.31 1.48 0.83 0.86
61 nM_152420.1 138199 Chromosome 9 open reading frame 41 C9orf41 0.21 0.97 1.31 1.84 1.77
62 nM_014183.1 83658 Dynein, light chain, roadblock-type 1 DynlRb1 0.57 0.85 0.55 0.72 1.26
63 pv3689 2045 eph receptor A7 ephA7 1.16 0.75 1.58 1.18 1.19
64 bC052805.1 2039 erythrocyte membrane protein band 4.9 (dematin) epb49 0.78 1.18 3.22 0.58 2.03
65 nM_004838.2 9454 homer homolog 3 (Drosophila) hOMeR3 0.20 1.57 0.90 0.96 1.59
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no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
31 bC053861.1 23133 phD finger protein 8 phf8 0.20 0.87 0.20 1.24 1.12
32 pv3501 5347 polo-like kinase 1 (Drosophila) plk1 0.84 0.43 4.30 0.85 0.40
33 nM_199415.1 22888 fAst kinase domains 5 UbOX5 0.20 0.94 0.20 2.11 1.36
34 nM_133336.1 7468 Wolf-hirschhorn syndrome candidate 1 WhsC1 0.20 0.59 3.96 1.33 5.87
35 bC010125.1 56941 Chromosome 3 open reading frame 37 C3orf37 2.52 0.20 3.51 0.20 0.22
36 nM_000485.1 353 Adenine phosphoribosyltransferase ApRt 0.20 3.14 0.22 0.84 2.00
37 bC034245.1 55118 Cartilage acidic protein 1 CRtAC1 0.20 1.33 0.27 2.16 1.33
38 pv3367 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.42 0.33 1.01 0.69
39 nM_005804.2 10212 DeAD (Asp-Glu-Ala-Asp) box polypeptide 39 DDX39 0.20 0.76 0.20 1.71 3.29
40 pv3870 4921 Discoidin domain receptor tyrosine kinase 2 DDR2 0.20 0.81 0.53 0.50 0.99
41 bC051695.1 83786 feRM domain containing 8 fRMD8 0.20 0.20 3.07 0.20 0.22
42 nM_194299.1 221711 synaptonemal complex protein 2-like syCp2l 0.20 0.92 0.35 1.30 1.55
43 nM_002461.1 4597 Mevalonate (diphospho) decarboxylase MvD 0.20 1.06 0.91 0.97 1.44
44 pv3682 11183 Mitogen-activated protein kinase kinase kinase kinase 5 MAp4k5 0.20 0.29 0.36 1.31 0.38
45 pv3757 85366 Myosin light chain kinase 2 Mylk2 0.65 1.73 0.20 1.37 1.63
46 nM_005884.2 10298 p21(CDkn1A)-activated kinase 4 pAk4 0.20 0.64 2.22 1.41 1.21
47 pv3813 5613 protein kinase, X-linked pRkX 0.22 2.04 4.08 2.06 6.41
48 nM_006621.3 10768 s-adenosylhomocysteine hydrolase-like 1 AhCyl1 0.20 0.80 1.52 0.20 0.22
49 pv3830 9748 ste20-like kinase (yeast) slk 0.23 0.75 0.91 3.10 0.75
50 nM_031472.1 83707 tRnA phosphotransferase 1 tRpt1 0.51 0.87 3.61 0.61 1.16
51 bC060786.1 55616 Development and differentiation enhancing factor-like 1 DDefl1 0.20 0.90 0.20 1.00 1.28
52 p3078 7525 v-yes-1 yamaguchi sarcoma viral oncogene homolog 1 yes1 0.20 1.29 0.20 2.29 1.49
53 nM_001615.2 72 Actin, gamma 2, smooth muscle, enteric ACtG2 0.20 0.86 0.46 0.95 1.68
54 nM_152328.3 122622 Adenylosuccinate synthase like 1 ADssl1 0.20 0.20 1.77 0.20 0.22
55 nM_005738.1 10124 ADp-ribosylation factor-like 4A ARl4A 0.20 0.43 0.27 0.87 0.74
56 nM_001124.1 133 Adrenomedullin ADM 0.20 0.80 0.43 1.01 1.53
57 bC047673.1 63941 n-terminal ef-hand calcium binding protein 3 neCAb3 0.20 0.20 2.02 0.20 0.22
58 nM_005434.3 7851 Mal, t-cell differentiation protein-like MAll 0.20 0.36 2.41 0.44 0.73
59 pv3826 1198 CDC-like kinase 3 Clk3 0.20 1.29 0.82 1.62 1.23
60 bC059950.1 6136 Ribosomal protein l12 Rpl12 0.23 0.31 1.48 0.83 0.86
61 nM_152420.1 138199 Chromosome 9 open reading frame 41 C9orf41 0.21 0.97 1.31 1.84 1.77
62 nM_014183.1 83658 Dynein, light chain, roadblock-type 1 DynlRb1 0.57 0.85 0.55 0.72 1.26
63 pv3689 2045 eph receptor A7 ephA7 1.16 0.75 1.58 1.18 1.19
64 bC052805.1 2039 erythrocyte membrane protein band 4.9 (dematin) epb49 0.78 1.18 3.22 0.58 2.03
65 nM_004838.2 9454 homer homolog 3 (Drosophila) hOMeR3 0.20 1.57 0.90 0.96 1.59
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no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
66 nM_139016.2 25943 Chromosome 20 open reading frame 194 C20orf194 0.28 0.20 2.16 0.20 0.22
67 bC012131.1 112849 Chromosome 14 open reading frame 149 C14orf149 0.20 0.44 0.83 0.66 1.11
68 bC033196.1 283229 ef-hand calcium binding domain 4A efCAb4A 0.20 1.79 2.02 1.31 2.61
69 bC008200.1 3856 keratin 8 kRt8 1.11 1.18 1.74 1.11 1.69
70 nM_018396.1 55798 Methyltransferase like 2b Mettl2b 0.20 0.63 0.39 0.57 0.91
71 bC031469.1 554207 hypothetical lOC554207 lOC554207 0.28 1.26 0.30 1.25 1.67
72 pv3835 4638 Myosin light chain kinase Mylk 0.45 0.67 0.20 2.27 0.74
73 nM_017506.1 26659 Olfactory receptor, family 7, subfamily A, member 5 OR7A5 0.20 0.49 0.63 1.45 1.20
74 nM_006695.2 10900 RUn domain containing 3A RUnDC3A 0.21 1.54 1.26 1.23 1.15
75 nM_198395.1 10146 Gtpase activating protein (sh3 domain) binding protein 1 G3bp1 1.09 0.89 1.15 3.03 1.48
76 bC020726.1 8796 sciellin sCel 1.46 1.18 4.60 2.60 1.61
77 nM_004169.2 6470 serine hydroxymethyltransferase 1 (soluble) shMt1 0.20 0.41 1.48 0.60 0.96
78 bC032825.2 6456 sh3-domain GRb2-like 2 sh3Gl2 0.79 0.20 3.20 0.20 0.22
79 bC018122.1 7296 thioredoxin reductase 1 tXnRD1 0.20 0.85 1.24 1.50 1.80
80 nM_003289.3 7169 tropomyosin 2 (beta) tpM2 0.20 0.20 2.56 0.20 0.22
81 pv3792 7272 ttk protein kinase ttk 0.38 1.36 2.13 1.88 0.76
82 pv3869 3815 v-kit hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog
kit 0.25 0.55 0.39 1.94 0.42
83 p2782 7535 Zeta-chain (tCR) associated protein kinase 70kDa ZAp70 0.22 0.57 3.36 1.46 0.36
84 bC004207.1 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.40 0.93 0.61 1.29
85 bC002448.2 3983 Actin binding liM protein 1 AbliM1 2.16 1.21 2.01 1.49 1.39
86 bC058926.1 1499 Catenin (cadherin-associated protein), beta 1, 88kDa Ctnnb1 0.20 1.40 0.46 1.36 1.72
87 nM_001277.1 1119 Choline kinase alpha ChkA 0.28 0.94 2.43 1.95 2.52
88 nM_080664.1 112487 Chromosome 14 open reading frame 126 C14orf126 0.54 0.73 4.09 2.32 1.38
89 bC023567.2 51379 Cytokine receptor-like factor 3 CRlf3 0.20 1.33 0.78 2.36 1.62
90 pv3354 2242 feline sarcoma oncogene fes 0.32 0.71 1.82 2.54 0.93
91 bC001772.1 5859 Glutaminyl-tRnA synthetase QARs 0.24 0.56 0.79 0.36 0.90
92 nM_018090.2 55707 neCAp endocytosis associated 2 neCAp2 0.20 0.96 2.23 0.90 1.26
93 bC031074.1 54956 poly (ADp-ribose) polymerase family, member 16 pARp16 0.20 0.65 0.88 1.63 0.97
94 bC017066.1 133619 proline-rich coiled-coil 1 pRRC1 0.20 0.90 1.46 0.51 1.16
95 nM_152646.2 196872 hypothetical lOC196872 MGC23270 0.86 2.49 3.13 0.81 2.66
96 nM_005550.2 3801 kinesin family member C3 kifC3 1.06 0.56 3.94 3.36 2.01
97 pv3370 4145 Megakaryocyte-associated tyrosine kinase MAtk 0.20 0.62 0.55 0.79 0.77
98 nM_005371.2 4234 Methyltransferase like 1 Mettl1 0.20 0.52 0.64 1.13 1.21
99 nM_002444.1 4478 Moesin Msn 0.20 1.56 0.44 1.47 2.68
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no. protoArray iD locuslink iD Gene name Gene symbol
Mouse 2nd 
Ab only (nev)
preimmune 
(1) (nev)
preimmune 
(2) (nev)
control immunized 
(nev)
pC346 immunized 
(depleted) (nev)
66 nM_139016.2 25943 Chromosome 20 open reading frame 194 C20orf194 0.28 0.20 2.16 0.20 0.22
67 bC012131.1 112849 Chromosome 14 open reading frame 149 C14orf149 0.20 0.44 0.83 0.66 1.11
68 bC033196.1 283229 ef-hand calcium binding domain 4A efCAb4A 0.20 1.79 2.02 1.31 2.61
69 bC008200.1 3856 keratin 8 kRt8 1.11 1.18 1.74 1.11 1.69
70 nM_018396.1 55798 Methyltransferase like 2b Mettl2b 0.20 0.63 0.39 0.57 0.91
71 bC031469.1 554207 hypothetical lOC554207 lOC554207 0.28 1.26 0.30 1.25 1.67
72 pv3835 4638 Myosin light chain kinase Mylk 0.45 0.67 0.20 2.27 0.74
73 nM_017506.1 26659 Olfactory receptor, family 7, subfamily A, member 5 OR7A5 0.20 0.49 0.63 1.45 1.20
74 nM_006695.2 10900 RUn domain containing 3A RUnDC3A 0.21 1.54 1.26 1.23 1.15
75 nM_198395.1 10146 Gtpase activating protein (sh3 domain) binding protein 1 G3bp1 1.09 0.89 1.15 3.03 1.48
76 bC020726.1 8796 sciellin sCel 1.46 1.18 4.60 2.60 1.61
77 nM_004169.2 6470 serine hydroxymethyltransferase 1 (soluble) shMt1 0.20 0.41 1.48 0.60 0.96
78 bC032825.2 6456 sh3-domain GRb2-like 2 sh3Gl2 0.79 0.20 3.20 0.20 0.22
79 bC018122.1 7296 thioredoxin reductase 1 tXnRD1 0.20 0.85 1.24 1.50 1.80
80 nM_003289.3 7169 tropomyosin 2 (beta) tpM2 0.20 0.20 2.56 0.20 0.22
81 pv3792 7272 ttk protein kinase ttk 0.38 1.36 2.13 1.88 0.76
82 pv3869 3815 v-kit hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog
kit 0.25 0.55 0.39 1.94 0.42
83 p2782 7535 Zeta-chain (tCR) associated protein kinase 70kDa ZAp70 0.22 0.57 3.36 1.46 0.36
84 bC004207.1 11200 Chk2 checkpoint homolog (s. pombe) Chek2 0.20 0.40 0.93 0.61 1.29
85 bC002448.2 3983 Actin binding liM protein 1 AbliM1 2.16 1.21 2.01 1.49 1.39
86 bC058926.1 1499 Catenin (cadherin-associated protein), beta 1, 88kDa Ctnnb1 0.20 1.40 0.46 1.36 1.72
87 nM_001277.1 1119 Choline kinase alpha ChkA 0.28 0.94 2.43 1.95 2.52
88 nM_080664.1 112487 Chromosome 14 open reading frame 126 C14orf126 0.54 0.73 4.09 2.32 1.38
89 bC023567.2 51379 Cytokine receptor-like factor 3 CRlf3 0.20 1.33 0.78 2.36 1.62
90 pv3354 2242 feline sarcoma oncogene fes 0.32 0.71 1.82 2.54 0.93
91 bC001772.1 5859 Glutaminyl-tRnA synthetase QARs 0.24 0.56 0.79 0.36 0.90
92 nM_018090.2 55707 neCAp endocytosis associated 2 neCAp2 0.20 0.96 2.23 0.90 1.26
93 bC031074.1 54956 poly (ADp-ribose) polymerase family, member 16 pARp16 0.20 0.65 0.88 1.63 0.97
94 bC017066.1 133619 proline-rich coiled-coil 1 pRRC1 0.20 0.90 1.46 0.51 1.16
95 nM_152646.2 196872 hypothetical lOC196872 MGC23270 0.86 2.49 3.13 0.81 2.66
96 nM_005550.2 3801 kinesin family member C3 kifC3 1.06 0.56 3.94 3.36 2.01
97 pv3370 4145 Megakaryocyte-associated tyrosine kinase MAtk 0.20 0.62 0.55 0.79 0.77
98 nM_005371.2 4234 Methyltransferase like 1 Mettl1 0.20 0.52 0.64 1.13 1.21
99 nM_002444.1 4478 Moesin Msn 0.20 1.56 0.44 1.47 2.68
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Table 2, continued.
no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
1 474.53 63.73 17.25 114.17 10.90 cytoplasm peptidase yes165 yes165
2 315.90 2.04 1.40 2.57 0.65 cytoplasm peptidase no no
3 1.95 0.77 0.59 2.03 0.59 unknown other no no
4 7.40 33.48 0.95 2.13 1.15 unknown other yes166 no
5 1.66 0.95 0.87 10.31 0.60 cytoplasm other no no
6 0.37 2.54 0.83 2.02 5.85 plasma membrane kinase no no
7 7.37 1.77 1.10 0.27 0.85 nucleus transcription regulator yes167 no
8 189.26 4.59 1.57 1.29 0.88 cytoplasm enzyme yes168 yes168
9 2.10 0.56 1.71 79.66 0.78 cytoplasm enzyme yes169 no
10 0.77 1.87 2.35 1.60 18.55 cytoplasm enzyme no no
11 0.31 3.62 0.95 0.35 1.48 plasma membrane transmembrane receptor yes170 no
12 2.45 0.56 0.20 2.60 0.36 plasma membrane kinase yes171 no
13 5.94 8.87 0.96 2.38 5.37 extracellular space cytokine no no
14 2.62 15.16 0.75 0.63 9.20 cytoplasm kinase yes172 no
15 1.02 1.11 12.36 0.29 1.02 extracellular space cytokine yes173 yes174
16 0.31 4.32 1.52 0.55 3.27 unknown other no no
17 0.31 3.88 0.20 0.20 1.79 cytoplasm kinase no no
18 1.47 5.91 0.59 0.97 4.85 nucleus transcription regulator no no
19 0.31 6.56 0.55 0.20 1.14 plasma membrane kinase no no
20 1.42 5.07 0.49 0.28 3.39 nucleus transcription regulator no no
21 9.81 23.47 1.63 0.61 1.39 plasma membrane other no no
22 5.16 1.53 0.20 1.05 13.11 nucleus kinase yes175 no
23 0.31 5.41 1.28 0.86 9.58 plasma membrane other yes176 yes177
24 0.34 18.14 0.34 0.49 0.48 nucleus kinase yes178 no
25 0.31 3.28 1.55 0.29 2.58 cytoplasm other no no
26 1.88 4.41 1.11 0.41 2.21 unknown enzyme no no
27 0.82 1.72 2.76 0.27 1.10 cytoplasm other no no
28 2.23 8.25 1.43 0.37 7.57 nucleus other no no
29 6.00 1.25 1.35 1.23 0.60 cytoplasm kinase no no
30 0.31 1.16 0.67 19.15 0.44 cytoplasm enzyme no no
31 0.31 1.45 1.96 1.56 0.96 unknown other no no
32 6.34 2.65 0.40 1.81 2.17 nucleus kinase yes179 yes179
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Table 2, continued.
no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
1 474.53 63.73 17.25 114.17 10.90 cytoplasm peptidase yes165 yes165
2 315.90 2.04 1.40 2.57 0.65 cytoplasm peptidase no no
3 1.95 0.77 0.59 2.03 0.59 unknown other no no
4 7.40 33.48 0.95 2.13 1.15 unknown other yes166 no
5 1.66 0.95 0.87 10.31 0.60 cytoplasm other no no
6 0.37 2.54 0.83 2.02 5.85 plasma membrane kinase no no
7 7.37 1.77 1.10 0.27 0.85 nucleus transcription regulator yes167 no
8 189.26 4.59 1.57 1.29 0.88 cytoplasm enzyme yes168 yes168
9 2.10 0.56 1.71 79.66 0.78 cytoplasm enzyme yes169 no
10 0.77 1.87 2.35 1.60 18.55 cytoplasm enzyme no no
11 0.31 3.62 0.95 0.35 1.48 plasma membrane transmembrane receptor yes170 no
12 2.45 0.56 0.20 2.60 0.36 plasma membrane kinase yes171 no
13 5.94 8.87 0.96 2.38 5.37 extracellular space cytokine no no
14 2.62 15.16 0.75 0.63 9.20 cytoplasm kinase yes172 no
15 1.02 1.11 12.36 0.29 1.02 extracellular space cytokine yes173 yes174
16 0.31 4.32 1.52 0.55 3.27 unknown other no no
17 0.31 3.88 0.20 0.20 1.79 cytoplasm kinase no no
18 1.47 5.91 0.59 0.97 4.85 nucleus transcription regulator no no
19 0.31 6.56 0.55 0.20 1.14 plasma membrane kinase no no
20 1.42 5.07 0.49 0.28 3.39 nucleus transcription regulator no no
21 9.81 23.47 1.63 0.61 1.39 plasma membrane other no no
22 5.16 1.53 0.20 1.05 13.11 nucleus kinase yes175 no
23 0.31 5.41 1.28 0.86 9.58 plasma membrane other yes176 yes177
24 0.34 18.14 0.34 0.49 0.48 nucleus kinase yes178 no
25 0.31 3.28 1.55 0.29 2.58 cytoplasm other no no
26 1.88 4.41 1.11 0.41 2.21 unknown enzyme no no
27 0.82 1.72 2.76 0.27 1.10 cytoplasm other no no
28 2.23 8.25 1.43 0.37 7.57 nucleus other no no
29 6.00 1.25 1.35 1.23 0.60 cytoplasm kinase no no
30 0.31 1.16 0.67 19.15 0.44 cytoplasm enzyme no no
31 0.31 1.45 1.96 1.56 0.96 unknown other no no
32 6.34 2.65 0.40 1.81 2.17 nucleus kinase yes179 yes179
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no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
33 0.33 4.21 1.80 0.32 1.73 nucleus other no no
34 6.09 6.23 1.93 0.44 2.02 nucleus other no no
35 4.90 0.23 0.20 3.19 1.87 unknown other no no
36 0.99 1.51 2.79 0.32 1.13 cytoplasm enzyme no no
37 0.84 1.41 2.79 0.20 1.05 extracellular space other no no
38 0.38 39.30 0.35 0.29 1.30 nucleus kinase yes178 no
39 1.18 0.63 1.19 0.26 0.82 nucleus enzyme no no
40 6.32 2.20 0.62 0.22 1.87 plasma membrane kinase no no
41 13.23 0.23 0.20 1.15 0.20 unknown other no no
42 1.13 2.68 1.41 0.38 2.56 unknown other no no
43 1.68 1.36 7.18 0.95 1.33 cytoplasm enzyme no no
44 1.24 2.03 0.20 0.42 2.66 cytoplasm kinase no no
45 0.31 2.95 1.30 0.20 3.64 cytoplasm kinase no no
46 21.28 6.36 0.74 0.90 1.48 cytoplasm kinase yes180 no
47 2.70 9.88 1.53 9.87 8.00 cytoplasm kinase no no
48 1.48 0.23 0.20 0.63 3.85 cytoplasm enzyme no no
49 0.98 3.75 3.92 0.63 3.20 nucleus kinase no no
50 5.69 1.61 0.97 2.05 4.01 unknown enzyme no no
51 0.85 1.50 2.80 0.21 1.19 unknown other no no
52 0.31 5.38 0.85 0.20 3.34 cytoplasm kinase no no
53 1.98 0.78 3.40 0.42 0.86 cytoplasm other yes181 no
54 2.15 0.23 0.20 1.75 0.20 cytoplasm enzyme no no
55 0.56 5.18 0.66 0.20 0.62 nucleus enzyme no no
56 2.03 1.25 2.86 0.40 1.42 extracellular space other yes182 no
57 1.54 0.23 0.20 20.11 0.20 cytoplasm other no no
58 4.85 2.81 0.65 0.50 0.64 plasma membrane other no no
59 1.17 7.73 1.30 0.23 0.99 nucleus kinase yes183 no
60 15.07 1.42 0.63 0.52 1.25 cytoplasm other no no
61 2.34 11.87 1.39 0.90 2.46 unknown other no no
62 0.89 1.68 3.02 0.28 0.87 cytoplasm other yes184 no
63 1.69 7.24 0.64 0.73 1.20 plasma membrane kinase yes185 no
64 3.73 4.04 1.49 1.20 2.74 plasma membrane other yes186 no
65 2.53 10.58 2.76 0.79 1.99 plasma membrane other no no
66 6.04 0.23 0.20 0.87 0.20 nucleus other no no
Flip_Jansen.indd   86 30-7-2013   8:43:49
ChApteR 3 87
no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
33 0.33 4.21 1.80 0.32 1.73 nucleus other no no
34 6.09 6.23 1.93 0.44 2.02 nucleus other no no
35 4.90 0.23 0.20 3.19 1.87 unknown other no no
36 0.99 1.51 2.79 0.32 1.13 cytoplasm enzyme no no
37 0.84 1.41 2.79 0.20 1.05 extracellular space other no no
38 0.38 39.30 0.35 0.29 1.30 nucleus kinase yes178 no
39 1.18 0.63 1.19 0.26 0.82 nucleus enzyme no no
40 6.32 2.20 0.62 0.22 1.87 plasma membrane kinase no no
41 13.23 0.23 0.20 1.15 0.20 unknown other no no
42 1.13 2.68 1.41 0.38 2.56 unknown other no no
43 1.68 1.36 7.18 0.95 1.33 cytoplasm enzyme no no
44 1.24 2.03 0.20 0.42 2.66 cytoplasm kinase no no
45 0.31 2.95 1.30 0.20 3.64 cytoplasm kinase no no
46 21.28 6.36 0.74 0.90 1.48 cytoplasm kinase yes180 no
47 2.70 9.88 1.53 9.87 8.00 cytoplasm kinase no no
48 1.48 0.23 0.20 0.63 3.85 cytoplasm enzyme no no
49 0.98 3.75 3.92 0.63 3.20 nucleus kinase no no
50 5.69 1.61 0.97 2.05 4.01 unknown enzyme no no
51 0.85 1.50 2.80 0.21 1.19 unknown other no no
52 0.31 5.38 0.85 0.20 3.34 cytoplasm kinase no no
53 1.98 0.78 3.40 0.42 0.86 cytoplasm other yes181 no
54 2.15 0.23 0.20 1.75 0.20 cytoplasm enzyme no no
55 0.56 5.18 0.66 0.20 0.62 nucleus enzyme no no
56 2.03 1.25 2.86 0.40 1.42 extracellular space other yes182 no
57 1.54 0.23 0.20 20.11 0.20 cytoplasm other no no
58 4.85 2.81 0.65 0.50 0.64 plasma membrane other no no
59 1.17 7.73 1.30 0.23 0.99 nucleus kinase yes183 no
60 15.07 1.42 0.63 0.52 1.25 cytoplasm other no no
61 2.34 11.87 1.39 0.90 2.46 unknown other no no
62 0.89 1.68 3.02 0.28 0.87 cytoplasm other yes184 no
63 1.69 7.24 0.64 0.73 1.20 plasma membrane kinase yes185 no
64 3.73 4.04 1.49 1.20 2.74 plasma membrane other yes186 no
65 2.53 10.58 2.76 0.79 1.99 plasma membrane other no no
66 6.04 0.23 0.20 0.87 0.20 nucleus other no no
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no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
67 1.74 1.29 1.00 0.42 2.81 unknown other no no
68 4.55 6.31 1.12 3.23 5.14 unknown other no no
69 3.24 13.41 1.53 0.47 1.46 cytoplasm kinase yes187 yes187
70 0.83 1.17 0.90 0.33 28.95 unknown enzyme no no
71 0.31 2.32 1.35 1.36 0.88 no no
72 0.31 4.22 0.42 0.20 1.43 cytoplasm kinase no no
73 1.49 0.93 0.95 0.37 10.01 plasma membrane other no no
74 1.47 1.32 5.70 0.38 0.97 cytoplasm other no no
75 1.83 3.55 2.23 2.62 3.78 nucleus enzyme no no
76 7.25 7.48 1.56 2.83 8.29 cytoplasm other no no
77 4.95 1.53 0.73 1.45 1.13 cytoplasm enzyme no no
78 5.59 0.23 0.20 1.21 0.20 plasma membrane enzyme no no
79 14.15 2.31 1.42 1.60 1.57 cytoplasm enzyme no no
80 2.91 0.23 0.20 2.75 0.20 cytoplasm other no no
81 2.54 31.31 1.77 2.07 3.53 nucleus kinase no no
82 0.70 3.58 0.52 0.20 3.05 plasma membrane kinase yes188 yes189
83 25.50 1.69 0.24 1.26 1.46 plasma membrane kinase no no
84 1.22 11.15 0.99 0.25 0.72 nucleus kinase yes178 no
85 3.14 8.23 1.09 0.76 2.19 cytoplasm other no no
86 15.97 1.75 1.25 0.45 1.34 nucleus transcription regulator yes190 no
87 22.35 2.18 1.29 0.42 1.82 cytoplasm kinase no no
88 6.72 1.31 1.09 4.00 1.50 unknown other no no
89 1.25 1.61 1.75 0.48 7.13 unknown other no no
90 1.87 3.63 0.48 0.35 7.62 cytoplasm kinase no no
91 6.71 1.50 0.55 0.46 0.38 cytoplasm enzyme no no
92 2.29 1.87 6.92 0.87 2.30 cytoplasm other no no
93 1.99 1.51 1.31 0.87 3.68 unknown other no no
94 1.76 2.22 0.86 1.66 1.79 unknown other no no
95 6.52 2.59 0.88 1.49 5.03 unknown other no no
96 5.47 4.82 2.10 2.30 2.13 cytoplasm enzyme no no
97 0.31 3.56 0.63 0.49 1.26 no no
98 1.39 3.46 0.98 0.43 0.83 unknown enzyme no no
99 0.31 4.14 1.27 0.47 1.79 plasma membrane other yes191 no
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no.
pC346 immunized 
(depleted - full) 
(nev) 
pC346 
immunized (full) 
(nev)
pC339 
immunized 
(depleted) (nev)
pC339 immunized 
(depleted - full) 
(nev)
pC339 
immunized 
(full) (nev) location type
prior linked to 
pCa
suggested as 
pCa biomarker
67 1.74 1.29 1.00 0.42 2.81 unknown other no no
68 4.55 6.31 1.12 3.23 5.14 unknown other no no
69 3.24 13.41 1.53 0.47 1.46 cytoplasm kinase yes187 yes187
70 0.83 1.17 0.90 0.33 28.95 unknown enzyme no no
71 0.31 2.32 1.35 1.36 0.88 no no
72 0.31 4.22 0.42 0.20 1.43 cytoplasm kinase no no
73 1.49 0.93 0.95 0.37 10.01 plasma membrane other no no
74 1.47 1.32 5.70 0.38 0.97 cytoplasm other no no
75 1.83 3.55 2.23 2.62 3.78 nucleus enzyme no no
76 7.25 7.48 1.56 2.83 8.29 cytoplasm other no no
77 4.95 1.53 0.73 1.45 1.13 cytoplasm enzyme no no
78 5.59 0.23 0.20 1.21 0.20 plasma membrane enzyme no no
79 14.15 2.31 1.42 1.60 1.57 cytoplasm enzyme no no
80 2.91 0.23 0.20 2.75 0.20 cytoplasm other no no
81 2.54 31.31 1.77 2.07 3.53 nucleus kinase no no
82 0.70 3.58 0.52 0.20 3.05 plasma membrane kinase yes188 yes189
83 25.50 1.69 0.24 1.26 1.46 plasma membrane kinase no no
84 1.22 11.15 0.99 0.25 0.72 nucleus kinase yes178 no
85 3.14 8.23 1.09 0.76 2.19 cytoplasm other no no
86 15.97 1.75 1.25 0.45 1.34 nucleus transcription regulator yes190 no
87 22.35 2.18 1.29 0.42 1.82 cytoplasm kinase no no
88 6.72 1.31 1.09 4.00 1.50 unknown other no no
89 1.25 1.61 1.75 0.48 7.13 unknown other no no
90 1.87 3.63 0.48 0.35 7.62 cytoplasm kinase no no
91 6.71 1.50 0.55 0.46 0.38 cytoplasm enzyme no no
92 2.29 1.87 6.92 0.87 2.30 cytoplasm other no no
93 1.99 1.51 1.31 0.87 3.68 unknown other no no
94 1.76 2.22 0.86 1.66 1.79 unknown other no no
95 6.52 2.59 0.88 1.49 5.03 unknown other no no
96 5.47 4.82 2.10 2.30 2.13 cytoplasm enzyme no no
97 0.31 3.56 0.63 0.49 1.26 no no
98 1.39 3.46 0.98 0.43 0.83 unknown enzyme no no
99 0.31 4.14 1.27 0.47 1.79 plasma membrane other yes191 no
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Figure 4. Top-ranked ProtoArray-identified proteins.
Heatmap of the top-25 PCa-derived proteins identified in immunized mice by ProtoArray 
analysis. A full overview of all identified proteins is depicted in Table 2.
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Validation of identified PCa-derived antigens 
in serum of xenograft-bearing mice
A second confirmation of the experimental setup consisted of the quantification 
of identified proteins in the serum of nude athymic mice, mice bearing a PC346 or 
PC339 xenograft and in the xenografted tissue. For this purpose, immunoassays 
were developed to estimate levels of the two proteins with the highest ProtoArray 
expression in immunized mice, aminoacylase 1 (ACY1) and proteasome subunit 
alpha type 1 (PSMA1). A commercial immunoassay was obtained to measure levels of 
another high-ranked candidate, TYRO3 tyrosine protein kinase (TYRO3), a member 
of the TAM family of receptor tyrosine kinases (RTKs) (Figure 4). Figure 5a shows 
that ACY1 is detectable in concentrated serum of PC346 and PC339 harbouring 
mice and was absent in the concentrated serum of normal non-xenografted nude 
mice. In addition, ACY1 was detected in both xenograft protein extracts. The 
protein with the second highest ProtoArray expression, PSMA1, was present in the 
serum of both xenograft-bearing mice as well as in both xenograft protein extracts, 
while absent in the serum of normal nude mice (Figure 5b). TYRO3 was detected in 
the concentrated serum of PC346 xenograft-bearing mice and the protein extracts 
of both xenografts but absent in the concentrated serum of normal non-xenografted 
nude mice and mice harbouring a PC339 xenograft (Figure 5c). Hence, the detection 
of ACY1, PSMA1 and TYRO3 in serum of xenograft-bearing mice confirms their 
identification by ProtoArray analysis and provides a second validation of the 
experimental setup.
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Figure 5. Expression of identified antigens in xenograft-bearing mice. Mean 
concentrations (± standard error of the mean) of ACY1 (panel A), PSMA1 (panel B) 
and TYRO3 (panel C) in serum of nude mice, serum of mice bearing a PC346 or PC339 
xenograft and PC346 and PC339 xenograft protein extracts.
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Pre-validation of identified candidate biomarkers in 
human serum samples
Concentrations of several identified candidate biomarkers were determined in sera 
of men with and without PCa. Since ACY1, PSMA1 and TYRO3 were detected in 
the serum of xenograft bearing mice, these were selected for initial validation. In 
addition, the two other members of the TAM receptor family, c-mer proto-oncogene 
tyrosine kinase (MERTK), and AXL receptor tyrosine kinase (AXL) were added, as 
MERTK was also among the high-ranked proteins identified by ProtoArray analysis. 
For validation, serum samples of men without PCa (n=40), men undergoing a radical 
prostatectomy for PCa with and without recurrence in the follow-up (n=80), and men 
with PCa metastasis (n=33) were retrospectively collected (Table 1). For TYRO3 and 
MERTK, serum concentrations were significantly increased in men with localized 
or metastasized PCa compared to men without PCa (Figures 6a and 6b). In contrast, 
serum concentrations of AXL were significantly lower in men with localized PCa, 
compared to men without PCa or PCa metastasis (Figure 6c). ACY1 serum levels 
were significantly higher in patients with PCa metastasis compared to patients 
with localized PCa or men without PCa (Figure 6d). PSMA1 concentrations did not 
differ significantly between the various groups (Figure 6e). To assess the value of 
the candidate markers in PCa detection, receiver operating characteristics (ROC) 
curves were generated for TYRO3, MERTK, AXL and ACY1, based upon analysis of 
men without PCa and men with localized PCa (Figure 7 and Table 3).
To summarize, these data show that several antigens to which an antibody response 
was identified in the xenograft mouse model also were differentially expressed in 
men with and without PCa.
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Figure 6. Expression of discovered PCa xenograft-derived antigens in human serum. 
Box plots of serum concentrations of TYRO3 (panel A), MERTK (panel B), AXL (panel 
C), ACY1 (panel D) and PSMA1 (panel E) in men without PCA, men with PCa without 
recurrence, men with PCa and recurrence and men with PCa metastasis. (Boxes, 
interquartile range, containing 50% of values; whiskers extending from the highest to 
lowest values; line across box, median).
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Figure 7. Predictive value of identified candidate biomarkers in PCa detection. 
ROC curves of TYRO3, MERTK, AXL and ACY1 based on men without PCa and the 
combined groups of men with localized PCa. Detailed information on the areas under 
the curve (AUCs) is depicted in Table 3.
Table 3. Backward stepwise logistic regression model of identified candidate 
biomarkers in PCa. Areas under the curve (AUCs) of TYRO3, MERTK, AXL and ACY1.
  AUC (95% Ci) p-value
tyRO3 0.84 (0.77-0.91) <0.0001
MeRtk 0.73 (0.63-0.84) <0.0001
AXl 0.80 (0.71-0.89) <0.0001
ACy1 0.55 (0.44-0.65) 0.41
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Discussion
The present study describes a unique xenograft-based biomarker discovery 
platform and proves its usefulness in the discovery of novel serum markers for PCa. 
By immunizing immuno-competent mice with serum from nude mice bearing PCa 
xenografts, an antibody response against xenograft-derived antigens was elicited. 
By probing protein microarrays with serum from immunized mice, several PCa-
derived antigens were identified, of which a subset was successfully retrieved in 
serum from mice bearing PCa xenografts (Figure 5) and validated in human serum 
samples (Figure 6).
A literature search learned that the majority of identified proteins have not been 
previously reported in relation with PCa, although some proteins have been proposed 
as possible markers (Table 2). Furthermore, the validated candidate biomarkers have 
been shown to be present in mouse and human sera in the ng/ml and pg/mL ranges, 
which is in the same serologic detection range as PSA, making them feasible for 
diagnostic purposes and confirming the ability of this biomarker discovery platform 
to detect the low abundant proteins. To exclude the presence of false-positive results 
due to possible background noise in the present ProtoArray and immunoassay based 
approaches, we performed several control experiments, including samples without 
the antigen, with standard series of antigen and preimmune serum hybridizations. 
In addition, a ProtoArray was developed with secondary antibody only, showing only 
a few protein spots that were quite strongly recognized by the secondary antibody.
Due to the heterogenic nature of PCa, a multitude of different PCa xenografts would 
be required to identify markers for each patient subpopulation. For this reason 
we utilized two different xenografts in this study, androgen sensitive PC346 and 
androgen unresponsive PC339, representing early and late stage disease, from 
which we indeed identified differences in antigens (Figure 4 and Table 2). Besides 
analysis of xenografts from different origin, also tumour location (e.g. subcutaneous, 
orthotopic or bone metastasis) might result in differential xenograft protein 
expression and can be studied using our approach.
Distinct differences are seen in detected xenograft-derived antigens between mice 
immunized with either full or depleted sera (Figure 4). Only for ACY1, a ProtoArray 
response is seen in all samples, while the antibody responses after immunization 
with either full or depleted serum seem exclusive. Overall, immunization with 
depleted serum showed the least pronounced ProtoArray responses.
This variability can be attributed to the individual antibody-responses between 
the immuno-competent mice, as is well-established192-194. Secondly, differences in 
antibody responses may be attributable to the use of either full or depleted serum. 
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After depletion of high abundant proteins, also low-molecular-weight proteins are 
removed, as albumin and immunoglobulin G function as carrier proteins195,196.
Overexpression of TAM receptors has been reported for a wide spectrum of cancers. 
With respect to PCa, different expression patterns of AXL and MERTK have been 
reported171,197-199. Differences in expression patterns were also observed in the serum 
concentrations of the TAM receptors in men with and without PCa in the present 
study (Figure 5), strengthened by data extracted from Oncomine, showing an 
increased gene expression of MERTK in PCa tissue compared to normal prostate 
tissue, while gene expression of AXL shows the opposite (Figure 8)200.
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Figure 8. Expression of MERTK and AXL in normal and PCa tissue. Oncomine gene 
expression results of TAM receptors over- or underexpressed in normal prostate 
compared to PCa tissue showing opposite patterns for MERTK and AXL. Significant 
results regarding TYRO3 expression in normal compared to malignant prostate tissue 
are not available. (P-value threshold: 1E-4; Outlier rank threshold: 50)
Recently, the proteasome β6 subunit was identified in serum from PCa patients141. 
The contrasting finding of high concentrations in serum xenograft-bearing mice 
and the absence of increased PSMA1 concentrations in men with PCa may be 
explained by the fact that the amount of released proteasomes from PCa cells does 
not significantly contribute to the total amount of proteasomes circulating under 
normal physiological conditions.
ACY1 has been detected as overexpressed in PCa needle biopsy specimens165. The 
present study showed that ACY1 concentrations were significantly higher in men 
with PCa metastasis compared to men without PCa or with localized PCa. ACY1 may 
thus function as a potential marker for patients suspected of having disseminated 
disease.
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To conclude, this study shows that by utilizing a unique xenograft-based 
immunization method it is possible to detect novel PCa biomarkers. The same 
approach could be taken for any human cancer, greatly assisting current biomarker 
discovery. The initial results of TYRO3, MERTK and AXL with respect to PCa 
detection are promising, although further validation of these and other candidate 
biomarkers in multi-center series is necessary.
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abstract
Background: Novel markers for prostate cancer (PCa) detection are needed. 
Total  prostate-specific antigen (tPSA) and percent free prostate-specific antigen 
(%fPSA = tPSA/fPSA) lack diagnostic specificity.
Objective: To evaluate the use of prostate-specific antigen (PSA) isoforms p2PSA 
and benign prostatic hyperplasia–associated PSA (BPHA).
Design, setting, and participants: Our study included 405 serum samples from the 
Rotterdam arm of the European Randomised Study of Screening for Prostate Cancer 
and 351 samples from the Urology Department of Innsbruck Medical University.
Measurements: BPHA, tPSA, fPSA, and p2PSA levels were measured by Beckman-
Coulter Access Immunoassay. In addition, the Beckman Coulter Prostate Health 
Index was calculated: phi = (p2PSA/fPSA) x √(tPSA).
Results and limitations: The p2PSA and phi levels differed significantly between 
men with and without PCa. No difference in BPHA levels was observed. The highest 
PCa predictive value in both cohorts was achieved by phi with areas under the 
curve (AUCs) of 0.750 and 0.709, a significant increase compared to tPSA (AUC: 
0.585 and 0.534) and %fPSA (AUC: 0.675 and 0.576). Also, %p2PSA (p2PSA/fPSA) 
showed significantly higher AUCs compared to tPSA and %fPSA (AUC: 0.716 and 
0.695, respectively). At 95% and 90% sensitivity, the specificities of phi were 23% and 
31% compared to 10% and 8% for tPSA, respectively. In both cohorts, multivariate 
analysis showed a significant increase in PCa predictive value after addition of 
p2PSA to a model consisting of tPSA and fPSA (increase in AUC from 0.675 to 0.755 
and from 0.581 to 0.697, respectively). Additionally, the specificity at 95% sensitivity 
increased from 8% to 24% and 7% to 23%, respectively. Furthermore, %p2PSA, phi, 
and the model consisting of tPSA and fPSA with or without the addition of p2PSA 
missed the least of the tumours with a biopsy or pathologic Gleason score ≥7 at 95% 
and 90% sensitivity.
Conclusions: This study shows significant increases in PCa predictive value and 
specificity of phi and %p2PSA compared to tPSA and %fPSA. p2PSA has limited 
additional value in identifying aggressive PCa (Gleason score ≥7).
introduction
Because serum total prostate-specific antigen (tPSA) and percent free prostate-
specific antigen (%fPSA) lack clear thresholds balancing specificity and sensitivity 
for the early detection of prostate cancer (PCa), continuous efforts are being made 
to discover new PCa markers. Detailed examination of the free prostate-specific 
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antigen (fPSA) fraction resulted in the identification of several distinctive fPSA 
forms, among which a mixture of precursor isoforms of prostate-specific antigen 
(pPSA or proPSA) and a form designated ‘‘benign’’ PSA (i.e., benign prostatic 
hyperplasia–associated PSA [BPHA])52-54,58,59,201. A study specifically concentrating 
on the precursor isoform of PSA containing two amino acids in the propeptide leader 
confirmed the presence of [-2]proPSA in serum of men with PCa, in which [-2]proPSA 
formed 25–95% of the fPSA fraction, in contrast with 6–19% in biopsy-negative 
men201. Initial reports investigating the clinical value of [-2]proPSA in screening for 
PCa showed that [-2]proPSA serum concentrations were in general higher in men 
with PCa compared to men without cancer61-64. Recently, reports by Sokoll et al.202 
and Stephan et al.203 showed that [-2]proPSA is able to significantly improve PCa 
detection. Characterisation of BPHA showed that it contains 237 amino acids like 
PSA but is clipped at several specific amino acid residues58. Measurement of BPHA 
concentrations in serum demonstrated that BPHA represented 25% of the fPSA 
in biopsy-negative men and was significantly higher in benign compared to PCa 
serum59. Furthermore, BPHA outperformed fPSA as well as tPSA in the prediction 
of transition zone enlargement60. A recent study evaluating the use of BPHA in 
discriminating PCa patients from patients without evidence of PCa showed that 
BPHA might improve PCa detection204. Results on a possible prognostic role for 
BPHA as well as [-2]proPSA have proven inconclusive81,82,203,204. In this two-centre 
study, both p2PSA and BPHA serum concentrations were measured in men with 
and without PCa to evaluate the additional clinical utility of p2PSA and BPHA next 
to tPSA and fPSA in a screening setting for PCa. (Note that the analyte is referred 
to as [-2]proPSA and the assay as p2PSA; for simplicity, p2PSA is used throughout 
the remainder of this report.) Also, several calculated derivatives, among which the 
Beckman Coulter Prostate Health Index (phi), a mathematical combination of PSA, 
fPSA, and p2PSA, were assessed. In addition, all analysed variables were assessed 
with respect to biopsy and pathologic Gleason scores and their ability to detect 
cancers with a Gleason score of ≥7.
patients and methods
Patient selection
Serum samples from site 1 were obtained from the biorepository of the Rotterdam 
arm of the European Study of Screening for Prostate Cancer. From 1994 to February 
1997, indications for a prostate biopsy consisted of a tPSA level >4.0 ng/ml, abnormal 
digital rectal examination (DRE), or abnormal transrectal ultrasound (TRUS). In 1997, 
this combination was replaced by PSA testing only205. Serum samples from site 2 were 
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enrolled from the PCa screening study at the Urology Department of the University 
of Innsbruck, which started in 1993. Indications for biopsy were based upon cancer 
probabilities estimated by an artificial neural network including tPSA, fPSA, age, 
DRE, and TRUS206. In addition, the concept of PSA velocity was incorporated in the 
diagnostic evaluation in 2005206. Only screen-detected samples of men with and 
without PCa were included in the present study. Inclusion criteria were age ≥50 yr, a 
tPSA concentration of 2–10 ng/ ml, a performed TRUS-guided needle biopsy (six or 
more cores), and a histologically confirmed diagnosis. Exclusion criteria were a prior 
history of PCa, acute prostatitis, urinary tract infection, prior transurethral resection 
of the prostate, and use of drugs or other therapies within 6 wk preceding blood 
draw that might influence PSA concentration. Blood specimens were processed and 
refrigerated within 3 h of blood draw and stored at -80 °C. A total of 405 men could 
be enrolled at site 1 (226 PCa cases, 179 non-PCa cases) and a total of 351 men at site 
2 (174 PCa cases, 177 non-PCa cases).
Measurement of tPSA, fPSA, p2PSA, and 
BPHA serum concentrations
At both sites, archival serum samples were analysed for tPSA, fPSA, p2PSA, and 
BPHA on the Access 2 Immunoassay System (Beckman Coulter, Brea, CA, USA) 
using the following serum assays: the US Food and Drug Association–approved 
Access Hybritech PSA and Access Hybritech free PSA; Access BPHA, which 
measures BPHA; and p2PSA, which measures p2PSA (the latter two for research 
use only, not for patient management). All assays were performed from one sample 
cup and used the same batch of calibrators. tPSA and fPSA results were obtained in 
single determinations, BPHA and p2PSA in duplicate determination. The analysis 
was repeated in case of a coefficient of variation >20%.
Statistical analysis
All statistical analyses were performed using the SPSS v.15.0 software package 
(SPSS, Chicago, IL, USA). Differences between men with and without PCa in median 
levels of tPSA, fPSA, BPHA, and p2PSA were examined using the Mann-Whitney 
U test with two-sided p values. Calculated derivatives of the assayed variables 
included Hybritech phi, Beckman Coulter’s mathematical combination of PSA, 
fPSA, and p2PSA. Beckman Coulter phi was calculated as (p2PSA/fPSA) x √(tPSA), 
representing a simplified version of a logistic regression model developed at 
Beckman Coulter. In addition, %fPSA (fPSA/tPSA x 100) and %p2PSA (p2PSA/fPSA 
x 100) were calculated. The areas under the receiver operator characteristic (ROC) 
area under the curve (AUC) as well as sensitivity and specificity were calculated to 
assess the diagnostic performances in PCa detection of the various assays. AUCs 
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of the ROC curves were compared using the method of DeLong et al207. In addition, 
p2PSA was added to a multivariate model based on tPSA and fPSA to specifically 
assess its additive value. Furthermore, using the Mann- Whitney U test with two-
sided p values, median values of all assessed variables were compared in tumours 
with biopsy or pathologic Gleason score below or above 7. The number of missed 
cancers with biopsy or pathologic Gleason score of ≥7 was calculated at sensitivities 
of 95% or 90% for tPSA, %fPSA, %p2PSA, and phi.
results
Patient characteristics are depicted in Table 1. Overall characteristics did not differ 
significantly except for the number of unknown pathologic Gleason scores and the 
number of men who underwent prostatectomy. In both cohorts, the percentage of 
tumours with a pathologic Gleason score ≥7 was higher than at the initial biopsy 
because of upgrading based on the prostatectomy specimen.
Table 1. Characteristics of both cohorts of men with and without prostate cancer to 
assess the additive value of p2PSA and BPHA next to total PSA and free PSA.
site 1 site 2 p-value
total no. of included men 405 351
pCa cases (%) 226 (55.8) 174 (49.6) ns
non-pCa cases (%) 179 (44.2) 177 (50.4) ns
Age range (yrs) (median) 55-75 (66) 50-77 (60) ns
tpsA range (ng/ml) (median) 2.0-10.0 (4.4) 2.0-9.7 (4.3) ns
biopsy Gleason score (%)
<7 168 (74.3) 122 (70.1) ns
≥7 55 (24.3) 48 (27.6) ns
Unknown 3 (1.3) 4 (2.3) ns
no. of men that underwent prostatectomy (%) 162 (71.7) 174 (100.0) p<0.0001
pathological Gleason score (%)
<7 96 (59.3) 88 (50.6) ns
≥7 53 (32.7) 86 (49.4) ns
Unknown 13 (8.0) 0 (0) p=0.0001
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At site 1, median levels of all assayed and calculated variables except BPHA differed 
significantly between men with and without PCa, with %fPSA, p2PSA, %p2PSA, and 
phi achieving the highest statistical significances (Table 2). At site 2, median levels 
of %fPSA, p2PSA, %p2PSA, and phi also differed significantly, in contrast with tPSA 
and fPSA, which did not differ between men with and without PCa. As BPHA was 
not significantly different between men with and without PCa in both cohorts, it 
was excluded from further analysis regarding PCa detection.
Table 3 shows the AUCs and specificities at sensitivities of 95% and 90% of the 
various univariate variables in both cohorts. In addition, Table 3 shows the specific 
additive effect of p2PSA to tPSA and fPSA by adding p2PSA to a multivariate logistic 
regression model consisting of tPSA and fPSA.
Table 2. Median levels of total PSA, free PSA, percent free PSA, BPHA, p2PSA, percent 
p2PSA, and Beckman Coulter Prostate Health Index in men with and without prostate 
cancer at sites 1 and 2 (ranges are depicted within brackets).
site 1 site 2
pCa non-pCa p-value pCa non-pCa p-value
tpsA (ng/ml) 4.69 (8.00) 4.34 (7.80) 0.003 4.44 (7.74) 4.03 (7.74) 0.3
fpsA (ng/ml) 0.65 (2.02) 0.76 (1.84) 0.004 0.48 (1.46) 0.49 (2.31) 0.5
%fpsA 14.07 (31.88) 18.4 (32.21) <0.0001 11.16 (22.96) 12.63 (24.85) 0.01
p2psA (ng/l) 10.90 (31.81) 9.31 (38.05) <0.0001 8.01 (113.30) 6.20 (369.04) <0.0001
%p2psA 1.66 (5.92) 1.27 (2.87) <0.0001 1.71 (21.61) 1.24 (31.06) <0.0001
bphA (ng/l) 157.30 (791.65) 180.52 
(940.18)
0.1 137.50 (977.08) 135.84 
(828.17)
0.7
phi 36.67 (108.93) 26.08 
(73.01)
<0.0001 34.67 (416.24) 25.60 
(910.29)
<0.0001
Flip_Jansen.indd   105 30-7-2013   8:43:52
Discovery anD valiDation of prostate cancer biomarkers106
Table 3. Univariate and multivariate analyses to assess the predictive value in prostate 
cancer detection and specificity at 95% and 90% sensitivity. The multivariate model 
compares the cancer predictive values of total PSA and free PSA (= base model) with or 
without p2PSA (confidence intervals are depicted within brackets; * = compared to the 
AUC of phi).
site 1
specificity(%)
sensitivity 95% (95% Ci) 90% (95% Ci) AUC (95% Ci) p-value*
Univariate:
tpsA (ng/ml) 9.7 (5.7-15.0) 16.5 (11.3-22.8) 0.585 (0.535-0.634) <0.001
fpsA (ng/ml) 6.0 (2.3-9.3) 15.6 (10.7-21.8) 0.582 (0.532-0.631) <0.001
%fpsA 5.7 (2.8-10.2) 22.2 (16.3-29.0) 0.675 (0.627-0.721) 0.009
p2psA (ng/l) 9.5 (5.6-14.8) 20.1 (14.5-26.7) 0.614 (0.565-0.662) <0.001
%p2psA 20.1 (14.5-26.7) 31.8 (25.1-39.2) 0.716 (0.669-0.759) 0.03
phi 22.7 (16.8-29.6) 34.7 (27.7-42.2) 0.750 (0.704-0.791) -
Multivariate:
base model 8.0 (4.4-13.0) 21.6 (15.8-28.4) 0.675 (0.627-0.720) 0.006
base model + 
p2psA
23.9 (17.8-30.9) 30.1 (23.4-37.5) 0.755 (0.710-0.796) 0.5
site 2
specificity (%)
sensitivity 95% (95% Ci) 90% (95% Ci) AUC (95% Ci) p-value*
Univariate:
tpsA (ng/ml) 7.9 (4.4-12.9) 10.2 (6.1-15.6) 0.534 (0.473-0.594) <0.001
fpsA (ng/ml) 9.0 (5.3-14.3) 11.3 (7.0-16.9) 0.521 (0.467-0.577) <0.001
%fpsA 9.0 (5.3-14.3) 11.9 (7.5-17.6) 0.576 (0.523-0.629) <0.001
p2psA (ng/l) 12.4 (8.0-18.2) 19.2 (13.7-25.8) 0.625 (0.572-0.675) <0.001
%p2psA 21.5 (15.7-28.3) 33.9 (27.0-41.4) 0.695 (0.644-0.743) 0.3
phi 30.5 (23.8-37.9) 31.1 (24.3-38.5) 0.709 (0.658-0.756) -
Multivariate:
base model 7.3 (4-0-12.2) 12.4 (8.0-18.2) 0.581 (0.527-0.633)* 0.001
base model + 
p2psA
23.2 (17.2-30.1) 36.2 (29.1-43.7) 0.697 (0.646-0.744) 0.3
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Figure 1. Receiver operator characteristic curves of total PSA, percent free PSA, 
percent p2PSA, Beckman Coulter Prostate Health Index, and the base model with 
p2PSA at (a) site 1 and (b) site 2 (tPSA = total prostate-specific antigen; %fPSA = 
percent free prostate specific antigen; %p2PSA = percent p2PSA; phi = Beckman 
Coulter Prostate Health Index).
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Table 4. Median values of total PSA, free PSA, p2PSA, and derivatives in serum of 
patients from site 1 and site 2 with tumours having biopsy or pathologic Gleason scores 
less or more than 7.
site 1
biopsy 
Gs <7
biopsy 
Gs ≥7 p-value
pathological 
Gs <7
pathological 
Gs ≥7 p-value
Univariate:
tpsA (ng/ml) 4.55 5.58 0.06 4.74 5.58 0.1
fpsA (ng/ml) 0.68 0.60 0.03 0.66 0.64 0.4
p2psA (ng/l) 10.86 11.17 0.9 11.09 11.08 0.9
bphA (ng/l) 150.60 174.54 0.6 149.21 204.24 0.3
%fpsA 15.54 11.42 <0.0001 14.51 11.9 0.01
%p2psA 1.60 1.91 0.002 1.63 1.84 0.09
phi 34.20 43.03 <0.0001 36.32 42.38 0.02
Multivariate:
base model 1.29 1.76 <0.0001 1.41 1.68 0.02
base model + 
p2psA
1.53 2.19 <0.0001 1.69 2.19 0.008
site 2
biopsy Gs 
<7
biopsy Gs 
≥7 p-value
pathological 
Gs <7
pathological 
Gs ≥7 p-value
Univariate:
tpsA (ng/ml) 4.13 5.37 0.004 4.34 4.80 0.3
fpsA (ng/ml) 0.45 0.54 0.03 0.48 0.47 0.8
p2psA (ng/l) 7.86 8.56 0.1 8.87 7.46 0.1
bphA (ng/l) 123.59 210.84 0.001 130.08 144.33 0.4
%fpsA 11.16 11.01 0.7 11.50 10.88 0.1
%p2psA 1.75 1.57 0.6 1.84 1.60 0.3
phi 34.05 35.83 0.2 35.51 33.95 0.5
Multivariate:
base model 0.98 1.04 0.3 0.96 1.05 0.1
base model + 
p2psA
1.11 1.15 0.3 1.11 1.14 0.8
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To investigate the influence of DRE results, all analyses described above were 
repeated after exclusion of all men with suspicious DRE results. This produced 
nearly identical results (data not shown). To assess the relationship between the 
assayed variables and Gleason score, median values were related to biopsy and 
pathologic Gleason score above or below 7. At site 1, the highest statistical difference 
in relationship to biopsy Gleason score was achieved by %fPSA, phi, and the base 
model with or without p2PSA (Table 4).
In relationship to pathologic Gleason score, the base model including p2PSA 
achieved the highest clinical significance followed by %fPSA and phi. In contrast, at 
site 2, the highest statistical difference in relationship to biopsy Gleason score was 
reached by BPHA followed by tPSA and fPSA. None of the assayed variables reached 
statistical significance in discriminating tumours with pathologic Gleason score 
above or below 7. In addition, we assessed which variable would miss the least 
number of tumours with a biopsy or pathologic Gleason score ≥7. At site 1, at 95% 
and 90% sensitivity, %p2PSA, phi, and the base model with or without p2PSA missed 
the least number of tumours with a biopsy or pathologic Gleason score ≥7 (Table 5).
At site 2, at 95% sensitivity, %p2PSA and the base model consisting of fPSA and 
tPSA missed the least number of tumours with a biopsy Gleason score of ≥7. At 90% 
sensitivity, the base model with the addition of p2PSA missed the least number of 
tumours with a biopsy Gleason score ≥7. At 95% sensitivity, %p2PSA missed the least 
number of tumours with a pathologic Gleason score ≥7, whereas at 90% sensitivity, 
the least number of tumours with a pathologic Gleason score ≥7 were missed by the 
base model with p2PSA included.
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Table 5. Cancers with biopsy or pathologic Gleason scores ≥7 missed by total PSA, 
percent free PSA, percent p2PSA, Beckman Coulter Prostate Health Index, and 
multivariate models at 95% and 90% sensitivity at both sites.
site 1 Cut-off no. biopsy Gs ≥7 no. pathological Gs ≥7
Missed Detected Missed Detected
sensitivity 95% 90% 95% 90% 95% 90% 95% 90% 95% 90%
Univariate:
tpsA (ng/ml) 2.56 2.93 4 6 51 49 3 5 50 48
%fpsA 28.10 22.95 1 2 54 53 1 2 52 51
%p2psA 0.91 1.05 1 1 54 54 1 2 52 51
phi 19.43 22.49 1 1 54 54 1 1 52 52
Multivariate:
base model 0.30 0.62 1 1 54 54 1 1 52 52
base model + p2psA 0.18 0.39 1 1 54 54 1 1 52 52
site 2 Cut-off no. biopsy Gs ≥7 no. pathological Gs ≥7
Missed Detected Missed Detected
sensitivity 95% 90% 95% 90% 95% 90% 95% 90% 95% 90%
Univariate:
tpsA (ng/ml) 2.36 2.50 1 3 47 45 7 10 79 76
%fpsA 17.65 19.12 2 4 46 44 4 7 82 79
%p2psA 0.89 1.05 0 4 48 44 1 8 85 78
phi 20.45 20.89 2 2 46 46 3 6 83 80
Multivariate:
base model 0.56 0.64 0 4 48 44 2 7 84 79
base model + p2psA 0.41 0.55 1 1 47 47 2 5 84 81
Discussion
The present two-centre study was initiated to assess the performance in PCa 
detection of the PSA isoforms p2PSA and BPHA in addition to tPSA and fPSA. 
Furthermore, the relationship between p2PSA and BPHA as well as biopsy and 
pathologic Gleason score and their ability to specifically detect cancers with a 
Gleason score ≥7 was assessed. In short, BPHA had no additional PCa predictive 
value over tPSA and %fPSA, whereas phi and %p2PSA showed significantly higher 
PCa predictive values combined with an increased specificity at 95% and 90% 
sensitivity (Table 3). This pattern was observed in both patient cohorts. Furthermore, 
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multivariate analysis showed that the addition of p2PSA to a logistic regression 
model consisting of tPSA and fPSA significantly increased PCa predictive value 
and specificity (Table 3). Exclusion of men with suspicious DRE results resulted 
in similar outcomes (data not shown). Regarding BPHA, our findings are similar 
compared to those of prior reports, which showed that BPHA as a single marker is 
unable to predict the presence of PCa59,60,63,82. However, BPHA might be of limited 
additional value in combination with existing markers, as was illustrated by a 
recent study by Stephan et al., but these results could not be reproduced by the 
present study (data not shown)204. In contrast, p2PSA and %p2PSA levels have 
been shown to be significantly elevated in men with PCa, resulting in an increase 
in PCa predictive value compared to %fPSA61,62,202,203. These results are confirmed 
in the present study, not only by univariate analysis but also by the addition of 
p2PSA to a logistic regression model consisting of tPSA and fPSA (Tables 2 and 
3). In addition, the present study evaluated the performance of phi, a calculated 
derivative of p2PSA, fPSA, and tPSA. Comparable to p2PSA levels, phi is significantly 
elevated in men with PCa (Table 2). With respect to PCa predictive value, phi 
performed significantly better than tPSA and %fPSA. In cohort 1, phi performed 
significantly better than %p2PSA, whereas in cohort 2, no difference was observed. 
When compared to the multivariate model consisting of tPSA, fPSA, and p2PSA, 
no significant difference in PCa predictive value was observed. Unfortunately, as 
data regarding prostate volume were lacking in a large proportion of patients, the 
performance of tPSA density and other density derivatives of the assayed variables 
could not be assessed. Regarding the detection of PCa with a Gleason score ≥7, 
phi, %fPSA, and the multivariate model with or without p2PSA performed equally 
in cohort 1, so showing no specific additional value of p2PSA (Tables 4 and 5). At 
site 2, BPHA and tPSA showed the highest significance in relationship to biopsy 
Gleason scores, whereas none of the assayed variables showed a significant 
relationship with pathologic Gleason score. Overall, no large differences between 
the various variables regarding the specific detection of PCa with Gleason score ≥7 
were observed. These results are in contrast with Catalona et al.81 and Stephan 
et al.203, who showed that %p2PSA had selectivity for detecting PCa with Gleason 
score ≥7. Another observation is the fact that tPSA and fPSA concentrations did not 
differ significantly between men with and without PCa at site 2 in contrast with 
site 1. These differences may largely result from discrepancies in the assays and 
nomograms used for initial patient screening, resulting in cohorts with different PCa 
characteristics (see section 2). A second explanation could be that at site 2, a greater 
proportion of PCa cases were detected in later screening rounds. It has been shown 
that the predictive value of tPSA decreases in successive screening rounds208-210. 
This might be reflected in the fact that no significant relationship between tPSA 
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and the presence of PCa was observed in cohort 2. Furthermore, the observed 
differences between the two cohorts regarding biopsy and pathologic Gleason score 
and the assayed variables, especially BPHA, might be contributable to the fact that 
Gleason scores were assigned by different pathologists at both centres. In addition, 
the number of patients with a known pathologic Gleason score might have been too 
small to detect significant relationships. Another point of concern could be the risk 
of a type one error resulting from the number of statistical tests and using an α level 
of 0.05. However, to reduce the risk of a type two error, we have chosen not to apply a 
correction method, such as the Bonferroni correction. Although differences between 
both PCa cohorts exist, p2PSA and phi differ significantly between men with and 
without PCa in both cohorts and are able to correctly predict the presence of PCa. 
In addition, p2PSA showed a specific additional increase in PCa predictive value 
when added to a multivariate model consisting of tPSA and fPSA. p2PSA has limited 
additional value in identifying men with aggressive PCa (Gleason score ≥7). Further 
study is needed to clearly define the definitive value of p2PSA in PCa detection 
and its ability to modify the number of men undergoing prostate biopsy. Especially, 
the performance of phi should be further evaluated, as other data investigating phi 
are currently lacking. Preferentially, these should be prospective studies based on 
direct PCa screening by p2PSA.
conclusions
The present study shows that p2PSA and, moreover, %p2PSA and phi could have 
additional value with respect to tPSA and %fPSA in PCa detection within the tPSA 
range of 2– 10 ng/ml by significantly increasing the predictive value and specificity 
for PCa. By increasing the clinical specificity of phi and p2PSA relative to tPSA 
and fPSA, the use of phi and p2PSA could potentially modify the number of men 
receiving a recommendation for biopsy. In addition, p2PSA has limited additional 
value in identifying men with aggressive PCa (Gleason score ≥7).
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abstract
Background: Clinicians may be unaware that replacement of the historical total 
prostate-specific antigen (tPSA) standard with the WHO 96/670 international 
standard leads to difficulties in interpreting tPSA results. Our aim was to investigate 
the relationship between the Hybritech and WHO calibrations of the Beckman 
Coulter tPSA assay, and to assess the impact on prostate cancer (PCa) detection.
Methods: tPSA concentrations were measured in 106 serum samples with both 
Hybritech and WHO calibrations. The established relationships were used for an in 
silico experiment with a cohort of 5865 men. Differences in prostate biopsy rates, 
PCa detection, and characteristics of missed cancers were calculated at biopsy 
thresholds of 3.0 and 4.0 ng/ml.
Results: A linear relationship was observed between the 2 calibrations, with a 20.3% 
decrease in tPSA values with the WHO standard compared with the Hybritech 
calibration. Applying the WHO calibration to the cohort of 5865 men yielded a 20% 
or 19% decrease in prostate biopsies and a 19% or 20% decrease in detected cancers 
compared with the Hybritech calibration, at a cut-off for biopsy of 3.0 or 4.0 ng/ml, 
respectively. The decrease in detected cancers declined to 9% or 11% if an abnormal 
result in a digital rectal examination or a transrectal ultrasound evaluation was used 
as trigger for prostate biopsy (cut-off of 3.0 or 4.0 ng/ml, respectively).
Conclusions: Application of the WHO standard for tPSA assays with commonly used 
tPSA thresholds leads to a significant decrease in PCa detection. Careful assessment 
of the relationship between the WHO standard and the thresholds used for prostate 
biopsy is hence necessary.
introduction
Numerous prostate-specific antigen (PSA) reagent sets are available for the 
measurement of total PSA (tPSA) concentrations. Several publications have shown 
that this wide variety of assays leads to very different values for tPSA. These 
findings cannot always be satisfactorily explained, but possible underlying reasons 
include differences in assay design, such as differential epitope recognition, cross-
reactivity with PSA-homologous antigens, and the lack of equimolarity5,112-115. The 
last issue, which causes tPSA assays to overreport tPSA concentrations in patients 
with benign prostate hyperplasia compared with those with prostate cancer (PCa), 
has largely been resolved through major modifications in many of the tPSA assays. 
Several studies have reported a small improvement in diagnostic performance, 
which has been attributed to changes in the equimolar response211,212. If the assay 
method applied and the specific reference range for the assay are unknown to the 
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clinician, tPSA values may be misinterpreted, possibly influencing the decision 
to recommend that patients undergo a prostate biopsy for PCa detection113. There 
may be clinical implications if serial tPSA measurements are used to calculate 
tPSA velocity or doubling time for the purpose of indicating PCa aggressiveness 
or treatment failure110,213-218. In addition, the lack of interchangeability of the various 
assays may prevent objective judgment and unbiased comparison of the results of 
previous studies. The First Stanford Conference was convened in 1992 to improve 
the interchangeability of tPSA assays. The Second Stanford Conference resulted in 
a reference standard consisting of 90% purified PSA– antichymotrypsin and 10% 
free PSA on a molar basis120. The WHO adoption of this standard resulted in the First 
International Standard for tPSA under the National Institute of Biological Standards 
and Control, also known as WHO 96/670116,117. Later, the WHO also introduced a 
standard for free PSA116,117. Differences among tPSA assays seem to have decreased 
since the introduction of the WHO 96/670 calibration, but they have not been 
completely resolved and eliminated118-120. Therefore, the term “harmonization” has 
become favoured instead of “standardisation,” because not all assays perform 
equally, even after standardisation219,220. To minimize the likelihood of clinical 
errors, several countries now require their laboratories to report tPSA concentrations 
in accordance with the WHO 96/670 preparation221. Although most clinicians are 
familiar with the fact that different tPSA assays produce different results, they 
may not be aware that restandardisation from a historical standard to the WHO 
calibration causes a shift in mass units, which yields a potential for underestimating 
tPSA values. If this shift is not fully appreciated, especially with respect to the 
tPSA threshold value for biopsy, a resulting decrease in PCa detection may produce 
life-altering consequences for individual patients. Thus, different cut-off values are 
required for the historical standard and the WHO calibration to achieve the same 
clinical performance. With the introduction of the WHO 96/670 calibration for tPSA, 
however, the question has arisen as to how this calibration would influence the 
clinical outcomes for the current tPSA thresholds. It is clear that the thresholds and 
methods used to measure tPSA are coupled; therefore, maintaining the established 
clinical validity requires that significant changes in the assay be evaluated for 
changes in reference values and cut-off thresholds. We describe our study focusing 
on the effects of implementing the WHO standard on the Beckman Coulter tPSA 
assay. This assay, the first tPSA assay to be approved by the US Food and Drug 
Administration, established the conventional 4.0- ng/ml cut-off value for prostate 
biopsy on the basis of a large multicenter prospective study by applying the gold 
standard Hybritech tPSA assay222. Although age-specific reference intervals are now 
available for tPSA, the 4.0- ng/ml tPSA threshold for prostate biopsy is well known, 
not only by healthcare professionals but also by the general public. We also applied a 
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cut-off value of 3.0- ng/ml because this concentration is currently used as indication 
for prostate biopsy by the European Randomized Study of Screening for Prostate 
Cancer (ERSPC)223.
methods
An overview of the analyses and an outline of the present study are depicted 
in Figure 1. First, we used the Access Hybritech Total PSA assay with both the 
Hybritech calibrator and the WHO calibrator to measure tPSA concentrations in 106 
fresh serum samples to compare the Beckman Coulter Hybritech calibration with 
the WHO 96/670 standard.
tPSA measurement in 
106 samples with the 
Beckman Coulter Access 
Hybritech and WHO 
96/670 calibration
formula describing the 
relationship between both 
calibrations
2. In silico experiment in a cohort of previously unscreened men (n=5.865)
Threshold for prostate 
biopsy of 3.0 or 4.0 
µg/L for both 
calibrations
1. Establishment of the relationship between the Beckman Coulter Access  
Hybritech and WHO 96/670 calibration
Comparison of PCa 
detection rates and 
PCa characteristics 
Figure 1. Overview of the present study. After establishing the relationship between 
the WHO 96/670 and Hybritech calibrations, we performed an in silico experiment to 
assess the clinical implications of the WHO 96/670 reference preparation.
The 106 serum samples were obtained from men included in the screening program 
of the Rotterdam center of the ERSPC. The study was approved by the Medical 
Ethics Committee of the Erasmus MC224. Hybritech tPSA concentrations varied from 
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0.1 ng/ ml to 9.1 ng/ml. PCa was detected after prostate biopsy in 4 of the 106 patients. 
The relationship between the WHO 96/670 and Hybritech tPSA calibrations was 
calculated with the Cusum test for linearity225. The resulting formula was then used 
to perform an in silico calculation of the tPSA concentrations based on the WHO 
96/670 standard for a cohort of men selected from the database of the Rotterdam 
center of the ERSPC. Patients were eligible for inclusion if they had undergone sextant 
biopsy of the prostate. Men were biopsied in the study either because of a Hybritech 
tPSA concentration ≥3.0 ng/ml or because of a Hybritech tPSA concentration of <3.0 
ng/ml at a repeat screening during a side study to test the value of free PSA for PCa 
detection226,227. Digital rectal examination (DRE) and transrectal ultrasound (TRUS) 
results were known for all men. All of the 5865 men included in the study were 
unbiopsied at the start of the study and were 55 to 75 years of age. The median 
tPSA concentration was 4.0 ng/ml (range, 0.1–315.7 ng/ml; see Figure 2. On the 
basis of the sextant biopsy results, PCa was diagnosed in 1539 patients (26%) in 
this cohort, 539 of whom eventually underwent a radical prostatectomy (RP). The 
characteristics of the PCa patients within the cohort are summarized in Table 1. 
This cohort of 5865 men was used in an in silico experiment that evaluated cut-
off values for prostate biopsy of ≥3.0 ng/ml and ≥4.0 ng/ml for both the Hybritech 
and WHO 96/670 calibrations. We subsequently calculated differences in prostate 
biopsy rates, PCa detection, and characteristics of the missed cancers. The SPSS 
12.0 software package was used for statistical analyses.
Table 1. Characteristics of PCa patients in a cohort of previously unbiopsied men from 
the Rotterdam center of the ERSPC (n=1539).
frequency 
Clinical stage t1 727 (47%)
t2 607 (39%)
t3 139 (13%)
t4 12 (1%)
biopsy Gleason score <7 1059 (69%)
7 375 (24%)
>7 96 (6%)
unknown 9 (1%)
Gleason score of Rp specimen (n=539) <7 323 (60%)
7 183 (34%)
>7 27 (5%)
unknown 6 (1%)
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Figure 2. Distribution of total PSA values in PCa and non-PCa cases in the cohort of 
previously unbiopsied men between tPSA 2-10 ng/ml.
results
We observed a linear relationship between the Hybritech and WHO 96/670 tPSA 
calibrations. This relationship is described by the formula: WHO calibration = 
(0.7964 x Hybritech calibration) + 0.007 ng/ml. The 95% confidence intervals for 
the slope and the y intercept were 0.78–0.81 and -0.004–0.024 ng/ml, respectively 
(Figure 3).
Flip_Jansen.indd   119 30-7-2013   8:43:54
Discovery anD valiDation of prostate cancer biomarkers120
0.0 2.5 5.0 7.5 10.0
0.0
2.5
5.0
7.5
10.0
Y=0.7964*X+0.007 
tPSA Hybritech (μg/L)
tP
SA
 W
H
O
 9
6/
67
0 
(μ
g
/L
)
Figure 3. tPSA concentrations measured with the Beckman Coulter Hybritech 
calibration plotted against those obtained with the WHO 96/670 calibration (n=106).
Use of this formula to calculate the WHO 96/670 tPSA concentrations for the cohort 
of previously unbiopsied men (characteristics summarized in Table 1) yielded a 
20.3% decrease in tPSA concentrations compared with the known Hybritech tPSA 
concentrations. A tPSA biopsy threshold of ≥3.0 ng/ml for the Hybritech calibration 
yielded 4419 biopsied patients from the 5865 cases (75%), leading to a total of 1430 
detected PCa cases (92%) (Table 2). A tPSA biopsy threshold of ≥4.0 ng/ml for the 
Hybritech calibration yielded 3004 biopsied patients (51%), leading to a total of 1073 
detected PCa cases (70%). Without adjusting the cut-offs for the WHO 96/670 tPSA 
calibration (i.e., ≥3.0 or ≥4.0 ng/ml, which is equal to a Hybritech tPSA cut-off of ≥3.6 
or ≥4.8 ng/ml, respectively), one obtains 3218 men (55%) as candidates for prostate 
biopsy, leading to 1130 detected cases of PCa (73%) with a cut-off of ≥3.0 ng/ml 
(Table 2).
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Table 2. In silico analysis of the clinical implications of the new PSA WHO calibration.
psA hybritech calibration
(biopsy threshold ≥3 ng/ml)
psA WhO 96/670 calibration
(biopsy threshold ≥3 ng/ml)
no. of biopsied patients
(% of all men in cohort) 
4,419 (75%) 3,218 (55%)
no. of detected pCa cases
(% of all pCa cases in cohort)
1,430 (92%) 1,130 (73%) 
psA hybritech calibration
(biopsy threshold ≥4 ng/ml)
psA WhO 96/670 calibration
(biopsy threshold ≥4 ng/ml)
no. of biopsied patients
(% of all men in cohort) 
3,004 (51%) 1,873 (32%)
no. of detected pCa cases
(% of all pCa cases in cohort)
1,073 (70%) 767 (50%) 
Nonadjustment yields a 20% decrease in the number of prostate biopsies (from 
75% to 55%) and a 19% decrease tPSA biopsy threshold of ≥3.0 ng/ml for the WHO 
96/670 calibration would miss 300 PCa cases that would have been detected with 
the Hybritech tPSA calibrator at the same threshold for prostate biopsy. At a cut-
off of ≥4.0 ng/ml for the WHO 96/670 calibration, 1873 men (32%) were candidates 
for prostate biopsy, leading to 767 detected cases of PCa (50%) and yielding a 19% 
decline in the biopsy rate and a subsequent 20% decrease in PCa detection. In the 
group of patients who underwent an RP, 507 (94%) of 539 cancers were detected 
by applying the Hybritech tPSA calibration at a biopsy threshold of ≥3.0 ng/ml, in 
contrast with the WHO calibration detecting 406 (75%) of 539 PCa cases, a decrease 
of 19%. Thus, use of the WHO calibration with a tPSA biopsy threshold of ≥3.0 ng/ml 
specifically missed 101 RP cases that would have been detected with the Hybritech 
tPSA calibrator at the same threshold for prostate biopsy. At a cut-off of ≥4.0 ng/
ml, application of the Hybritech tPSA calibration detected 386 (72%) of 539 cancers, 
in contrast with 272 (50%) of 539 PCa cases detected with the WHO calibration. 
The clinical and pathologic stages and the biopsy and RP sample Gleason scores 
of the missed cancers are depicted in Tables 3 and 4. At biopsy thresholds of ≥3.0 
ng/ml and ≥4.0 ng/ml, there are significant differences in cancer characteristics 
between the cancers that are missed by application of the WHO 96/670 standard 
and the cancers that are detected with the Hybritech calibration. Overall, the 
group of missed cancers consists of tumours with lower clinical and pathologic 
tumour stages and lower biopsy and RP Gleason scores. At a 3.0- ng/ml cut-off, an 
abnormal DRE result is found in 109 (36%) of the 300 missed cancer cases, and an 
abnormal TRUS result is present in 97 (32%) of the 300 missed cancer cases. When 
an abnormal DRE or TRUS result is used as a trigger for prostate biopsy, 146 (49%) 
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of the 300 missed cancer cases will be detected despite the application of the WHO 
96/670 reference standard. This approach yields a decrease in PCa detection of 9% 
compared with the Hybritech calibration. At a threshold of 4.0 ng/ml, an abnormal 
DRE result and an abnormal TRUS result are found in 111 cases (36%) and 90 cases 
(29%), respectively, of the 306 missed PCa cases. Use of an abnormal DRE or TRUS 
result as a trigger for prostate biopsy results in the detection of 139 (45%) of the 
306 missed cancer cases, leading to a decrease in PCa detection of 11% compared 
with the Hybritech calibration. Biopsy frequencies and PCa-detection rates were 
similar after the linear relationship between the 2 calibrations was used to correct 
the biopsy threshold for the WHO 96/670 calibration to 2.4 or 3.2 ng/ml.
Table 3. Characteristics of PCa cases detected by the Hybritech calibration (column 
2) and of PCa cases specifically missed by applying the WHO 96/670 calibration that 
were detected by the Hybritech calibration (column 3), at tPSA biopsy thresholds of 
≥3.0 ng/ml and ≥4.0 ng/ml.
biopsy threshold 
of ≥ 3.0 ng/ml
pCa cases detected 
by hybritech 
calibration (n=1430)
pCa cases specifically 
missed by the WhO 
96/670 calibration (n=300) p-value
Clinical stages t1 647 (45%) 154 (51%) ns
t2 583 (41%) 130 (43%) ns
t3 188 (13%) 15 (5%) <0.001
t4 12 (1%) 1 (0%) ns
biopsy Gleason 
score 
<7 966 (68%) 241 (80%) <0.001
7 361 (25%) 49 (16%) <0.001
>7 94 (7%) 10 (3%) 0.03
unknown 9 (1%) 1 (0%) ns
biopsy threshold 
of ≥ 4.0 ng/ml
pCa cases detected 
by hybritech 
calibration (n=1073)
pCa cases specifically 
missed by the WhO 
96/670 calibration (n=306) p-value
Clinical stages t1 468 (44%) 166 (54%) <0.001
t2 427 (40%) 111 (36%) ns
t3 167 (16%) 29 (10%) 0.007
t4 11 (1%) 0 (0%) ns
biopsy Gleason 
score 
<7 677 (63%) 236 (77%) <0.001
7 304 (28%) 59 (19%) 0.002
>7 83 (8%) 11 (4%) 0.01
unknown 9 (1%) 0 (0%) ns
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Table 4. Characteristics of RP cases that were detected with the Hybritech calibration 
(column 2) and of RP cases specifically missed by applying the WHO 96/670 calibration 
that were detected with the Hybritech calibration (column 3), at biopsy thresholds of 
≥3.0 ng/ml and ≥4.0 ng/ml.
biopsy threshold 
of ≥3.0 ng/ml
pCa cases detected 
by hybritech 
calibration n(=507)
Rp cases specifically 
missed by the WhO 
96/670 calibration (n=101) p-value
pathological 
stages
t2 387 (76%) 88 (87%) 0.02
t3 98 (19%) 11 (11%) 0.04
t4 21 (4%) 2 ( 2%) ns
unknown 1 (0%) 0 (0%) ns
Gleason score of 
Rp specimen
<7 300 (59%) 65 (64%) ns
7 175 (35%) 33 (33%) ns
>7 26 (5%) 3 (3%) ns
unknown 6 (1%) 0 (0%) ns
biopsy threshold 
of ≥4.0 ng/ml
pCa cases detected 
by hybritech 
calibration (n=386)
Rp cases specifically 
missed by the WhO 
96/670 calibration (n=114) p-value
pathological 
stages
t2 283 (73%) 97 (85%) 0.01
t3 83 (22%) 13 (11%) 0.02
t4 19 (5%) 4 (4%) ns
unknown 1 (0%) 0 (0%) ns
Gleason score of 
Rp specimen
<7 223 (58%) 77 (68%) ns
7 134 (35%) 30 (26%) ns
>7 23 (6%) 6 (5%) ns
unknown 6 (2%) 1 (1%) ns
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Discussion
Our results show that application of the WHO 96/670 calibration for tPSA yields 
a 20.3% decrease in tPSA values compared with the historical Beckman Coulter 
Hybritech calibration. If the threshold for prostate biopsy is not adjusted accordingly, 
there will be a significant decline in prostate biopsy rates (20% or 19%) and a 
subsequent decrease in detected PCa cases (19% or 20%) for the Beckman Coulter 
tPSA assay at commonly used cut-offs for biopsy (3.0 and 4.0 ng/ml, respectively). 
This decrease in detected PCa cases is limited to 9% or 11% if an abnormal DRE or 
TRUS result is used as a trigger for prostate biopsy (threshold of 3.0 or 4.0 ng/ml, 
respectively). In addition, significant shifts in tumour stages and Gleason scores 
were observed with the application of the WHO 96/670 tPSA calibration. Missed 
PCa cases showed fewer high-stage tumours and fewer tumours with high Gleason 
scores than for PCa cases that were detected with the Hybritech calibration at a 
biopsy threshold of ≥3.0 ng/ml or ≥4.0 ng/ml. Biopsy and PCa-detection rates were 
similar after the linear relationship between the WHO and Hybritech calibrations 
was used to correct the biopsy threshold for the WHO 96/670 calibration to 2.4 ng/ml 
or 3.2 ng/ml, respectively. One possible limitation of our study is that the second part 
is based on in silico calculations of WHO 96/670 tPSA concentrations, instead of on 
direct measurements of serum concentrations. This in silico calculation was based 
on the linear relationship established in a study of a smaller cohort (n=106) that used 
both calibrations for actual serum measurements; however, the 20.3% negative shift 
in tPSA values that is introduced by application of the WHO calibration is virtually 
identical to the findings of earlier studies by Kort et al. and Roddam et al., who found a 
22% and 19% difference, respectively, in tPSA concentrations (mean, 20.5%) between 
the WHO 96/670 and Hybritech calibrations119,221. Whereas we used an in silico 
experiment to evaluate the clinical effects of applying the WHO standard for tPSA, 
the actual relationship between the WHO calibration and the original Hybritech 
calibration was established with clinical serum samples. Because tPSA assays are 
known to be highly sensitive to the matrix of the sample, the use of clinical samples 
avoids biases that arise from the use of artificial samples219. A second limitation is 
that a cohort of screen detected PCas in asymptomatic men was used instead of 
a cohort of clinically detected PCa cases to assess the clinical impact of the new 
WHO calibration. Implications for a cohort of clinically detected PCas will be similar, 
more or less, with probably fewer missed PCa cases because of initially higher tPSA 
concentrations. We did not investigate the relationships between other tPSA assays 
and the new WHO standard in this study. This choice was partly because tPSA 
measurements made within the screening program of the ERSPC have always been 
based on the Hybritech system. The strategy has been to use the same method 
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during the entire study to minimize errors in medical decision making. Such errors 
may occur if different assays are used during patient monitoring. Kort et al. recently 
concluded that the results of other assays also deviate from expected tPSA values 
if the WHO 96/670 reference preparation is applied (regression slopes between 0.99 
and 1.08), showing that further efforts are needed to improve the interchangeability 
of tPSA assays118,119,221. In addition, we emphasize that although use of a biopsy cut-
off of 3.0 or 4.0 ng/ml is common practice, tPSA is a continuous, not a dichotomous, 
biomarker; therefore, the risk of PCa increases as the PSA concentration increases228. 
As far as we know, this study is the first to evaluate the clinical effects of the 
WHO 96/670 calibration for tPSA in a large screening cohort. Therefore, we have 
not been able to compare the number of missed cancers and the shifts in PCa 
characteristics with those of previous studies. Significant changes in PCa detection 
and PCa characteristics have also been observed in studies that have assessed 
the interchangeability of various tPSA assays, although a study by Yurdakul et al. 
concluded that different tPSA assays detected PCa cases with identical histological 
features114,218,229,230. This study and others, however, evaluated the effects of different 
tPSA assays, which have different performance characteristics. This approach 
contrasts with that of our study, in which the only difference was the reference 
standard. For the present study, the difference in cancer characteristics between 
the cancers missed by the WHO 96/670 calibration and the cancers detected by 
the Hybritech calibration can be explained by the distribution of tumour stages 
and Gleason scores in the entire population of the screening cohort. The group of 
missed cancers has Hybritech tPSA values of 3.0–3.6 ng/ml or 4.0–4.8 ng/ml and 
contains fewer high-stage and high-grade tumours than the cohort of all PCa cases 
with Hybritech tPSA concentrations ≥3.0 ng/ml or ≥4.0 ng/ml, respectively. The 
finding of a decrease in cancer detection caused by application of the WHO 96/670 
calibration may also have positive implications in light of the current discussions 
on limiting PCa overdetection and subsequent overtreatment231-234. Because the 
group of missed cancers contains significantly fewer tumours with a high stage or 
a high Gleason score and more tumours with favourable characteristics (Tables 3 
and 4), missing these cancers may not have clinical consequences and so may limit 
the overdetection and overtreatment of PCa. Furthermore, we have shown that the 
decrease in detected PCa cases caused by application of the WHO 96/670 standard is 
less dramatic when abnormal DRE or TRUS results are applied as triggers for prostate 
biopsy. Given the limited predictive value of an abnormal DRE or TRUS result in a 
screening setting, however, especially in the low tPSA range of approximately 3.0 
ng/ml or 4.0 ng/ml, the actual decrease in PCa detection most likely will be closer to 
19% or 20%, respectively, than to 9% or 11%235-239. The recalibration is also expected 
to affect PCa detection through effects on other PSA threshold values for biopsy. 
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Adaptation to the WHO 96/670 reference standard will also affect tPSA-derived 
variables, such as tPSA velocity, tPSA doubling time, and age-adjusted tPSA values, 
with potential consequences for the individual patient. In conclusion, the present 
study has shown that a decision to adapt tPSA testing to the WHO 96/670 reference 
standard requires both careful assessment of the relationship between the historical 
standard and the WHO standard and subsequent establishment of a new threshold 
for prostate biopsy. In this study, we found that the threshold for prostate biopsy 
shifted from 3.0  ng/ml or 4.0 ng/ml with the historical Hybritech calibration to 
2.4 ng/ml or 3.2 ng/ml, respectively, after application of the WHO 96/670 calibration. 
If not adjusted, this leads to a 19% or 20% decrease in PCa detection. Hence, if 
clinicians are unaware of the replacement of their historical tPSA standard with the 
WHO 96/670 reference preparation and do not adapt the threshold concentration 
for prostate biopsy, the number of prostate biopsies and subsequent PCa-detection 
rates will shift considerably in their clinic.
Grant/funding support: an educational grant for this study was provided by 
Beckman Coulter International.
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the xenograft model system 
detects novel pca markers
In spite of major investments, decades of intensive research, and hundreds of papers 
proposing possible novel markers for PCa, only very few markers have reached the 
clinic. This is especially remarkable in the light of all the advanced techniques 
that are currently available to discover and validate possible novel markers, which 
did not exist during the time that PSA was discovered. A large portion of these 
failures is formed by so-called ‘false discoveries’, novel markers that seem initially 
highly promising in the discovery phase but fail to show clinical significance in the 
validation phase240. An important factor herein is that a large part of these false 
discoveries are based on series of human serum samples, with the accompanying 
issues of human serum complexity, variability and dynamic range, next to biases 
resulting from poor study design, inappropriate sample selection and statistical 
issues such as overfitting of data.
human prostate cancer
Athymic nude mouse Immuno-competent mouse
Mouse serum with 
prostate cancer proteins
Immunize 
Serum with antibodies 
against prostate cancer 
proteins
Athymic nude mouse
Mouse serum
Figure 1. The two xenograft-based biomarker discovery platforms utilized in 
this thesis. After inoculation with a human prostate cancer graft, PCa proteins are 
secreted into the mouse bloodstream (middle mouse). By comparing serum of tumour-
bearing mice (middle mouse) with serum of non-tumour-bearing mice (left mouse), 
PCa-derived proteins can be identified (Chapter 2). In addition, an immune-competent 
congenic mouse (right mouse) can be immunized with serum drawn from a tumour-
bearing mouse (middle mouse) to generate an antibody response against human PCa-
derived proteins (Chapter 3).
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To bypass these issues we have chosen the xenograft model system as a platform 
for the discovery of new biomarkers for PCa123. In this system, human prostate 
tumour fragments are transplanted onto athymic nude mice. We hypothesized that, 
once securely grafted, these xenografts will shed tumour proteins into the mouse 
circulation. Thus, a normal nude mouse has only mouse proteins in its circulation, 
while the serum of a nude mouse bearing a human xenograft contains also human 
proteins deriving from the prostate tumour (Figure 1). This means that any protein 
identified as human specific is directly derived from the xenograft itself.
This approach evades the issues associated with comparing large series of human 
serum samples as described above. There is no detrimental sample variation: a 
single recipient mouse carrying a PCa xenograft should in principle suffice for the 
identification of PCa-derived proteins from mouse serum. Given the subsequent 
limited number of samples needed, a comprehensive and detailed scan of all 
high and low abundant PCa-derived proteins from a single serum sample can be 
performed by employing the latest MS technologies. The challenge with respect 
to the enormous dynamic range of serum protein expression can thus partially be 
overcome. As has already been reported, this model system is indeed capable of 
identifying human proteins that are shed into the circulation by human PCa cells124.
In Chapter 2, 44 tumour-derived proteins were identified utilizing this xenograft 
model. Amongst these were almost all subunits of the proteasome, a proteolytic 
protein complex. We hypothesize that their presence reflects the dysregulation of 
protein synthesis and degradation in cancer cells in contrast to normal cells in which 
the proteasome complex plays a crucial role in controlling essential cellular functions 
such as transcription, stress response, cell cycle regulation, cellular differentiation, 
and DNA repair143. Several subunits of the proteasome have indeed been linked to 
PCa, as well as to other malignancies241-245. However, one should keep in mind that the 
transplanted xenograft is relatively large in size compared to the total blood volume 
of the nude mouse. Translated to the human situation, this could mean that the 
number of circulating proteasomes deriving from PCa cells is undetectable against 
the high background levels of naturally circulating proteasomes. This is illustrated 
in Chapter 3, which showed no significant differences in concentrations of the 
PSMA1 proteasome subunit in men with or without PCa. In contrast, elevated serum 
levels of the 20S proteasome have been shown in patients with other solid tumours, 
such as breast cancer and renal cell carcinoma241,242. Nevertheless, the possibility 
still exists that specific posttranslational processes such as glycosylation created 
a more PCa specific proteasome isoform. Recently, the presence of a proteasome β 
subunit exclusively present in thymic cortical epithelial cells was discovered and 
shown to be useful in differentiating thymic carcinomas245.
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Another question that has to be elucidated is which of the identified PCa-derived 
proteins are specifically secreted by cancer cells and not by normal prostate 
cells. Most likely, the majority of these proteins are also secreted under normal 
circumstances, but in cancer cells the proportion of secreted proteins might differ, 
resulting in higher serum levels of specific proteins. However, it might well be that 
indeed some of the identified proteins are specifically secreted by PCa cells, and 
are not secreted by normal prostate tissue. Also, the disruption of the normal tissue 
architecture in PCa may play an important role, such as is the case for the elevated 
serum levels of PSA in PCa patients. A first start to elucidate some of these questions 
is a control experiment, in which human proteins are identified in the serum of mice 
inoculated with normal prostate tissue.
prostate cancer-derived proteins in the xenograft 
model systems are part of exosomes
Another observation is that about half of the discovered tumour-derived proteins 
in Chapter 2 are not formally known as secreted proteins but are annotated as 
being cytoplasmatic. This remarkable observation put us on the path of exosomes. 
Exosomes are small membrane vesicles, secreted by virtually every cell type, 
including tumour cells126. They are formed in multivesicular bodies by inward 
budding, thereby encapsulating cytoplasmic components (Figure 2)126,127. The exact 
function of exosomes in tumour cells has still to be elucidated, but is expected 
to relate to roles in cell-to-cell crosstalk, tumour-stromal interaction, protein 
degradation and antigen presentation126,127.
A recently published study reported that exosomes which are secreted by tumour 
cells can inhibit the binding of tumour-reactive antibodies to tumour cells. In this 
way exosomes might help tumour cells to escape from immune surveillance246.
An in-depth analysis of the PCa-secreted exosomes was performed in Chapter 2. 
After isolation of exosomes derived from PCa cells, these were analysed for their 
protein content by MS. This showed that indeed a large portion of the proteins 
inside exosomes could be annotated as cytoplasmic, next to the presence of cell 
membrane-associated proteins. This finding was confirmed in a recent review by 
György et al. describing the subcellular localisation of proteins identified in exosomes 
from six different studies247. It has been hypothesized that inside exosomes these 
cytoplasmic proteins are protected from degradation in human plasma, hereby 
enabling these cytoplasmic proteins to act distant from the site of their production.
Another fascinating finding was the presence of almost all proteasome subunits 
amongst the identified exosomal proteins. This observation was recently confirmed 
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in recent report from Lai et al. investigating the protein content in exosomes derived 
from mesenchymal stem cells, showing the presence of all seven α and β subunits 
of the 20S proteasome inside exosomes248. The presence of proteasomes inside 
exosomes might point towards the occurrence of specific proteolytic processes 
inside exosomes, which is suggested by the finding of a distinct 30-kDa ENO1 band 
specifically present in the exosome fraction as described in Chapter 2. Unfortunately, 
our attempts to specifically identify this 30-kDa ENO1 band by MS/MS were not 
successful.
Golgi apparatus 
PSA 
Rough endoplasmatic reticulum 
PSA 
Exosomes 
Multi-vesicular body 
Early endosome 
Clathrin-coated pit 
Consecutive secretory pathway Exosome secretion 
Figure 2. In the consecutive secretory pathway proteins such as PSA (prostate-
specific antigen) are formed in the rough endoplasmatic reticulum, a membrane-bound 
compartment in the cell. The proteins are then transferred to the many compartments 
of the Golgi apparatus and finally end up in a vesicle that fuses with the cell plasma 
membrane, releasing the proteins outside of the cell. In contrast to the consecutive 
secretory pathway, exosomes are formed in multivesicular bodies by inward budding, 
thereby encapsulating cytoplasmic proteins, such as cytoskeletal proteins, kinases, 
metabolic enzymes, and also RNA.
In addition to analysing the exosomal protein content, we specifically identified 
the TMPRSS2:ERG gene fusion transcript inside exosomes from PCa cell cultures. 
Surprisingly, this is also the case in the human situation. In a small pilot study, 
Nilsson et al. were able to detect the TMPRSS2:ERG fusion mRNA in exosomes 
isolated in urine from men with PCa249. Although the exact function of mRNA inside 
exosomes remains speculative, it has been shown that the exosomal RNA is not a 
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random sample from the cellular RNA pool, as certain mRNA transcripts are enriched 
up to several 100-fold in exosomes, suggesting a specific sorting mechanism250,251. 
Additionally, it has been shown that the number of exosomes is elevated in the 
circulation of cancer patients compared to normal controls252,253.
In conclusion, exosomes represent a fingerprint of the cancer cell, and as exosome 
concentrations are elevated in the circulation of cancer patients, exosomes present 
biomarker treasure chests. By specific enrichment for PCa-derived exosomes, 
utilizing tissue-specific membrane proteins present on exosomes, also the challenge 
of the dynamic range problem associated with the search for novel biomarkers 
might be overcome. As it has been proven that exosomes are relatively stable under 
multiple cycles of freezing and thawing, large scale purification of PCa-derived 
exosomes from biobank samples would be feasible254. Up to date, several studies 
have already been performed investigating the clinical usefulness of exosomes in 
PCa detection and prognosis. However preliminary, these studies have shown that 
it is indeed possible to identify, stage and monitor men with PCa based on their 
exosome-associated biosignature255-258.
Regarding future exosome research, a stable high-throughput assay should be 
developed to analyse exosomal protein content, allowing for a first large scale 
validation of possible exosomal protein markers. Then, a robust and clinical 
applicable assay should be developed, to isolate and analyse PCa-derived exosomes 
from men without and men with different stages of PCa, in order to facilitate the 
entry of a novel biomarker into routine clinical practice.
In addition, investigations regarding the possible functional role of exosomes might 
elucidate important mechanisms, such as cancer metastasis. Recently, it was shown 
that melanoma-derived exosomes harbour specific messenger proteins, enhancing 
metastatic invasion by directing bone marrow-derived cells toward a prometastatic 
phenotype, initiating a metastatic niche259. In turn, this might also have important 
consequences from a therapeutical point of view, regarding the prevention and 
prediction of metastases.
a unique xenograft-based immunization method 
detects novel prostate cancer biomarkers.
The approach taken in Chapter 2 is far more specific and has less variability than 
analysing hundreds of human serum samples. However, its results are still limited by 
the protein complexity of mouse serum itself and the resolution and mass accuracy 
of current mass spectrometers. In Chapter 3, we utilized the highly sensitive and 
specific mouse immune system to discover novel biomarkers for PCa. We developed 
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a xenograft-based biomarker discovery platform, in which immuno-competent mice 
are immunized with serum from PCa xenograft-bearing nude mice (Figure 1). In this 
system, the donor and recipient mice are congenic, so only the human PCa-derived 
proteins will specifically generate immunoglobulin biomarkers. Subsequently, a 
protein microarray-based method was utilized to profile the antibody production 
and identify PCa xenograft-derived proteins.
This approach resulted in the identification of 99 proteins to which an antibody 
response was observed. Amongst these were proteasome subunit PSMA1, 
ACY1, and two members of the TAM receptor family, TYRO3 and MERTK. After 
validation of these proteins by ELISA in serum samples from xenografted mice, 
a prevalidation was performed on series of human serum samples. Significantly 
different concentrations of several of the identified proteins were shown, in men 
with or without PCa and in men with PCa metastasis or PCa recurrence, proving that 
this unique xenograft-based immunization method is indeed capable of detecting 
possible novel PCa biomarkers.
However, as so many possible biomarkers are identified in the discovery phase 
by utilizing the approach in Chapters 2 and 3, it is virtually impossible to assess 
the value of all discovered proteins in a validation phase. To solve this dilemma, a 
selection was made based on imprecise criteria, such as the number of identified 
peptides of a specific protein, ProtoArray signal intensities, the presence of a protein 
in a specific cellular compartment, or results of previously published data. In this 
way, valuable candidates may be overlooked. Thus, high-throughput assays are 
needed to validate all identified candidates in a limited amount of time and effort.
Despite these dilemmas and challenges, both xenograft-based biomarker discovery 
platforms provide an important addition to existing means of biomarker discovery. 
In the future, a high-throughput assay should be developed to analyse the presence 
of all possible markers in a first validation series, so the most promising candidates 
can be selected. Then, further large scale identification in multi-centre series is 
needed to assess if any of the discovered proteins holds its promise as a novel 
biomarker. In addition, by investigating the role in PCa tumorigenesis and metastasis 
of the proteins identified by the xenograft-based biomarker discovery platforms, 
biologically related proteins may be identified, which in turn could represent novel 
biomarkers. Last of all, this might also have implications for PCa therapy. For 
example, it has been shown that inhibition of MERTK and AXL promotes apoptosis 
and inhibits tumour growth260-262.
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validation of isoforms of prostate-specific 
antigen as diagnostic markers
As mentioned previously, a disappointingly low number of novel biomarkers have 
reached the clinic during the last decades. Often, a novel candidate is presented with 
great promise, but later on subsequent validation studies show inconsistent or even 
contradictionary results. There are multiple possible explanations which can clarify 
the discrepancies encountered in validation studies, varying from methodological 
differences, poor study design, the use of inappropriate statistical tests, insufficient 
sample sizes and the use of unstandardised assays. On the other hand, if subsequent 
validation studies do show a consistent but limited improvement in diagnostic or 
prognostic value, chances of clinical incorporation are small, in sharp contrast with 
small improvements in the therapeutic field, such as an increased survival of several 
weeks to months240. A possible explanation for this phenomenon is that clinicians 
tend to over-treat patients, rather than incorporating biomarkers with less than 
perfect prediction into their clinical decision making.
During the last decades, several initiatives have been launched to improve the quality 
of reporting on validation of novel biomarkers. Examples are the STARD initiative 
(Standards for Reporting of Diagnostic Accuracy), presenting a checklist of 25 items 
to ensure reporting of all relevant information, and the REMARK recommendation 
(Reporting recommendations for tumour Marker prognostic studies), a guideline to 
encourage transparent and complete reporting263,264.
In Chapter 4, a retrospective multi-centre validation study is described. In this 
study, the PSA isoforms p2PSA and BPHA were analysed for their capacity in PCa 
detection as well as prognostic power. It was shown that p2PSA and, moreover, 
%p2PSA and phi could have additional value with respect to tPSA and %fPSA in 
PCa detection within the tPSA range of 2– 10 ng/ml, by significantly increasing the 
predictive value and specificity for PCa. In contrast, %p2PSA and phi seemed to 
have limited additional value in identifying men with aggressive PCa. Several very 
recent reports have confirmed that %p2PSA, and especially phi, are superior over 
tPSA and fPSA regarding predictive value in PCa detection. Studies by Stephan, 
Lazzeri, Catalona, Guazzoni and Le et al. showed a more than doubled specificity 
and significantly greater predictive value of %p2PSA and moreover phi in initial 
PCa screening, compared to tPSA and fPSA265-269. Amongst these were several 
prospective and multi-centre studies. In addition, the majority of these reports 
showed a correlation between higher levels of phi and the presence of PCa with a GS 
≥7. A systematic review and meta-analysis by Filella et al., analysing twelve studies, 
confirmed these results on the diagnostic performance as well as on the relationship 
of phi and %p2PSA with PCa aggressiveness270.
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Interestingly, reports investigating the performance of phi compared to PCA3 and 
TMPRSS2:ERG in initial PCa screening showed similar or superior results for phi 
compared to the latter two271-273.
So, as randomized controlled trials are awaited, preferably performed according to 
a biomarker reporting checklist or guideline, there are very strong indications that 
%p2PSA and especially phi are significantly better predictors for the presence of PCa 
than tPSA alone within a tPSA range of 2-10 ng/ml. As a result, the implementation of 
phi in routine clinical practice might result in fewer unnecessary prostate biopsies, 
reducing healthcare costs, as has been calculated in a recent report274. Recently, 
phi was granted premarket approval by the FDA for men 50 years and older with 
a tPSA value between 4 and 10 ng/ml and a digital rectal exam with no suspicion 
of cancer (http://www.accessdata.fda.gov/cdrh_docs/pdf9/p090026a.pdf). This is a 
first step into the implementation of phi in current clinical practice, however the 
most appropriate cut-off levels for phi and %p2PSA should still be established.
total prostate-specific antigen 
standardisation issues
As mentioned previously, also assay standardisation issues are related to 
discrepancies resulting from biomarker validation studies. Ideally, there should 
be only one assay platform from one manufacturer which is used worldwide to 
measure a certain biomarker. However, as there are huge financial interests in 
screening for specific diseases, there are often multiple manufacturers developing 
their own commercial assays. The resulting interassay variability can at least partly 
be overcome by using a specific calibration standard, and ideally this standard 
should be agreed upon before widespread clinical use of a specific assay, however 
this is rarely implemented. For example, it has taken more than a decade after its 
introduction before a calibration standard was adopted by the WHO for the tPSA 
assay, indeed decreasing interassay variabilities. However, by introducing a novel 
calibration standard long after widespread clinical use of a specific test, confusion 
is created as reported values will shift for certain assay platforms.
In Chapter 5, it is shown that for the Beckman Coulter tPSA assay, the introduction of 
the WHO reference standard resulted in a 20% decrease in tPSA concentrations with 
a subsequent decrease in the number of prostate biopsies and detected cancers. 
However, in the light of PCa overdetection and overtreatment it may be discussed if 
this is actually a negative or positive consequence of standardisation, as the great 
majority of the missed cancers were low-grade cancers. A more recent study from 
Fileé et al. produced nearly identical results275. To conclude, as long as significant 
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differences in tPSA values are reported by different assay platforms, physicians 
should be aware which assay platform is applied in their local hospital as well as 
which calibration method is used, before making possible far-reaching decisions at 
a patient level.
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Although results from prostate cancer screening studies are still under debate, 
screening for prostate cancer will always be carried out, either in an opportunistic 
or more organised way. This results from the reality that a substantial number 
of men bear in mind the possibility of being the one patient with an aggressive 
form of prostate cancer, which could be cured, but only if discovered in an early 
phase. Instead, it is more likely that they belong to the larger group of men with 
insignificant disease that will suffer from the consequences of overtreatment of 
indolent prostate cancer. The longer it takes before novel markers are introduced 
into clinical practice, the more men will suffer from the confusion that has resulted 
from the present studies evaluating screening for prostate cancer. A first step in 
improving the detection of prostate cancer could be the implementation of phi 
into routine clinical practice, integrating phi with existing markers and prostate 
cancer risk calculators. With relatively little effort and costs, this would lead to a 
significantly better performance in prostate cancer detection. Furthermore, it is 
clear that the biggest challenges lie now in the field of biomarker validation, as 
this thesis shows that the presented xenograft-based biomarker platforms are able 
to circumvent some of the major issues associated with contemporary biomarker 
discovery. The first challenge now is to develop novel high throughput methods to 
assess and validate the huge number of possible biomarkers in a large population of 
patients and controls.
Flip_Jansen.indd   139 30-7-2013   8:43:56
Flip_Jansen.indd   140 30-7-2013   8:43:56
sUMMARy 141
summary
In the Netherlands, 10,391 new cases of prostate cancer (PCa) were diagnosed in 
2010. This makes PCa the most common malignancy in men (source: Dutch Cancer 
Registry). To detect PCa in an early stage, prostate-specific antigen (PSA), which 
can be detected in blood, is frequently utilized. However, as PSA is not PCa specific, 
elevated levels can also be detected in men with benign prostate hyperplasia (BPH). 
In addition, a low PSA value does not rule out the presence of PCa. Thus, PSA should 
rather be regarded as a risk spectrum of PCa. A definitive diagnosis can only be made 
after taking prostate biopsies, an invasive procedure with associated morbidity. 
Also, the prognostic value of PSA is limited, as it is not unambiguously correlated to 
PCa aggressiveness. Thus, as an indirect consequence of utilizing PSA to identify 
men at risk of being diagnosed with PCa, there is a substantial overdiagnosis and 
overtreatment of PCa. A novel biomarker for the detection and prognosis of PCa 
could limit these significantly. Ideally, this biomarker should be able to differentiate 
between men with or without PCa, differentiate between indolent and aggressive 
disease, and be suitable for follow-up after treatment. Most likely, not one marker 
will possess all these characteristics, but a panel of carefully selected markers 
probably will be able to fulfil these criteria. Without doubt, PSA will be one of these, 
as physicians are so familiar to making PSA-based clinical decisions.
There are several challenges that should be met and numerous strategies that can 
be followed discovering novel markers. A frequently utilized approach is based upon 
comparing serum samples of large groups of men with PCa to the normal population. 
However, this approach is seriously hampered by the enormous variability of protein 
content among men, the often limited sample availability, and the time-consuming 
and laborious analyses that would arise from such an approach. In addition, due to the 
vast dynamic range in protein concentrations in human serum and the dominance of 
a small number of high abundant proteins, the presence of low abundant proteins, 
such as possible novel biomarkers, might be masked.
To bypass these issues we based our approach on a xenograft mouse model for PCa. 
In this system, human prostate tumour fragments are transplanted onto athymic 
nude mice. We hypothesized that once securely grafted, these xenografts will shed 
tumour proteins into the mouse circulation. Thus, a normal nude mouse has only 
mouse proteins in its circulation, while the serum of a nude mouse bearing a human 
xenograft contains also human proteins. Subsequently, these tumour-derived and 
human specific proteins can be identified utilizing mass spectrometry (MS). As 
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there is no detrimental sample variation, a single recipient mouse carrying a PCa 
xenograft should in principle suffice for the identification of PCa-derived proteins 
from mouse serum. In addition, by mimicking the human situation, the xenograft 
model is able to specifically expose tumour-secreted proteins, as is the case for most 
tumour markers applied in the clinic today.
In Chapter 2, the utilization of this xenograft mouse model led to the identification 
of 44 PCa-derived proteins. As expected, part of these proteins have been annotated 
as being actively secreted by cells. However, a large portion of the identified 
proteins has not been described as being secreted by cells, but has been annotated 
as being cytoplasmic. We hypothesised that the presence of these proteins in 
the mouse circulation results from the secretion of exosomes. These are small 
membrane vesicles, secreted by virtually every cell type, containing content from 
the cytoplasmic compartment. A subsequent in-depth analysis of the proteins 
present in exosomes secreted from PCa cell lines resulted in the identification 
of almost exclusively cytoplasmic proteins, amongst which were several of the 
proteins that had earlier been identified in the circulation of xenografted mice. In 
addition, analyses of exosomal RNA resulted in the identification of the PCa specific 
TMPRSS2:ERG gene fusion. So, we conclude that PCa-derived exosomes are ideal 
candidates for the discovery of novel biomarkers for PCa.
In Chapter 3, this xenograft model was further exploited for the discovery of novel 
biomarkers. By injecting immune-competent mice with serum drawn from PCa 
xenograft-bearing nude mice, we hypothesized that an immune-response would 
be generated against human PCa-derived proteins. A protein microarray based 
approach was subsequently utilized to profile the antibody production and thus 
indirectly identify PCa xenograft-derived antigens. Amongst 99 other proteins, 
this resulted in the identification of TYRO3, AXL, MERTK, ACY1 and PSMA1, of 
which the first three were pre-validated in series of human serum samples. This pre-
validation showed significantly different concentrations of the identified proteins 
in men with or without PCa, and in men with PCa metastasis or PCa recurrence, 
hereby proving that this unique xenograft-based immunization model is indeed 
capable of detecting novel PCa biomarkers.
In Chapter 4, we evaluated the additional value of the PSA-isoforms p2PSA and 
BPHA, both part of the free PSA (fPSA) fraction, with respect to PCa detection. 
In addition, the value of phi (prostate health index, calculated as (p2PSA/fPSA) x 
√(tPSA)) was investigated. This multicenter study included 756 serum samples of 
men with or without PCa and a total PSA (tPSA) concentration between 2 and 10 ng/
ml, deriving from the European Randomised Study of Screening for Prostate Cancer 
(ERSPC) and the Urology Department of Innsbruck Medical University. This study 
showed a significant increase in PCa predictive value and specificity of phi (31 versus 
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10%) compared to tPSA. Also, %p2PSA (p2PSA/fPSA) performed significantly better 
than tPSA. A multivariate model predicting the presence of PCa was significantly 
improved after the addition of p2PSA. Thus, we conclude that the introduction of 
%p2PSA and moreover phi into routine clinical practice will significantly improve 
PCa detection, thereby limiting the number of negative prostate biopsies.
Currently, several dozens of different assays are available to measure tPSA 
concentrations in human serum. As this has resulted in significant inter-assay 
differences, the World Health Organization (WHO) introduced the WHO 96/670 
calibration standard. However, it is anticipated that replacement of the original 
calibration standard with the WHO 96/670 calibration might lead to significant 
changes in tPSA results, with serious consequences for cut-off points for taking 
prostate biopsies, and subsequent changes in PCa detection rates.
In Chapter 5, the consequences of the introduction of the WHO 96/670 calibration 
for the Beckman Coulter tPSA assay were evaluated. It is shown that as a result 
of introducing the WHO 96/670 calibration standard, reported tPSA concentrations 
decreased by approximately 20% for the Beckman Coulter tPSA assay. Without 
correction of the applied tPSA thresholds for prostate biopsies, this results in a 
significant decrease in PCa detection rates. Hence, physicians should be aware 
which calibration method is utilized in their local hospital, and carefully assess 
which thresholds are used for taking prostate biopsies.
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In 2010 werden in Nederland 10.391 nieuwe gevallen van prostaatkanker vastgesteld. 
Hiermee is prostaatkanker de meest voorkomende vorm van kanker bij mannen 
(bron: Nederlandse Kankerregistratie). Om prostaatkanker in een vroeg stadium op 
te sporen wordt veelvuldig gebruik gemaakt van het prostaat specifiek antigeen 
(PSA), dat in het bloed te bepalen is. Nadeel van de PSA test is echter dat deze niet 
specifiek is voor prostaatkanker en ook een verhoogde uitslag kan geven indien er 
alleen sprake is van een goedaardige prostaatvergroting. Tevens kan bij een lage 
PSA waarde de aanwezigheid van prostaatkanker niet worden uitgesloten. De PSA 
waarde geeft dus alleen een risico inschatting van de kans op de aanwezigheid 
van prostaatkanker weer. Daarnaast is de prognostische waarde van PSA beperkt, 
aangezien de hoogte hiervan niet eenduidig is gerelateerd aan de agressiviteit 
en bijbehorende prognose van de gevonden prostaattumor. De definitieve aan- 
of afwezigheid van prostaatkanker valt alleen vast te stellen middels het nemen 
van prostaatbiopten, een invasieve procedure met de bijbehorende morbiditeit. 
Als gevolg hiervan is er sprake van een enorme overdiagnose en overbehandeling 
van prostaatkanker. Een nieuwe biomerker voor de detectie en prognose van 
prostaatkanker zou dit probleem significant kunnen beperken. De ideale merker 
zou in een vroeg stadium in staat moeten zijn te differentiëren tussen de aan- of 
afwezigheid van prostaatkanker, zou wat over de agressiviteit van de tumor moeten 
zeggen en geschikt moeten zijn voor regelmatige follow-up. Waarschijnlijk is er niet 
één merker die aan al deze criteria voldoet, maar met een panel van verschillende 
merkers is dit mogelijk wel te bereiken. Tevens valt het niet te verwachten dat door 
een nieuwe merker het PSA uit de kliniek verdwijnt, gezien de vertrouwdheid en 
ervaring van clinici met het nemen van medische beslissingen op basis van PSA 
uitslagen.
Bij het zoeken naar nieuwe merkers zijn er een aantal uitdagingen en strategieën. Een 
mogelijke aanpak is het vergelijken van grote groepen patiënten met prostaatkanker 
met de normale populatie. Lastig hierbij is de enorme variabiliteit binnen patiënten 
en controles, de vaak beperkte aantallen samples die beschikbaar zijn en de 
langdurige analyses die nodig zijn om nieuwe merkers te detecteren. Verder zijn 
er zoveel verschillende eiwitten in serum aanwezig dat die de aanwezigheid van 
eiwitten die in zeer lage concentraties voorkomen, zoals waarschijnlijk nieuwe 
merkers, verhullen. Om deze problemen te omzeilen kan men ook gebruik maken 
van een muismodel. Hierbij wordt gebruik gemaakt van muizen met een niet-
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werkend immuunsysteem waarop humane prostaattumoren kunnen groeien. Met 
behulp van massa spectrometrie kunnen vervolgens de eiwitten die circuleren in 
het bloed van deze muizen worden geanalyseerd. Het bloed van een muis zonder 
tumor zal alleen ‘muizen-eiwitten’ bevatten, het bloed van de muis met tumor zal 
daarnaast mogelijk ook eiwitten bevatten afkomstig van de prostaattumor. Deze 
eiwitten onderscheiden zich van de ‘muizen-eiwitten’ doordat ze als humaan 
specifiek kunnen worden herkend. Voordeel van dit muismodel is dat er hierbinnen 
nauwelijks variatie is, aangezien alle muizen genetisch identiek zijn en er steeds 
gebruikt gemaakt kan worden van dezelfde tumor, waarvan de karakteristieken 
bekend zijn. Een ander voordeel van deze aanpak is dat de meeste merkers die in de 
kliniek gebruikt worden, direct worden uitgescheiden door de tumor, een situatie 
die met het muismodel wordt nagebootst.
In hoofdstuk 2 werden met behulp van dit muismodel 44 eiwitten gevonden die 
afkomstig waren van de verschillende prostaattumoren. Deze eiwitten bestaan, 
zoals verwacht, voor een deel uit eiwitten waarvan het reeds bekend is dat ze actief 
door cellen worden uitgescheiden. Een opmerkelijke bevinding is echter dat er 
daarnaast ook een groot aantal eiwitten werd geïdentificeerd die normaal niet door 
cellen worden uitgescheiden, zogenaamde cytoplasmatische eiwitten. Mogelijk zijn 
deze in het bloed terechtgekomen als gevolg van uitscheiding in exosomen, zeer 
kleine blaasjes die door cellen worden uitgescheiden vanuit het cytoplasma. Nadere 
analyse van exosomen afkomstig van prostaatkankercellen toonde aan dat vrijwel 
alle eiwitten die hierin gevonden werden normaal gesproken alleen in het cytoplasma 
aanwezig zijn en niet actief worden uitgescheiden. Verschillende van deze eiwitten 
werden eerder teruggevonden in het bloed van muizen met prostaatkanker. Tevens 
werd in deze exosomen op RNA niveau het prostaatkanker specifieke fusiegen 
TMPRSS2:ERG aangetoond. Al met al lijken exosomen dus ideale kandidaten voor 
de ontdekking van nieuwe merkers voor prostaatkanker.
In hoofdstuk 3 wordt op een andere manier gebruik gemaakt van het muismodel. 
Door muizen met een intact afweersysteem te immuniseren met bloed afkomstig 
van muizen met een humane prostaattumor werd een antilichaam respons 
opgewekt tegen eiwitten afkomstig van deze prostaattumor. Deze eiwitten konden 
vervolgens worden geïdentificeerd door eiwit microarrays te incuberen met bloed 
van geïmmuniseerde muizen. Dit leverde onder andere de identificatie op van de 
eiwitten TYRO3, AXL, MERTK, ACY1 en PSMA1, waarvan de eerste drie werden 
gevalideerd in humaan serum. Hierbij werden inderdaad significante verschillen 
gevonden tussen verschillende groepen van mannen met en zonder prostaatkanker. 
Ook deze methode lijkt dus in staat tot het vinden van nieuwe merkers voor 
prostaatkanker, hoewel grootschalige validatie van mogelijke merkers nog moet 
plaatsvinden.
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In hoofdstuk 4 werd de additionele waarde van de PSA isovormen p2PSA en BPHA 
naast tPSA (totaal PSA) en fPSA met betrekking tot de detectie van prostaatkanker 
onderzocht. Deze PSA isovormen maken onderdeel uit van de vrije PSA fractie 
(fPSA). Tevens werd de bruikbaarheid van phi (prostate health index, (p2PSA/
fPSA) x √(tPSA)) onderzocht. In totaal werden 756 serum samples geanalyseerd van 
mannen met en zonder prostaatkanker en een tPSA waarde tussen de 2 en 10 ng/
ml. Het betrof hier een multicenter studie met samples afkomstig van de European 
Randomised Study of Screening for Prostate Cancer en de Medische Universiteit 
van Innsbruck. Uit de resultaten blijkt dat phi de beste voorspeller is voor de 
aanwezigheid van prostaatkanker, significant beter dan tPSA. Ook de specificiteit 
van phi is significant beter dan die van tPSA (31 versus 10%). Ook %p2PSA (p2PSA/
fPSA) presteerde significant beter dan tPSA. Bij multivariaat analyse zorgde de 
toevoeging van p2PSA voor een significante verbetering van het voorspellende 
model. De invoering van phi in de dagelijkse klinische praktijk zou dus de detectie 
van prostaatkanker kunnen verbeteren en hierdoor tevens het aantal negatieve 
prostaatbiopten kunnen beperken.
Wereldwijd worden er tientallen platformen van verschillende fabrikanten gebruikt 
om de waarde van tPSA in serum te kunnen bepalen. Aangezien deze elk hun eigen 
kalibratie methode gebruiken leidt dit tot substantiële verschillen in tPSA uitslagen. 
Om deze verschillen te beperken werd door de World Health Organization (WHO) 
een kalibratie standaard in het leven geroepen, de WHO 96/670. Vervanging van 
de originele kalibratie door de WHO 96/670 kalibratie standaard zou echter kunnen 
leiden tot een verschuiving in tPSA waarden, met gevolgen voor afkappunten voor 
het nemen van prostaatbiopten, weer resulterend in mogelijke veranderingen in 
prostaatkankerdetectie. In hoofdstuk 5 werden de gevolgen van de introductie van 
de WHO 96/670 kalibratie standaard voor de tPSA bepaling van Beckman Coulter 
onderzocht. Hieruit blijkt dat bij toepassing van de WHO 96/670 kalibratie de 
tPSA waarden 20% lager uitvallen. Wanneer de afkappunten voor het nemen van 
prostaatbiopten vervolgens niet adequaat worden aangepast resulteert dit ook 
in een vermindering van het aantal gedetecteerde prostaattumoren. Hoewel het 
overgrote deel hiervan relatief ‘gunstige’ prostaattumoren betreft is het van groot 
belang dat clinici zich ervan bewust zijn welke tPSA bepaling er in hun ziekenhuis 
wordt gebruikt en welke kalibratie standaard er wordt toegepast.
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Alhoewel ik me ’s avonds en ’s nachts soms niet geheel aan de indruk kon onttrekken, 
een proefschrift schrijf je natuurlijk nooit alleen. Zonder de hulp van velen was dit 
boekje er nooit gekomen. Bij dezen wil ik dan ook iedereen bedanken die iets aan het 
ontstaan van dit proefschrift heeft bijgedragen. 
Dit proefschrift was er zonder u zeker niet gekomen: Professor Bangma, beste 
Chris, dank voor het vertrouwen dat je me vanaf het begin hebt gegeven om mijn 
promotieonderzoek onder jouw leiding uit te kunnen voeren. Toen het gentherapie 
project uiteindelijk geen doorgang kon vinden heb je mij tijdig van het zinkende 
schip gehaald. Gelukkig vaart het weer! Op onze wekelijkse besprekingen hield je 
altijd de grote lijnen in de gaten en de klinische toepasbaarheid van onze meest 
recente ontdekkingen. 
Onderzoeker pur sang: beste Guido, en inmiddels zelfs professor Jenster. Ik heb er 
even op moeten wachten (en jij ook), maar ik ben er trots op dat ik nu als eerste onder 
jouw leiding mag promoveren. Ik ken niemand die ondanks chronisch slaapgebrek 
altijd met zulke scherpzinnige en creatieve oplossingen aankwam als ik ergens op 
was vastgelopen. Je zei altijd dat het erbij hoorde dat negen van de tien experimenten 
in het lab op niks uitdraaide, maar ik kan me niet aan de indruk onttrekken dat het 
bij ons iets lager lag. Have fun!
Abracadabra was het af en toe voor mij, die statistiek. Dr. Roobol, beste Monique, 
bedankt voor je geduld en uitleg en daarnaast voor de begeleiding van het meer 
klinische gedeelte van mijn proefschrift en het zitting nemen in de leescommissie. 
Professor Schröder, ik ben u dankbaar voor de mogelijkheid die u mij bood om een 
review artikel te schrijven over de PSA isovormen en het ter beschikking stellen van 
de serumsamples uit de biobank van de ERSPC. 
Professor Looijenga en professor Sillevis Smitt, dank voor het beoordelen van mijn 
manuscript en het zitting nemen in de leescommissie van mijn proefschrift. 
Alle medeauteurs wil ik bedanken voor hun bijdragen aan de verschillende 
hoofdstukken van dit proefschrift. Professor Staal, dank voor uw hulp en expertise 
bij de ProtoArray experimenten. Dr. Willemsen, beste Rob, bedankt voor de mooie 
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plaatjes van de exosomen met de elektronenmicroscoop. Dr. van Schaik, beste 
Ron, dank voor al je adviezen en hulp bij de artikelen over PSA calibratie en PSA 
isovormen. Dr. Luider en dr. Dekker, beste Theo en Lennard, bedankt voor jullie 
hulp bij het uitvoeren en analyseren van de massaspectometrie experimenten. Beste 
Gert-Jan, dr. Van den Bemd, dankzij jou lag er voldoende materiaal klaar om direct 
aan de slag te kunnen gaan en hier het eerste artikel op te baseren. Dank voor al je 
adviezen en hulp hierbij. Dr. Krijgsveld, beste Jeroen, dank voor je expertise en het 
ter beschikking stellen van je lab voor het uitvoeren van de massaspectrometrie 
experimenten. Dr. Wildhagen, beste Mark, bedankt voor je bijdrage op het gebied 
van de statistiek. Dr. Van Weerden, beste Wytske, dank voor je hulp en uitleg bij 
het opzetten van de muisexperimenten. En als laatste, maar zeker niet de minsten; 
Angelique en Mirella, ‘mijn’ analisten. Jullie hulp bij het uitvoeren van de talloze 
experimenten op het lab en het helpen zoeken als ik weer eens iets niet kon vinden 
in de vriezer was onmisbaar. Zonder jullie was dit boekje er zeker niet gekomen. 
Dr. Fijnheer, beste Rob. Het is al weer wat langer geleden, maar jij bent degene 
geweest onder wiens leiding ik voor het eerst kennis maakte met het doen van 
basaal wetenschappelijk onderzoek. Ik weet nog goed dat je zei dat jij de ELISA 
eigenlijk had uitgevonden, ik geloofde het toch zeker vijf seconden. 
Iedereen van het urologie lab in het JNI: Ellen en Wytske, mijn eerste kamergenoten, 
bedankt voor al de adviezen, jullie hebben me niet aan de thee gekregen! Wilma, 
Sigrid, Natasja en Robert, dank voor al jullie hulp op het lab. Susan en Corina, de 
‘muizendames’, dank voor het uitvoeren van alle experimenten met de muizen. Ik had 
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abbreviations
ACY1 aminoacylase 1
AUC area under the curve
AXL AXL receptor tyrosine kinase
BPH benign prostatic hyperplasia
BPHA (or BPSA) benign prostatic hyperplasia–associated PSA (or ‘benign’PSA)
CD9 tetraspanin 29
DRE digital rectal examination
ELISA enzyme-linked immunosorbent assay
ENO1 alpha enolase
ERSPC European Randomized Study of Screening for Prostate Cancer
fPSA free PSA
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GS Gleason score
hK2 human kallikrein 2
MERTK c-mer proto-oncogene tyrosine kinase
MS mass spectroscopy
PCa prostate cancer
PC339 androgen insensitive PCa cell line
PC346 androgen sensitive PCa cell line
phi Prostate Health Index ( = (p2PSA/fPSA) x √(tPSA))
pPSA proPSA
PSA prostate-specific antigen
PSMA1 proteasome subunit, alpha type, 1
p2PSA (-2)proPSA
tPSA total PSA
TRUS transrectal ultrasound
TYRO3  TYRO3 protein tyrosine kinase
WHO World Health Organization
%fPSA fPSA/tPSA
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